FedInvent™ Patent Applications

Application Details for Thursday, October 21, 2021 

This page was updated on Friday, October 22, 2021 at 07:19 PM GMT

Department of Health and Human Services (HHS) 

US 20210321594 Kaczorowski et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute on Aging (NIA)
APPLICANT(S) The Jackson Laboratory (Bar Harbor, Maine)
ASSIGNEE(S) The Jackson Laboratory (Bar Harbor, Maine)
INVENTOR(S) Catherine Kaczorowski (Bar Harbor, Maine);  Sarah M. Neuner (Bar Harbor, Maine)
ABSTRACT Provided herein, in some embodiments, are methods for modulating expression and/or activity of disks large-associated protein 2 (DLGAP2), as well as methods of treating age-related cognitive decline, such as Alzheimer's disease.
FILED Friday, April 30, 2021
APPL NO 17/245431
CURRENT CPC
Animal Husbandry; Care of Birds, Fishes, Insects; Fishing; Rearing or Breeding Animals, Not Otherwise Provided For; New Breeds of Animals
A01K 67/0275 (20130101) Original (OR) Class
A01K 2227/105 (20130101)
A01K 2267/0312 (20130101)

Preparations for Medical, Dental, or Toilet Purposes
A61K 45/06 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210321874 Wang et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
APPLICANT(S) California Institute of Technology (Pasadena, California)
ASSIGNEE(S) California Institute of Technology (Pasadena, California)
INVENTOR(S) Lihong Wang (Arcadia, California);  Liming Nie (St. Louis, Missouri);  Xin Cai (St. Louis, Missouri);  Konstantin Maslov (Pasadena, California);  Mark A. Anastasio (St. Louis, Missouri);  Chao Huang (St. Louis, Missouri);  Robert W. Schoonover (St. Louis, Missouri)
ABSTRACT Systems and methods of reconstructing photoacoustic imaging data corresponding to a brain of a subject through a skull of a subject utilizing a reconstruction method that incorporates a spatial model of one or more acoustic properties of the brain and skull of the subject derived from an adjunct imaging dataset.
FILED Thursday, April 22, 2021
APPL NO 17/302041
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 5/0035 (20130101)
A61B 5/0042 (20130101)
A61B 5/055 (20130101)
A61B 5/0095 (20130101) Original (OR) Class
A61B 5/725 (20130101)
A61B 5/4839 (20130101)
A61B 5/4848 (20130101)
A61B 5/7282 (20130101)
A61B 6/032 (20130101)
A61B 6/501 (20130101)

Devices for Introducing Media Into, or Onto, the Body; Devices for Transducing Body Media or for Taking Media From the Body; Devices for Producing or Ending Sleep or Stupor
A61M 31/005 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 29/2418 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210321961 Harrison et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
APPLICANT(S) Rensselaer Polytechnic Institute (Troy, New York)
ASSIGNEE(S) Rensselaer Polytechnic Institute (Troy, New York)
INVENTOR(S) Daniel David Harrison (Delanson, New York);  Ge Wang (Loudonville, New York)
ABSTRACT Systems and method for performing X-ray computed tomography (CT) that can improve spectral separation and decrease motion artifacts without increasing radiation dose are provided. The systems and method can be used with either a kVp-switching source or a single-kVp source. When used with a kVp-switching source, an absorption grating and a filter grating can be disposed between the X-ray source and the sample to be imaged. Relative motion of the filter and absorption gratings can by synchronized to the kVp switching frequency of the X-ray source. When used with a single-kVp source, a combination of absorption and filter gratings can be used and can be driven in an oscillation movement that is optimized for a single-kVp X-ray source. With a single-kVp source, the absorption grating can also be omitted and the filter grating can remain stationary.
FILED Tuesday, June 22, 2021
APPL NO 17/354286
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 6/032 (20130101)
A61B 6/482 (20130101)
A61B 6/4007 (20130101)
A61B 6/4035 (20130101) Original (OR) Class
A61B 6/4085 (20130101)
A61B 6/5258 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210321963 MANOR et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (La Jolla, California)
ASSIGNEE(S)
INVENTOR(S) Uri MANOR (La Jolla, California);  Linjing FANG (La Jolla, California)
ABSTRACT A method to, is provided for collecting an image from a sample. The method includes selecting a radiation level for a first probe to meet a desired radiation dosage, and providing, with the first probe, a radiation at a selected point within a region of the sample. The method includes identifying a second selected point within the region of the sample based on a down sampling scheme, and providing a second radiation amount at the second selected point within the region of the sample. The method also includes interpolating a first datum and a second datum based on an up sampling scheme to obtain a plurality of data, and forming an image of the region of the sample with the plurality of data. A system to perform the above method and including the first probe is also provided.
FILED Wednesday, August 21, 2019
APPL NO 17/269986
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 6/542 (20130101)
A61B 6/4035 (20130101)
A61B 6/4258 (20130101) Original (OR) Class
A61B 6/5282 (20130101)
A61B 6/5288 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322010 Roundy et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Center for Advancing Translational Sciences (NCATS)
APPLICANT(S) Oregon Health and Science University (Portland, Oregon)
ASSIGNEE(S) Oregon Health and Science University (Portland, Oregon)
INVENTOR(S) Neil Roundy (Portland, Oregon);  Rachel Dreilinger (Lake Oswego, Oregon)
ABSTRACT Surgical clips and surgical applicators used in performing rapid tissue closure in either minimally invasive surgeries or traditional open procedures are provided. In one example approach, a surgical clip comprises opposing sides extending from a top portion and terminating at tips positioned below the top portion. The resting position of the clip is its closed position, and in the closed position, the tips are set at a first distance apart. Each side has a cut-out (or hole or aperture) opposite one another. Each cut-out is fully surrounded by the side and does not extend to the top or tips. Each cut-out is configured to engage an inwardly turned hook at the end of a clip array or clip applicator such that the sides bend outwardly away from each other when pressure is applied on the top portion of the clip, thereby placing the clip in an open position.
FILED Thursday, July 01, 2021
APPL NO 17/365344
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 17/083 (20130101) Original (OR) Class
A61B 17/128 (20130101)
A61B 17/1227 (20130101)
A61B 17/1285 (20130101)
A61B 2017/0645 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322341 NICHOLS et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Center for Research Resources (NCRR)
National Heart, Lung, and Blood Institute (NHLBI)
APPLICANT(S) BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (Baton Rouge, Louisiana)
ASSIGNEE(S)
INVENTOR(S) Charles D. NICHOLS (New Orleans, Louisiana);  Bangning YU (New Orleans, Louisiana)
ABSTRACT Activation of 5-HT2A receptors using agonists at surprisingly low concentrations was shown to potently inhibit TNF-α-induced inflammation in multiple cell types. Significantly, proinflammatory markers were also inhibited by the agonist, (R)-DOI, even many hours after treatment with TNF-α. With the exception of a few natural toxins, no current drugs or small molecule therapeutics demonstrate a comparable potency for any physiological effect. TNF-α and TNF-α receptor mediated inflammatory pathways have been strongly implicated in a number of diseases, including atherosclerosis, asthma, rheumatoid arthritis, psoriasis, type II diabetes, depression, schizophrenia, and Alzheimer's disease. Importantly, because (R)-DOI can significantly inhibit the effects of TNF-α many hours after the administration of TNF-α, potential therapies could be aimed not only at preventing inflammation, but also treating inflammatory injury that has already occurred or is ongoing.
FILED Tuesday, December 01, 2020
APPL NO 17/108153
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/48 (20130101)
A61K 31/138 (20130101) Original (OR) Class
A61K 31/397 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322346 Gu et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
APPLICANT(S) The Research Foundation for The State University of New York (Albany, New York);  Chem-Master International Inc. (Albany, New York)
ASSIGNEE(S) The Research Foundation for The State University of New York (Albany, New York);  Chem-Master International Inc. (East Setauket, New York)
INVENTOR(S) Ying Gu (Centereach, New York);  Hsi-ming Lee (Setauket, New York);  Lorne M. Golub (Smithtown, New York);  Francis Johnson (Setauket, New York);  Guirong Wang (Syracuse, New York);  Osama Abdel-Razek (Syracuse, New York);  Yongan Xu (Syracuse, New York)
ABSTRACT A method of increasing production of one or more lipoxins in a subject in need thereof comprising administering to the subject an amount of a compound having the structure: or a pharmaceutically acceptable salt or ester thereof, so as to thereby increase production of the one or more lipoxins in the subject.
FILED Monday, June 21, 2021
APPL NO 17/353504
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/12 (20130101)
A61K 31/44 (20130101)
A61K 31/165 (20130101) Original (OR) Class
A61K 31/444 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322355 Abaffy et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute on Deafness and Other Communication Disorders (NIDCD)
APPLICANT(S) Duke University (Durham, North Carolina)
ASSIGNEE(S) Duke University (Durham, North Carolina)
INVENTOR(S) Tatjana Abaffy (Durham, North Carolina);  Hiro Matsunami (Durham, North Carolina)
ABSTRACT The present disclosure provides, in part, modulators of prostate-specific G-protein receptor (OR51E2/PSGR) and methods of treating, preventing, and diagnosing prostate cancer using the same.
FILED Wednesday, June 23, 2021
APPL NO 17/355898
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/19 (20130101)
A61K 31/203 (20130101) Original (OR) Class
A61K 31/352 (20130101)
A61K 31/565 (20130101)
A61K 31/568 (20130101)
A61K 31/7016 (20130101)
A61K 47/06 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322357 Mohsen
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
APPLICANT(S) Univeersity of Pittsburgh - Of the Commonwealth System of Higher Eduction (Pittsburgh, Pennsylvania)
ASSIGNEE(S)
INVENTOR(S) Al-Walid A. Mohsen (Gibsonia, Pennsylvania)
ABSTRACT A method of treating medium chain acyl-CoA dehydrogenase deficiency, very long chain acyl-CoA dehydrogenase deficiency, long chain hydroxyacyl-CoA dehydrogenase deficiency, trifunctional protein deficiency, or CPT II deficiency in a patient is provided comprising administering to the patient a therapeutic amount of a triglyceride or other conjugated fatty acid, that bypasses or leads to an intermediate that bypasses the deficient enzyme. Amino acid-conjugated fatty acids also are provided as well as compositions comprising the amino acid-conjugated fatty acids.
FILED Thursday, July 11, 2019
APPL NO 17/258877
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/0053 (20130101)
A61K 31/221 (20130101) Original (OR) Class
A61K 31/232 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 3/00 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322363 Brosnan
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) The Regents of the University of California (Oakland, California)
ASSIGNEE(S) The Regents of the University of California (Oakland, California)
INVENTOR(S) Robert J. Brosnan (Davis, California)
ABSTRACT The present invention provides methods for determining the selectivity of an anesthetic for an anesthetic-sensitive receptor by determining the molar water solubility of the anesthetic. The invention further provides methods for modulating the selectivity of an anesthetic for an anesthetic-sensitive receptor by altering or modifying the anesthetic to have higher or lower water solubility. The invention further provides methods of inducing anesthesia in a subject by administering via the respiratory pathways (e.g., via inhalational or pulmonary delivery) an effective amount of an anesthetic compound identified according to the present methods.
FILED Monday, November 02, 2020
APPL NO 17/087365
CURRENT CPC
Veterinary Instruments, Implements, Tools, or Methods
A61D 7/04 (20130101)

Preparations for Medical, Dental, or Toilet Purposes
A61K 9/007 (20130101)
A61K 31/02 (20130101)
A61K 31/08 (20130101)
A61K 31/025 (20130101)
A61K 31/045 (20130101)
A61K 31/341 (20130101)
A61K 31/351 (20130101) Original (OR) Class
A61K 31/357 (20130101)

Devices for Introducing Media Into, or Onto, the Body; Devices for Transducing Body Media or for Taking Media From the Body; Devices for Producing or Ending Sleep or Stupor
A61M 16/01 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322383 AIZENMAN et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
National Institute of Neurological Disorders and Stroke (NINDS)
APPLICANT(S) UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (Pittsburgh, Pennsylvania)
ASSIGNEE(S)
INVENTOR(S) Elias AIZENMAN (Pittsburgh, Pennsylvania);  Carlos Jaime CAMACHO (Pittsburgh, Pennsylvania)
ABSTRACT Disclosed herein are small molecule compounds capable of disrupting Kv2.1-syntaxin binding. The compounds are useful for treating a variety of neurological disorders, diseases, and injuries.
FILED Wednesday, July 31, 2019
APPL NO 17/264982
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/53 (20130101)
A61K 31/428 (20130101)
A61K 31/506 (20130101)
A61K 31/4155 (20130101) Original (OR) Class
A61K 31/4178 (20130101)
A61K 31/4409 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 25/28 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322396 Kohane et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute on Deafness and Other Communication Disorders (NIDCD)
APPLICANT(S) Children's Medical Center Corporation (Boston, Massachusetts)
ASSIGNEE(S) Children's Medical Center Corporation (Boston, Massachusetts)
INVENTOR(S) Daniel S. Kohane (Newton, Massachusetts);  Rong Yang (Cambridge, Massachusetts)
ABSTRACT The present disclosure provides compositions and methods for delivery of therapeutic agents across a barrier. The compositions include a therapeutic agent (e.g., antimicrobial agent, antibiotic, or anesthetic agent), a permeation enhancer which increases the flux of the therapeutic agent across the barrier, and a matrix forming agent, wherein the composition comprises between about 0.5-5.0% wt/vol of a permeation enhancer that is sodium dodecyl sulfate; wherein the compositions comprise between about 0.5-2.5% wt/vol of a permeation enhancer that is bupivacaine; wherein the compositions comprise between about 1.5-12.0% wt/vol of a permeation enhancer that is limonene; and wherein the compositions comprise between about 9.0-19.0% wt/vol of a polymer that is poloxamer 407-poly(butoxy)phosphoester; and optionally further comprises between about 0.01-0.50% wt/vol of another therapeutic agent that is a sodium channel blocker anesthetic agent (e.g., tetrodotoxin).
FILED Friday, August 30, 2019
APPL NO 17/272212
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/0046 (20130101)
A61K 31/445 (20130101) Original (OR) Class
A61K 31/496 (20130101)
A61K 31/529 (20130101)
A61K 31/573 (20130101)
A61K 45/06 (20130101)
A61K 47/06 (20130101)
A61K 47/20 (20130101)
A61K 47/34 (20130101)

Devices for Introducing Media Into, or Onto, the Body; Devices for Transducing Body Media or for Taking Media From the Body; Devices for Producing or Ending Sleep or Stupor
A61M 25/0021 (20130101)
A61M 31/00 (20130101)
A61M 2210/0662 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322398 Tang et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) Wisconsin Alumni Research Foundation (Madison, Wisconsin)
ASSIGNEE(S)
INVENTOR(S) Weiping Tang (Middleton, Wisconsin);  Ka Yang (Madison, Wisconsin);  Hao Wu (Madison, Wisconsin)
ABSTRACT Histone deacetylase (“HDAC”)-selective inhibitors covalently bonded to a linker covalently bonded to an E3 ubiquitin ligase ligand, and salts thereof; pharmaceutical compositions containing them; methods of using the composition to inhibit neoplastic cell growth in mammals, including humans.
FILED Monday, June 28, 2021
APPL NO 17/359857
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/4439 (20130101) Original (OR) Class

Heterocyclic Compounds
C07D 401/14 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322405 Ding et al.
FUNDED BY
Department of Energy (DOE)
Battelle Memorial Institute (BATTELLE)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) Washington University (St. Louis, Missouri);  The General Hospital Corporation d/b/a Massachusetts General Hospital (Boston, Massachusetts);  The Broad Institute, Inc. (Cambridge, Massachusetts);  Battelle Memorial Institute (Richland, Washington)
ASSIGNEE(S)
INVENTOR(S) Li Ding (St. Louis, Missouri);  Song Cao (St. Louis, Missouri);  Yige Wu (St. Louis, Missouri);  Alla Karpova (St. Louis, Missouri);  Liang-Bo Wang (St. Louis, Missouri);  Milan Chheda (St. Louis, Missouri);  Feng Chen (St. Louis, Missouri);  Ramaswamy Govindan (St. Louis, Missouri);  Albert Kim (St. Louis, Missouri);  Michael Gillette (Boston, Massachusetts);  Steven Carr (02142, Massachusetts);  Shankha Satpathy (Cambridge, Massachusetts);  Tao Liu (Richland, Washington);  Karin D. Rodland (Richland, Washington);  Richard D. Smith (Richland, Washington)
ABSTRACT The present disclosure provides for compositions and methods of treating cancer. In some embodiments, PTPN11 is targeted with and anti-PTPN11 drug, such as a Shp2 inhibitor (e.g., SHP099). In some embodiments, other upregulated, hyperphosphorylated, or hyperacetylated target proteins are inhibited or targeted.
FILED Thursday, April 15, 2021
APPL NO 17/231273
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/497 (20130101) Original (OR) Class
A61K 31/685 (20130101)
A61K 31/702 (20130101)
A61K 31/4985 (20130101)
A61K 45/06 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322414 Smith et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Eye Institute (NEI)
National Institute of Child Health and Human Development (NICHD)
Non-Profit Organization (NPO)
Massachusetts Lions Eye Research Fund, Inc.
APPLICANT(S) Children's Medical Center Corporation (Boston, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Lois Smith (West Newton, Massachusetts);  Jean-Sebastien Joyal (Boston, Massachusetts)
ABSTRACT The instant invention provides methods and compositions related to discovery of Free Fatty Acid Receptor 1 (FFA1) as a therapeutic target for treatment or prevention of diseases or disorders of neurons that are characterized by angiogenesis, or of vascular diseases of the eye, retinal degeneration and/or tumors more generally. Therapeutic and/or prophylactic uses and compositions of known FFA1 inhibitors, including small molecules and nucleic acid agents, are described. Methods for identification of novel FFA1 inhibitors are also provided.
FILED Friday, February 17, 2017
APPL NO 15/999535
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/352 (20130101)
A61K 31/513 (20130101) Original (OR) Class
A61K 31/519 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/5044 (20130101)
G01N 2800/50 (20130101)
G01N 2800/164 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322415 BARRY et al.
FUNDED BY
Department of Health and Human Services (HHS)
APPLICANT(S) ASTRAZENE CA AB (Sodertalje, Sweden);  THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH AND HUMAN SERVICES (Bethesda, Maryland)
ASSIGNEE(S) ASTRAZENECA AB (Södertälje, Sweden);  THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH AND HUMAN SERVICES (Bethesda, Maryland)
INVENTOR(S) Simon BARRY (Cambridge, United Kingdom);  Jane KENDREW (Cheshire, United Kingdom);  Tony HO (Gaithersburg, Maryland);  Stephen Robert WEDGE (Cambridge, United Kingdom);  Susan Percy IVY (Bethesda, Maryland);  Elise KOHN (Bethesda, Maryland);  Jung-Min LEE (National Institutes of Health, Maryland)
ABSTRACT Methods comprising repeating cycles of administration of a composition comprising cediranib according to a fixed intermittent dosing regimen comprising administration of an effective amount of the composition comprising cediranib on one or more consecutive days of a cycle followed by one or more consecutive days of rest on which said composition is not administered are disclosed herein, and may be used as monotherapy or may comprise administration of one or more partner drugs or therapies and may be used in combination therapy. Such methods may produce an antiangiogenic and/or vascular permeability reducing effect, treat at least one disease state associated with angiogenesis, reduce the total dose of cediranib required to provide effective VEGF inhibition, reduce adverse events and toxicity due to cediranib administration, maintain cover on the VEGF pathway despite reduction of total doses of cediranib, and/or increase repair of healthy, non-cancerous tissue during treatment of cancer using combination therapies.
FILED Tuesday, February 14, 2017
APPL NO 16/077720
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/502 (20130101)
A61K 31/517 (20130101) Original (OR) Class
A61K 39/39558 (20130101)
A61K 45/06 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322416 Wang et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
APPLICANT(S) REGENTS OF THE UNIVERSITY OF MINNESOTA (Minneapolis, Minnesota);  Emory University (Atlanta, Georgia)
ASSIGNEE(S) REGENTS OF THE UNIVERSITY OF MINNESOTA (Minneapolis, Minnesota)
INVENTOR(S) Zhengqiang Wang (Minneapolis, Minnesota);  Stefanos G. Sarafianos (Atlanta, Georgia)
ABSTRACT The invention provides a compound of formula I, formula II, or formula III: or a salt thereof, wherein R1-R10 have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful as HIV-1 CA-targeting molecules and as antiviral agents.
FILED Monday, April 05, 2021
APPL NO 17/222433
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/167 (20130101)
A61K 31/405 (20130101)
A61K 31/495 (20130101)
A61K 31/513 (20130101)
A61K 31/517 (20130101) Original (OR) Class
A61K 31/4178 (20130101)
A61K 31/4184 (20130101)
A61K 31/4439 (20130101)
A61K 45/06 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 31/18 (20180101)

Acyclic or Carbocyclic Compounds
C07C 233/88 (20130101)

Heterocyclic Compounds
C07D 209/34 (20130101)
C07D 235/02 (20130101)
C07D 239/54 (20130101)
C07D 239/96 (20130101)
C07D 241/08 (20130101)
C07D 401/12 (20130101)
C07D 403/12 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322425 Gendelman et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute on Aging (NIA)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute on Drug Abuse (NIDA)
National Institute of Mental Health (NIMH)
National Institute of Neurological Disorders and Stroke (NINDS)
APPLICANT(S) Board of Regents of the University of Nebraska (Lincoln, Nebraska)
ASSIGNEE(S)
INVENTOR(S) Howard Gendelman (Omaha, Nebraska);  Benson Edagwa (Omaha, Nebraska)
ABSTRACT The present invention provides prodrugs and methods of use thereof.
FILED Monday, May 24, 2021
APPL NO 17/303229
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/0019 (20130101)
A61K 9/1641 (20130101)
A61K 31/5365 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 31/18 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322427 LEE et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
APPLICANT(S) The Johns Hopkins University (Baltimore, Maryland)
ASSIGNEE(S)
INVENTOR(S) Seulki LEE (Ellicott City, Maryland);  Han Seok KO (Lutherville, Maryland);  Ted M. DAWSON (Baltimore, Maryland);  Martin G. POMPER (Baltimore, Maryland);  Donghoon KIM (Seoul, South Korea);  Yumin OH (Elkridge, Maryland);  Seung-Hwan KWON (Ellicott City, Maryland);  Yong Joo PARK (Suwon-si, Gyeonggi-do, South Korea)
ABSTRACT Provided herein are compositions comprising a RIPK2 inhibitor and methods of using the RIPK2 inhibitor for treating or preventing neurodegenerative diseases or disorders. Also provided herein are methods of screening or identifying therapeutic agents useful for treating or preventing neurodegenerative diseases or disorders.
FILED Friday, August 30, 2019
APPL NO 17/271966
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/44 (20130101)
A61K 31/504 (20130101)
A61K 31/519 (20130101)
A61K 31/529 (20130101)
A61K 31/4439 (20130101)
A61K 31/4709 (20130101)
A61K 31/5025 (20130101)
A61K 31/5377 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 25/28 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322441 Serhan et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) The Brigham and Women's Hospital, Inc. (Boston, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Charles N. Serhan (Needham, Massachusetts);  Jesmond P. Dalli (Brookline, Massachusetts);  Nan Chiang (Somerville, Massachusetts)
ABSTRACT A family of bioactive compounds identified in self-resolving inflammatory exudates is disclosed. The compounds give UV chromophores characteristic of a conjugated triene double bond system coupled to an auxochrome allylic to the triene. Further elucidation of the compounds reveals that they have a resolvin backbone conjugated to a peptide or amino acid moiety via an auxochrome. In some embodiments the auxochrome is sulfur. However, the auxochrome may be NH, CH2 or O. The compounds have potent bioactivity, in vitro, and, in vivo, including promoting resolution of infection, stimulating macrophage phagocytosis of bacteria; protecting tissues from neutrophil mediated damage, promoting tissue repair and regeneration and preventing or limiting second organ reflow/reperfusion damage.
FILED Tuesday, June 15, 2021
APPL NO 17/347842
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/557 (20130101) Original (OR) Class
A61K 47/64 (20170801)
A61K 47/542 (20170801)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322451 ALBERINI et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Mental Health (NIMH)
APPLICANT(S) New York University (New York, New York)
ASSIGNEE(S)
INVENTOR(S) Cristina Maria ALBERINI (New York, New York);  Dirk TRAUNER (New York, New York);  Christopher James ARP (The Woodlands, Texas)
ABSTRACT Provided are compositions and methods for memory enhancement, including recovery of memory impairment. The compositions and methods relate to mannose-6-phosphate and derivatives of mannose-6-phosphate. The methods relate to administration of M6P or derivatives thereof to individuals in whom memory enhancement is desired.
FILED Monday, August 12, 2019
APPL NO 17/267721
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/7028 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 25/28 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322454 Martin
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
APPLICANT(S) Baylor College of Medicine (Houston, Texas)
ASSIGNEE(S)
INVENTOR(S) James F. Martin (Houston, Texas)
ABSTRACT Embodiments of the disclosure encompass methods and compositions related to modulating the Hippo pathway to inhibit fibrosis and/or inflammation in a tissue and/or organ of an individual in need thereof. In specific embodiments, the disclosure concerns modulation of LATS1, LATS2, or both, such as providing to the individual an effective amount of one or more agents that increase the levels of LATS1, LATS2, or both in the individual. In specific cases, cardiac fibrosis is treated with effective levels of vector(s) comprising LATS1, LATS2, or both.
FILED Tuesday, April 23, 2019
APPL NO 17/049891
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/713 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 9/10 (20180101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/86 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322455 Blazar et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Allergy and Infectious Diseases (NIAID)
APPLICANT(S) Regents of the University of Minnesota (Minneapolis, Minnesota);  New York University (New York, New York)
ASSIGNEE(S)
INVENTOR(S) Bruce R. Blazar (Golden Valley, Minnesota);  Cameron McDonald-Hyman (St. Paul, Minnesota);  Michael Dustin (New York, New York);  Sudha Kumari (New York, New York);  Tom Neubert (New York, New York);  James Muller (New York, New York);  Keli Hippen (Minneapolis, Minnesota)
ABSTRACT Methods and compositions for increasing the suppressive function of regulatory T-cells (Tregs) are provided.
FILED Friday, April 23, 2021
APPL NO 17/238773
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/7105 (20130101) Original (OR) Class
A61K 35/17 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 5/0637 (20130101)
C12N 15/1137 (20130101)
C12N 15/1138 (20130101)
C12N 2310/14 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322456 Juliano et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Center for Advancing Translational Sciences (NCATS)
National Cancer Institute (NCI)
APPLICANT(S) The University of North Carolina at Chapel Hill (Chapel Hill, North Carolina)
ASSIGNEE(S)
INVENTOR(S) Rudolph L. Juliano (Chapel Hill, North Carolina);  Silvia M. Kreda (Mebane, North Carolina);  Ling Wang (Chapel Hill, North Carolina);  Xin Ming (Chapel Hill, North Carolina);  Lindsey Ingerman James (Chapel Hill, North Carolina);  Ranathunga Arachchillage Yamuna Kumari Ariyarathna (Carrboro, North Carolina)
ABSTRACT This disclosure is directed to methods, compounds and compositions for delivering nucleic acids to a cell of interest. In particular, it provides salts that are particularly effective in delivering nucleic acids to cells in the lung for disorders such as cystic fibrosis (CF).
FILED Monday, June 21, 2021
APPL NO 17/352716
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/4184 (20130101)
A61K 31/4985 (20130101)
A61K 31/7125 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 11/00 (20180101)

Heterocyclic Compounds
C07D 235/30 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/113 (20130101)
C12N 2310/314 (20130101)
C12N 2310/3233 (20130101)
C12N 2320/31 (20130101)
C12N 2320/33 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322457 Jain et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Eye Institute (NEI)
APPLICANT(S) Advaite LLC. (Chicago, Illinois)
ASSIGNEE(S) Advaite LLC. (Chicago, Illinois)
INVENTOR(S) Sandeep Jain (Oak Park, Illinois);  Karthik Musunuri (Chester Springs, Pennsylvania)
ABSTRACT The present invention provides an ophthalmic formulation consisting essentially of one or more pharmaceutically acceptable excipients; a pharmaceutically active compound that is capable of reducing the amount of inflammatory neutrophil product on the ocular surface; and optionally a second pharmaceutically active compound selected from the group consisting of a steroid, an anti-inflammatory agent, a mucolytic agent and a combination thereof. In particular, the present invention provides an ophthalmic formulation where the pharmaceutically active compound is capable of treating a clinical condition selected from the group consisting of inflammatory and immunological ocular surface disease that can cause symptoms of ocular discomfort, mucocellular aggregates/debris in tear film, symblepheron formation, fornix foreshortening, eyelid margin/conjunctival keratinization, corneal neovascularization/pannus, subconjunctival fibrosis, and herpetic eye disease. The present invention also provides a method for diagnosing or monitoring an ocular surface disease.
FILED Monday, June 28, 2021
APPL NO 17/361310
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/727 (20130101) Original (OR) Class
A61K 45/06 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 27/02 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322462 NEWMAN et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
APPLICANT(S) CALIFORNIA INSTITUTE OF TECHNOLOGY (Pasadena, California);  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, California)
ASSIGNEE(S)
INVENTOR(S) Dianne K. NEWMAN (Pasadena, California);  Melanie A. SPERO (Pasadena, California);  Manuela MARTINS-GREEN (Riverside, California);  John D. COATES (Walnut Creek, California)
ABSTRACT Wound healing matrices, compounds, compositions, methods and systems comprising one or more chlorates, one or more chlorites, one or more antibiotics, one or more other antimicrobials, and/or one or more wound healing agents.
FILED Monday, April 19, 2021
APPL NO 17/234656
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/06 (20130101)
A61K 9/0014 (20130101)
A61K 31/43 (20130101)
A61K 31/198 (20130101)
A61K 31/355 (20130101)
A61K 31/424 (20130101)
A61K 31/427 (20130101)
A61K 31/431 (20130101)
A61K 31/496 (20130101)
A61K 31/545 (20130101)
A61K 31/546 (20130101)
A61K 31/4164 (20130101)
A61K 31/7036 (20130101)
A61K 31/7056 (20130101)
A61K 33/00 (20130101) Original (OR) Class
A61K 33/14 (20130101)
A61K 33/18 (20130101)
A61K 38/1808 (20130101)
A61K 38/1841 (20130101)
A61K 38/1858 (20130101)
A61K 38/1866 (20130101)
A61K 38/4886 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 17/02 (20180101)
A61P 31/02 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322472 Medin et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) The Medical College of Wisconsin, Inc. (Milwaukee, Wisconsin)
ASSIGNEE(S)
INVENTOR(S) Jeffrey A. Medin (Shorewood, Wisconsin);  Daniel H. Fowler (Milwaukee, Wisconsin);  Murtaza S. Nagree (Milwaukee, Wisconsin);  Tania Felizardo (Milwaukee, Wisconsin)
ABSTRACT The present disclosure provides methods of treating lysosomal storage disorders. The method comprises producing vector-transduced T-Rapa cells that express a transgene of interest and administering the cells to a patient in need thereof.
FILED Monday, April 29, 2019
APPL NO 17/050949
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 35/17 (20130101) Original (OR) Class
A61K 38/47 (20130101)
A61K 38/443 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 43/00 (20180101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 5/0636 (20130101)
C12N 15/86 (20130101)

Enzymes
C12Y 101/01205 (20130101)
C12Y 302/01022 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322484 SUSSMAN et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
APPLICANT(S) SAN DIEGO STATE UNIVERSITY (SDSU) FOUNDATION, DBA SAN DIEGO STATE UNIVERSITY RESE (San Diego, California)
ASSIGNEE(S)
INVENTOR(S) Mark A. SUSSMAN (San Diego, California);  Megan M. MONSANTO (San Diego, California)
ABSTRACT In alternative embodiments, provided are macrocellular structures or artificially configured plurality of cells, the so-called “cardioclusters” as provided herein, comprising: a core region or cluster: comprising a plurality of first cardiac stem cells or cardiac progenitor cells; and a second region or a peripheral region positioned at least partially surrounding the outer surface of the core region or cluster, or at least partially around the core region or cluster, comprising a plurality of second cardiac stem cells; and methods for making and using them. In alternative embodiments, the second cardiac progenitor cells are cardiac progenitor cells or cardiac stem cells, mesenchymal stem cells or mesenchymal progenitor cells, or endothelial progenitor cells or endothelial stem cells.
FILED Tuesday, June 15, 2021
APPL NO 17/348038
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 35/28 (20130101)
A61K 35/34 (20130101) Original (OR) Class
A61K 35/44 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 5/0657 (20130101)
C12N 2502/28 (20130101)
C12N 2502/1352 (20130101)
C12N 2513/00 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322507 Langer et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
APPLICANT(S) Massachusetts Institute of Technology (Cambridge, Massachusetts);  The General Hospital Corporation (Boston, Massachusetts);  The Brigham and Women's Hospital, Inc. (Boston, Massachusetts)
ASSIGNEE(S) Massachusetts Institute of Technology (Cambridge, Massachusetts);  The General Hospital Corporation (Boston, Massachusetts);  The Brigham and Women's Hospital, Inc. (Boston, Massachusetts)
INVENTOR(S) Robert S. Langer (Newton, Massachusetts);  Carlo Giovanni Traverso (Newton, Massachusetts);  Ameya R. Kirtane (Somerville, Massachusetts);  Daniel Cahill (Winchester, Massachusetts);  Ganesh Shankar (Brookline, Massachusetts)
ABSTRACT Provided herein are pharmaceutical compositions for local administration of metabolic inhibitors, methods of locally administering such compositions, and rapid diagnostic methods for identifying mutant allele during the course of a surgical procedure.
FILED Wednesday, June 30, 2021
APPL NO 17/363897
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/0019 (20130101)
A61K 9/51 (20130101)
A61K 38/005 (20130101) Original (OR) Class
A61K 47/6937 (20170801)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 9/0006 (20130101)
C12N 9/1077 (20130101)

Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6858 (20130101)
C12Q 1/6886 (20130101)
C12Q 2600/106 (20130101)
C12Q 2600/156 (20130101)

Enzymes
C12Y 101/01041 (20130101)
C12Y 204/02012 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322510 MENDELOWITZ et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
APPLICANT(S) THE GEORGE WASHINGTON UNIVERSITY (Washington, District of Columbia)
ASSIGNEE(S)
INVENTOR(S) David MENDELOWITZ (Vienna, Virginia);  Vivek JAIN (McLean, Virginia);  Heather JAMESON (Lynnfield, Massachusetts);  Jay Shawn KIMBRO (Stevensville, Maryland)
ABSTRACT The present disclosure provides methods for treating obstructive sleep apnea (OSA) and OSA induced cardiorespiratory diseases. The disclosure provides, inter alia, methods for treating or alleviating: OSA or OSA induced hypertension, cardiac arrhythmias, myocardial ischemia, sudden cardiac death or stroke, by administering oxytocin. The disclosure further provides methods for improving sleep satisfaction in OSA patients by administering oxytocin.
FILED Wednesday, November 18, 2020
APPL NO 16/951048
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/0043 (20130101)
A61K 38/095 (20190101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322512 Marshall
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
APPLICANT(S) CALDER BIOSCIENCES INC. (New York, New York)
ASSIGNEE(S)
INVENTOR(S) Christopher Patrick Marshall (New York, New York)
ABSTRACT The present invention provides methods of making engineered viral proteins and protein complexes that are useful as vaccine immunogens, engineered viral proteins and protein complexes made using such methods, and pharmaceutical compositions comprising such engineered viral proteins and protein complexes. Such engineered viral proteins and protein complexes may comprise one or more cross-links that stabilize the conformation of an antibody epitope, such as a quaternary neutralizing antibody, and may exhibit an enhanced ability to elicit a protective immune response when administered to a subject as a component of a vaccine.
FILED Monday, November 30, 2020
APPL NO 17/107067
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 38/162 (20130101) Original (OR) Class

Peptides
C07K 14/005 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 7/00 (20130101)
C12N 2740/16051 (20130101)
C12N 2740/16122 (20130101)
C12N 2740/16134 (20130101)

Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture
C12P 21/00 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/56988 (20130101)

Technologies for Adaptation to Climate Change
Y02A 50/30 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322522 SUSSMAN et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute on Aging (NIA)
APPLICANT(S) SAN DIEGO STATE UNIVERSITY (SDSU) FOUNDATION (San Diego, California)
ASSIGNEE(S)
INVENTOR(S) Mark A SUSSMAN (San Diego, California);  John A. MURASKI (San Clemente, California)
ABSTRACT The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding the serine/threonine kinase PIM-1, and methods for making and using them; including methods for inducing cellular proliferation, and protecting cardiac cells from hypoxia and cellular apoptosis. The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding PIM-1, and methods for enhancing the regenerative potential of stem cells in the heart.
FILED Wednesday, March 31, 2021
APPL NO 17/219749
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 35/28 (20130101)
A61K 38/45 (20130101) Original (OR) Class
A61K 2035/124 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 9/12 (20130101)
C12N 15/86 (20130101)

Enzymes
C12Y 207/11 (20130101)
C12Y 207/12 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322524 Qi
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
NIH Office of the Director (NIHOD)
National Institute of Neurological Disorders and Stroke (NINDS)
APPLICANT(S) CASE WESTERN RESERVE UNIVERSITY (Cleveland, Ohio)
ASSIGNEE(S)
INVENTOR(S) Xin Qi (Cleveland, Ohio)
ABSTRACT A method of inhibiting aberrant ATAD3A activation and/or oligomerization in mitochondria of a cell includes administering to the cell a therapeutic agent that inhibits binding or complexing of ATAD3A with Drp1 in the mitochondria of the cell.
FILED Wednesday, July 31, 2019
APPL NO 17/264923
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 38/46 (20130101) Original (OR) Class
A61K 38/162 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 25/28 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322536 Compans et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
APPLICANT(S) Emory University (Atlanta, Georgia)
ASSIGNEE(S)
INVENTOR(S) Richard Compans (Atlanta, Georgia);  Elena Vassilieva (Roswell, Georgia)
ABSTRACT This disclosure relates to boosting the immunogenicity of vaccines using an adjuvant combination comprising a saponin and an agonist of the intracellular stimulator of interferon genes pathway. In certain embodiments, the vaccine comprises an inactivated virus, attenuated virus, virus protein, virus like particle, or virosome. In certain embodiments, the human subject is of advanced age or elderly. In certain embodiments, the viral vaccine is an influenza vaccine.
FILED Friday, April 16, 2021
APPL NO 17/233333
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 39/39 (20130101)
A61K 39/145 (20130101) Original (OR) Class
A61K 2039/55577 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 31/16 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322548 YUNG et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
APPLICANT(S) THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (Boston, Massachusetts)
ASSIGNEE(S) THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (Boston, Massachusetts)
INVENTOR(S) Lai-Ming YUNG (Jamison, Pennsylvania);  Paul B. YU (Boston, Massachusetts)
ABSTRACT The technology described herein is directed to methods and compositions for the treatment of hypertension, e.g. pulmonary arterial hypertension, relating to inhibition of TGFβ1, TGFβ3, and/or GDF-15.
FILED Monday, April 26, 2021
APPL NO 17/239983
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 39/3955 (20130101) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 11/00 (20180101)

Peptides
C07K 16/22 (20130101)
C07K 2319/30 (20130101)
C07K 2319/32 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322557 Burdick et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Dental and Craniofacial Research (NIDCR)
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Materials Research (DMR)
APPLICANT(S) The Trustees of the University of Pennsylvania (Philadelphia, Pennsylvania)
ASSIGNEE(S)
INVENTOR(S) Jason Alan Burdick (Philadelphia, Pennsylvania);  Sujata Sahoo (Wilmington, Delaware);  Cindy Chung (Parsippany, New Jersey)
ABSTRACT Provided are polysaccharide compositions capable of controllable hydrolytic degradation and suitable for controlled release of therapeutic agents. Also provided are methods for synthesizing such compositions and a variety of applications in which the compositions may be used.
FILED Wednesday, June 23, 2021
APPL NO 17/355660
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 47/36 (20130101) Original (OR) Class

Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles
A61L 27/18 (20130101)
A61L 27/52 (20130101)
A61L 27/54 (20130101)
A61L 27/58 (20130101)
A61L 27/3834 (20130101)
A61L 2300/414 (20130101)
A61L 2300/426 (20130101)
A61L 2300/442 (20130101)
A61L 2300/604 (20130101)
A61L 2430/06 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 5/0012 (20130101)
C12N 5/0663 (20130101)
C12N 2533/40 (20130101)
C12N 2533/80 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322559 Kessler et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
U.S. Army Medical Research and Materiel Command (USAMRMC)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
APPLICANT(S) University of Utah Research Foundation (Salt Lake City, Utah)
ASSIGNEE(S)
INVENTOR(S) Julian Kessler (Salt Lake City, Utah);  Michael S. Yu (Salt Lake City, Utah);  Yang Li (Salt Lake City, Utah)
ABSTRACT Disclosed are peptide conjugates comprising an active agent, a spacer moiety, and a dimeric collagen hybridizing peptide comprising a first and second collagen hybridizing peptide, a linker; and a branch point, wherein the first and second collagen hybridizing peptides comprise the sequence of at least (GXY)n, wherein G is glycine, wherein X and Y are any amino acid, and wherein n is any number between 3 and 12. Also disclosed are methods of detecting denatured collagen in a sample comprising contacting a composition comprising any one of the disclosed peptide conjugates to a sample, wherein the active agent comprises a therapeutic agent, and detecting the presence or absence of binding of the peptide conjugate to denatured collagen, the presence of binding indicating the presence of denatured collagen in the sample. Also disclosed are methods of treating a disease or injury involving collagen damage comprising administering to a subject having a disease or injury involving collagen damage any one of the disclosed peptide conjugates.
FILED Wednesday, February 24, 2021
APPL NO 17/184289
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 47/64 (20170801)
A61K 47/65 (20170801)
A61K 47/641 (20170801) Original (OR) Class

Peptides
C07K 14/78 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/6887 (20130101)
G01N 2333/78 (20130101)
G01N 2500/20 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322569 BUCHMAN et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) THE REGENTS OF THE UNIVERSITY OF MICHIGAN (Ann Arbor, Michigan);  THE UNIVERSITY OF KANSAS (Lawrence, Kansas)
ASSIGNEE(S)
INVENTOR(S) Steven R. BUCHMAN (Ann Arbor, Michigan);  Mark COHEN (Ann Arbor, Michigan);  Alexis DONNEYS (Ann Arbor, Michigan);  Noah NELSON (Ann Arbor, Michigan);  Laird FORREST (Lawrence, Kansas);  Ti ZHANG (Lawrence, Kansas);  Qiuhong YANG (Lawrence, Kansas)
ABSTRACT The present invention relates to novel therapeutic nanoparticles. In particular, the present invention is directed to nanoparticles associated (e.g., complexed, conjugated, encapsulated, absorbed, adsorbed, admixed) with angiogenesis-activating-agents, methods of synthesizing the same, devices or compositions comprising such nanoparticles, as well as systems and methods utilizing the nanoparticles (e.g., in therapeutic settings for enhancing and/or activating angiogenesis at targeted tissue region).
FILED Tuesday, June 22, 2021
APPL NO 17/354514
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/5169 (20130101)
A61K 31/16 (20130101)
A61K 47/61 (20170801)
A61K 47/6939 (20170801) Original (OR) Class

Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles
A61L 27/20 (20130101)
A61L 27/50 (20130101)
A61L 27/54 (20130101)
A61L 27/58 (20130101)
A61L 2300/412 (20130101)
A61L 2300/624 (20130101)
A61L 2300/626 (20130101)
A61L 2400/12 (20130101)
A61L 2430/02 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 19/00 (20180101)
A61P 19/08 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322622 Miller et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Center for Advancing Translational Sciences (NCATS)
APPLICANT(S) The Johns Hopkins University (Baltimore, Maryland)
ASSIGNEE(S)
INVENTOR(S) Lloyd S. Miller (Ellicott City, Maryland);  Hai-Quan Mao (Baltimore, Maryland);  Alyssa Ashbaugh (Baltimore, Maryland);  Xuesong Jiang (Lutherville-Timonium, Maryland);  Jesse Zheng (Johns Creek, Georgia);  Sashank Reddy (Baltimore, Maryland);  Bart Kachniarz (Baltimore, Maryland)
ABSTRACT The presently disclosed subject matter provides a composite film which allows for the co-delivery of two or more bioactive agents with independent control of loading level and release profile for each bioactive agent, bandages and/or medical devices coated with the composite film, methods for preparing the composite film, and use of the composite film for treating infections or preventing biofilm formation in a subject.
FILED Friday, August 16, 2019
APPL NO 17/267714
CURRENT CPC
Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles
A61L 15/26 (20130101)
A61L 15/44 (20130101) Original (OR) Class
A61L 15/46 (20130101)
A61L 15/425 (20130101)
A61L 2300/406 (20130101)
A61L 2400/12 (20130101)
A61L 2420/02 (20130101)

Working-up; General Processes of Compounding; After-treatment Not Covered by Subclasses C08B, C08C, C08F, C08G or C08H
C08J 5/18 (20130101)

Use of Inorganic or Non-macromolecular Organic Substances as Compounding Ingredients
C08K 7/02 (20130101)
C08K 2201/011 (20130101)

Compositions of Macromolecular Compounds
C08L 67/04 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322632 Bertassoni et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Dental and Craniofacial Research (NIDCR)
APPLICANT(S) OREGON HEALTH and SCIENCE UNIVERSITY (Portland, Oregon)
ASSIGNEE(S)
INVENTOR(S) Luiz E. Bertassoni (Portland, Oregon);  Avathamsa Athirasala (Portland, Oregon);  Anthony Tahayeri (Sherwood, Oregon)
ABSTRACT A modular synthetic tissue-graft scaffold (10) includes one or more nominally identical scaffold cages (12) configured to facilitate regrowth of tissue of an organism in and around the scaffold cages. Each scaffold cage comprises a volumetric enclosure (18) bounded by a perforated wall structure (40). A recess (24) formed at one end of the volumetric enclosure defines an inner stepped coupling surface. An annular raised portion (26) positioned at the other end of the volumetric enclosure forms an outwardly projecting stepped seating surface sized to form a complementary matable surface to the inner stepped coupling surface for whenever an inner stepped coupling surface of another one of the cages is placed on the outer stepped seating surface of the scaffold cage. Corridors (46) extending through the perforated wall structure and communicating with passageways (54) within the volumetric enclosure enable migration of material within and out of the scaffold cage.
FILED Friday, July 26, 2019
APPL NO 17/263873
CURRENT CPC
Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles
A61L 27/12 (20130101) Original (OR) Class
A61L 27/52 (20130101)
A61L 27/105 (20130101)
A61L 2430/02 (20130101)

Shaping or Joining of Plastics; Shaping of Material in a Plastic State, Not Otherwise Provided For; After-treatment of the Shaped Products, e.g Repairing
B29C 64/124 (20170801)

Additive Manufacturing, i.e Manufacturing of Three-dimensional [3-D] Objects by Additive Deposition, Additive Agglomeration or Additive Layering, e.g by 3-d Printing, Stereolithography or Selective Laser Sintering
B33Y 70/10 (20200101)
B33Y 80/00 (20141201)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 5/0691 (20130101)
C12N 2501/135 (20130101)
C12N 2501/155 (20130101)
C12N 2501/165 (20130101)
C12N 2513/00 (20130101)
C12N 2533/14 (20130101)
C12N 2533/18 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322647 Dumont et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
APPLICANT(S) REGENTS OF THE UNIVERSITY OF MICHIGAN (Ann Arbor, Michigan)
ASSIGNEE(S)
INVENTOR(S) Courtney M. Dumont (Ypsilanti, Michigan);  Mitchell A. Carlson (Ann Arbor, Michigan);  Lonnie D. Shea (Ann Arbor, Michigan)
ABSTRACT Biomaterial implants and methods for facilitating tissue repair and regeneration are provided herein. The implants may include organized hydrogel structures. Such implants are fabricated using a 2-phase polymerization technique, wherein hydrogel-based microspheres are formed as an intermediate product of the 2-phase polymerization technique. The implants of various embodiments provide an aligned substrate to guide tissue regeneration and can be cut or formed to conform to the size and shape of an injury.
FILED Friday, April 26, 2019
APPL NO 17/050876
CURRENT CPC
Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles
A61L 27/18 (20130101)
A61L 27/52 (20130101) Original (OR) Class
A61L 27/56 (20130101)
A61L 2430/32 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322648 Rivnay et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
APPLICANT(S) Northwestern University (Evanston, Illinois)
ASSIGNEE(S)
INVENTOR(S) Jonathan Rivnay (Chicago, Illinois);  Anthony J. Petty (Evanston, Illinois);  Cheng Sun (Wilmette, Illinois);  Henry Oliver T. Ware (Evanston, Illinois)
ABSTRACT Biocompatible polymer hydrogel composite structures, methods of making the composite structures, and methods of using the composite structures as scaffolds for biological tissue growth and regeneration are provided. The methods for making the composite structures start with a porous high resolution three-dimensional hydrogel scaffold in which polymer precursors are infused and then polymerized in situ to form a water-soluble, electrically conducting polymer that is bonded to and/or entrapped within the hydrogel.
FILED Wednesday, April 14, 2021
APPL NO 17/230195
CURRENT CPC
Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles
A61L 27/44 (20130101)
A61L 27/52 (20130101) Original (OR) Class
A61L 27/56 (20130101)
A61L 27/3695 (20130101)

Macromolecular Compounds Obtained by Reactions Only Involving Carbon-to-carbon Unsaturated Bonds
C08F 20/20 (20130101)

Macromolecular Compounds Obtained Otherwise Than by Reactions Only Involving Unsaturated Carbon-to-carbon Bonds
C08G 61/126 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322652 PURCELL et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
APPLICANT(S) THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (Philadelphia, Pennsylvania)
ASSIGNEE(S)
INVENTOR(S) Brendan Patrick PURCELL (Brooklyn, New York);  Jason Alan BURDICK (Philadelphia, Pennsylvania);  Leo L. WANG (Philadelphia, Pennsylvania)
ABSTRACT The invention concerns methods of delivering a hydrogel to the heart, comprising: introducing a hydrogel composition into a subject, said hydrogel comprising components mixed prior to introduction; the introducing being performed such that the hydrogel composition resides between the epicardium and the pericardium of the subject. In some embodiments, the injection is performed using a syringe or catheter.
FILED Friday, August 30, 2019
APPL NO 17/271778
CURRENT CPC
Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles
A61L 31/16 (20130101) Original (OR) Class
A61L 31/18 (20130101)
A61L 31/042 (20130101)
A61L 31/145 (20130101)
A61L 2300/80 (20130101)
A61L 2300/232 (20130101)
A61L 2300/424 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322668 Oberstar et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
APPLICANT(S) Wisconsin Alumni Research Foundation (Madison, Wisconsin)
ASSIGNEE(S)
INVENTOR(S) Erick Louis Oberstar (Verona, Wisconsin);  Michael Antonio Speidel (Madison, Wisconsin)
ABSTRACT Aspects of the disclosure are directed to methods and/or apparatuses involving modifying flow and/or concentration of an agent being injected for characterizing a vascular system. As may be implemented in accordance with one or more embodiments, a liquid including an agent is injected into a vascular system, by dynamically modulating a flow rate of the agent being injected over a range of flow rates. The vascular system is characterized based on a response of the vascular system to the dynamic modulation. In some implementations, such an approach involves using an injector that operates to separately control the rate at which an agent and other liquid such as saline are injected. These approaches can be implemented with modulation schemes using one or more of a variety of functions.
FILED Wednesday, August 07, 2019
APPL NO 16/534725
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 5/0263 (20130101)
A61B 6/481 (20130101)
A61B 6/507 (20130101)

Devices for Introducing Media Into, or Onto, the Body; Devices for Transducing Body Media or for Taking Media From the Body; Devices for Producing or Ending Sleep or Stupor
A61M 5/007 (20130101) Original (OR) Class
A61M 5/1408 (20130101)
A61M 5/1452 (20130101)
A61M 2205/3334 (20130101)
A61M 2230/04 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322771 Wagner et al.
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
Department of the Army (DOA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
APPLICANT(S) Highland Instruments, Inc. (Somerville, Massachusetts)
ASSIGNEE(S) Highland Instruments, Inc. (Somerville, Massachusetts)
INVENTOR(S) Timothy Andrew Wagner (Somerville, Massachusetts);  Uri Tzvi Eden (Somerville, Massachusetts)
ABSTRACT The invention generally relates to methods of stimulating tissue based upon filtering properties of the tissue. In certain aspects, the invention provides methods for stimulating tissue that involve analyzing at least one filtering property of a region of at least one tissue, and providing a dose of energy to the at least one region of tissue based upon results of the analyzing step.
FILED Monday, April 19, 2021
APPL NO 17/233762
CURRENT CPC
Physical Therapy Apparatus, e.g Devices for Locating or Stimulating Reflex Points in the Body; Artificial Respiration; Massage; Bathing Devices for Special Therapeutic or Hygienic Purposes or Specific Parts of the Body
A61H 23/0236 (20130101)
A61H 23/0245 (20130101)

Electrotherapy; Magnetotherapy; Radiation Therapy; Ultrasound Therapy
A61N 1/36025 (20130101) Original (OR) Class
A61N 1/36082 (20130101)
A61N 5/02 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322775 Grill et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
APPLICANT(S) Duke University (Durham, North Carolina)
ASSIGNEE(S)
INVENTOR(S) Warren M. Grill (Durham, North Carolina);  Isaac Cassar (Durham, North Carolina);  Nathan Titus (Durham, North Carolina)
ABSTRACT Systems and methods for determining optimal temporal patterns of neural stimulation are disclosed. According to an aspect, a method includes selecting a temporal pattern for neural stimulation. The method also includes determining a mutation type for altering a pattern of pulses of the temporal pattern. The method also includes identifying a location within the pattern of pulses of the temporal pattern to alter based on the determined mutation type. The method further includes altering the pattern of pulses of the temporal pattern based on the identified location and mutation type for application of the altered temporal pattern to a subject.
FILED Tuesday, June 22, 2021
APPL NO 17/355092
CURRENT CPC
Electrotherapy; Magnetotherapy; Radiation Therapy; Ultrasound Therapy
A61N 1/025 (20130101)
A61N 1/36139 (20130101)
A61N 1/36178 (20130101) Original (OR) Class
A61N 1/36185 (20130101)
A61N 1/37235 (20130101)

Healthcare Informatics, i.e Information and Communication Technology [ICT] Specially Adapted for the Handling or Processing of Medical or Healthcare Data
G16H 20/40 (20180101)
G16H 50/50 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322788 Liu et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) Mayo Foundation for Medical Education and Research (Rochester, Minnesota)
ASSIGNEE(S)
INVENTOR(S) Wei Liu (Scottsdale, Arizona);  Jie Shan (Scottsdale, Arizona)
ABSTRACT Robust optimization systems and methods are provided for intensity modulated proton therapy (IMPT) that may be deployed in a clinically practical way to enable users to control the balance between nominal plan quality and plan robustness in a user-defined way. The method may include a normalized dose interval volume histogram (NDIVH)-based robust optimization, where the normalized dose interval (NDI) is calculated for each voxel considering dose variations in the face of uncertainties. It is then used to create a NDIVH. The area under this NDIVH curve may then be used to quantify plan robustness. By using normalized dose interval volume constraints (NDIVC) to control the shape of the NDIVH curves, plan robustness may be adjusted. The tradeoff between nominal plan quality and plan robustness can be modified in a user-defined way by adjusting positions of the NDIVCs on the NDIVH curves.
FILED Wednesday, August 28, 2019
APPL NO 17/271751
CURRENT CPC
Electrotherapy; Magnetotherapy; Radiation Therapy; Ultrasound Therapy
A61N 5/1031 (20130101) Original (OR) Class
A61N 2005/1087 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322796 Hubbard et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Center for Advancing Translational Sciences (NCATS)
APPLICANT(S) The University of North Carolina at Chapel Hill (Chapel Hill, North Carolina)
ASSIGNEE(S)
INVENTOR(S) Devin Kerry Hubbard (Chapel Hill, North Carolina);  Nicole Lewis Wiley (Pittsboro, North Carolina);  Ethan John Smith (Garner, North Carolina)
ABSTRACT Face mask devices, systems, and methods of use include a frame that holds a suitable filter material, including a face mask, over the user's face to form a seal and prevent unfiltered air from being inhaled through the nose or mouth of the user without first passing through the filter material. The frame is removably attached over the users face by, for example, adjustable straps. The frame may be adjustable in size to be suitable for use on user's having different facial sizes, shapes, and/or geometries.
FILED Friday, April 16, 2021
APPL NO 17/232596
CURRENT CPC
Outerwear; Protective Garments; Accessories
A41D 13/1161 (20130101)

Devices, Apparatus or Methods for Life-saving
A62B 7/10 (20130101) Original (OR) Class
A62B 18/02 (20130101)
A62B 18/082 (20130101)
A62B 18/084 (20130101)
A62B 23/025 (20130101)

Separation
B01D 39/16 (20130101)
B01D 39/083 (20130101)
B01D 46/0005 (20130101)
B01D 2239/0622 (20130101)
B01D 2239/0627 (20130101)
B01D 2279/65 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322976 NG Pitti et al.
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
Department of Health and Human Services (HHS)
Food and Drug Administration (FDA)
APPLICANT(S) President and Fellows of Harvard College (Cambridge, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Carlos Francisco NG Pitti (Jamaica Plain, Massachusetts);  Ulri Nicole Lee (Seattle, Washington);  Richard Novack (Boston, Massachusetts);  Olivier Yves Frederic Henry (Brookline, Massachusetts);  Remco Franciscus Peter Van Erp (Sint Anthonis, Netherlands);  Donald E. Ingber (Boston, Massachusetts)
ABSTRACT A fluidic device includes a fluidic layer, a capture material, and an electronics layer, the fluidic layer includes a main channel and a pair of sample channels fluidly coupled to the main channel. The pair of sample channels is configured to receive and introduce a sample material into the device. The sample material includes an analyte. The capture material is positioned in a portion of the main channel that is spaced from the pair of sample channels. The capture material has a three-dimensional matrix of receptors therein configured to bond with the analyte. The capture material has a length that is associated with a dynamic range of the fluidic device and a cross-sectional area that is associated with a sensitivity of the fluidic device. The electronics layer includes electrodes configured to measure an electrical resistance through a portion of the capture material.
FILED Wednesday, March 14, 2018
APPL NO 16/494230
CURRENT CPC
Chemical or Physical Laboratory Apparatus for General Use
B01L 3/502707 (20130101) Original (OR) Class
B01L 3/502715 (20130101)
B01L 2300/069 (20130101)
B01L 2300/0645 (20130101)
B01L 2300/0867 (20130101)
B01L 2300/0896 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 27/08 (20130101)
G01N 33/48707 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210323045 Lujan et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
National Science Foundation (NSF)
APPLICANT(S) BOISE STATE UNIVERSITY (Boise, Idaho)
ASSIGNEE(S)
INVENTOR(S) Trevor Lujan (Boise, Idaho);  Sean Nelson (Meridian, Idaho);  Madison Wale (Boise, Idaho);  Danielle Siegel (Boise, Idaho);  Jaremy Creechley (Laramie, Wyoming)
ABSTRACT A system may include a blade die, a first clamping caul positioned on a first side of the blade die, and a second clamping caul positioned on a second side of the blade die. A molding surface of the blade die and a molding surface of the first clamping caul may be configured to bend a first interchangeable blade positioned therebetween into a first shape in response to a first compression force. A second molding surface of the blade die and a molding surface of the second clamping caul may be configured to bend a second interchangeable blade positioned therebetween into a second shape in response to a second compression force.
FILED Monday, April 19, 2021
APPL NO 17/234606
CURRENT CPC
Working or Processing of Sheet Metal or Metal Tubes, Rods or Profiles Without Essentially Removing Material; Punching Metal
B21D 28/34 (20130101) Original (OR) Class
B21D 43/003 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210323919 SRIDHAR et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
National Institute on Minority Health and Health Disparities (NIMHD)
Research Centers in Minority Institutions Program (RCMI)
APPLICANT(S) Xavier University of Louisiana (New Orleans, Louisiana)
ASSIGNEE(S)
INVENTOR(S) Jayalakshmi SRIDHAR (New Orleans, Louisiana);  Melyssa BRATTON (New Orleans, Louisiana);  Rajesh KOMATI (Thibodaux, Louisiana)
ABSTRACT The present disclosure relates to compounds that act as protein kinase inhibitors, especially RPS6K1 and the synthesis of the same. Further, the present disclosure teaches the utilization of such compounds in a treatment for proliferative diseases, including cancer, particularly breast cancer, and especially ER+ and/or HER2+ breast cancer, prostate cancer, lung cancer, and metastatic cancer.
FILED Friday, April 16, 2021
APPL NO 17/232469
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 45/06 (20130101)

Heterocyclic Compounds
C07D 209/56 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210323926 Zhang et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) Purdue Research Foundation (West Lafayette, Indiana)
ASSIGNEE(S) Purdue Research Foundation (West Lafayette, Indiana)
INVENTOR(S) Zhong-Yin Zhang (West Lafayette, Indiana);  Jianping Lin (West Lafayette, Indiana)
ABSTRACT The present disclosure relates to novel lymphoid-specific tyrosine phosphatase (LYP, encoded by the PTPN22 gene) inhibitors, and to methods of making and using the novel LYP inhibitors. Thus, the compounds according to the disclosure may be used for treating diseases or disorders associated with PTPN22 genetic polymorphism, including type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosis, Graves' disease, Addison's disease, vitiligo, juvenile arthritis, Hashimoto thyroiditis, and other rarer diseases. Furthermore, these LYP inhibitors may be served for a novel class of cancer immunotherapy. The compounds can be injected or orally administered.
FILED Friday, February 05, 2021
APPL NO 17/168212
CURRENT CPC
Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

Heterocyclic Compounds
C07D 215/56 (20130101) Original (OR) Class
C07D 401/12 (20130101)
C07D 405/12 (20130101)
C07D 409/06 (20130101)
C07D 471/04 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210323928 MALONEY et al.
FUNDED BY
Department of Health and Human Services (HHS)
APPLICANT(S) THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (Bethesda, Maryland);  VANDERBILT UNIVERSITY (Nashville, Tennessee);  The UAB Research Foundation (Birmingham, Alabama);  The Trustees of the University of Pennsylvania (Philadelphia, Pennsylvania)
ASSIGNEE(S)
INVENTOR(S) David J. MALONEY (Point of Rocks, Maryland);  Alex Gregory WATERSON (Nashville, Tennessee);  Ganesh Rai BANTUKALLU (Arlington, Virginia);  Kyle Ryan BRIMACOMBE (Bethesda, Maryland);  Plamen CHRISTOV (Nashville, Tennessee);  Chi V. DANG (Penn Valley, Pennsylvania);  Victor DARLEY-USMAR (Birmingham, Alabama);  Xin HU (Frederick, Maryland);  Ajit JADHAV (Chantilly, Virginia);  Somnath JANA (Nashville, Tennessee);  Kwangho KIM (Nashville, Tennessee);  Jennifer L. KOUZNETSOVA (Silver Spring, Maryland);  William J. MOORE (Hagerstown, Maryland);  Bryan T. MOTT (College Park, Maryland);  Leonard M. NECKERS (Bethesda, Maryland);  Anton SIMEONOV (Bethesda, Maryland);  Gary Allen SULIKOWSKI (Nashville, Tennessee);  Daniel Jason URBAN (Rockville, Maryland);  Shyh Ming YANG (Doylestown, Pennsylvania)
ABSTRACT Provided is a compound of formula (I)[Formula (I) should be inserted here], in which Ar1, R1, U, V, W, X, and p are as described herein. Also provided are methods of using a compound of formula (I), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a method of inhibiting lactate dehydrogenase A (LDHA) and/or lactate dehydrogenase B (LDHB) activity in a cell.
FILED Thursday, January 28, 2021
APPL NO 17/160868
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/415 (20130101)
A61K 31/422 (20130101)
A61K 31/427 (20130101)
A61K 31/437 (20130101)
A61K 31/454 (20130101)
A61K 31/496 (20130101)
A61K 31/501 (20130101)
A61K 31/506 (20130101)
A61K 31/519 (20130101)
A61K 31/4155 (20130101)
A61K 31/4178 (20130101)
A61K 31/4439 (20130101)
A61K 31/5355 (20130101)
A61K 45/06 (20130101)

Heterocyclic Compounds
C07D 231/20 (20130101) Original (OR) Class
C07D 231/38 (20130101)
C07D 401/04 (20130101)
C07D 403/04 (20130101)
C07D 403/06 (20130101)
C07D 409/04 (20130101)
C07D 413/04 (20130101)
C07D 417/04 (20130101)
C07D 417/14 (20130101)
C07D 471/04 (20130101)
C07D 495/04 (20130101)
C07D 495/14 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210323932 Montano et al.
FUNDED BY
Department of Veterans Affairs (DVA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) CASE WESTERN RESERVE UNIVERSITY (Cleveland, Ohio)
ASSIGNEE(S)
INVENTOR(S) Monica Montano (Shaker Heights, Ohio);  Matthew C. Lawes (Shaker Heights, Ohio)
ABSTRACT Compounds for use in treating cancer include inhibitors of KDM5B and/or inducers of HEXIM1 and/or p21 are described herein.
FILED Monday, April 19, 2021
APPL NO 17/234343
CURRENT CPC
Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

Heterocyclic Compounds
C07D 241/44 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210323933 Suto et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) Southern Research Institute (Birmingham, Alabama)
ASSIGNEE(S) UAB Research Foundation (Birmingham, Alabama)
INVENTOR(S) Mark J. Suto (Homewood, Alabama);  Vandana V. Gupta (Birmingham, Alabama);  Wei Zhang (Wilmington, Massachusetts);  Joanne Murphy-Ullrich (Birmingham, Alabama)
ABSTRACT The present disclosure is concerned with piperazine-2,5-diones that are capable of inhibiting TGF-β and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, and methods of treating fibrotic conditions using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
FILED Monday, August 05, 2019
APPL NO 17/265357
CURRENT CPC
Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 19/04 (20180101)
A61P 35/04 (20180101)

Heterocyclic Compounds
C07D 241/08 (20130101)
C07D 241/52 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210323934 Pierce et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) NORTH CAROLINA STATE UNIVERSITY (Raleigh, North Carolina)
ASSIGNEE(S)
INVENTOR(S) Joshua G. Pierce (Raleigh, North Carolina);  Jonathan J. Mills (Raleigh, North Carolina)
ABSTRACT Provided herein are oxazolidinone derivatives that can exhibit anti-microbial activity and/or activity as biofilm modulating agents (e.g., activity as biofilm inhibitors and/or activity as biofilm dispersal agents). The compounds can exhibit potent activity anti-microbial activity (e.g., potent activity against Gram-positive positive bacteria including methicillin-resistant Staphylococcus aureus). The compounds can exhibit potent activity against biofilms. In some cases, the compounds can exhibit both anti-microbial activity and biofilm modulation properties.
FILED Monday, November 23, 2020
APPL NO 17/101722
CURRENT CPC
Preservation of Bodies of Humans or Animals or Plants or Parts Thereof; Biocides, e.g as Disinfectants, as Pesticides or as Herbicides; Pest Repellants or Attractants; Plant Growth Regulators
A01N 43/76 (20130101)

Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles
A61L 27/54 (20130101)
A61L 29/16 (20130101)
A61L 31/08 (20130101)
A61L 31/16 (20130101)
A61L 2300/204 (20130101)
A61L 2300/404 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 31/04 (20180101)

Heterocyclic Compounds
C07D 263/40 (20130101) Original (OR) Class
C07D 263/46 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210323941 Sibley et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
APPLICANT(S) The United States of America, as represented by the Secretary, Department of Health and Human (Bethesda, Maryland);  The University of Kansas (Lawrence, Kansas)
ASSIGNEE(S)
INVENTOR(S) David R. Sibley (Bethesda, Maryland);  Amy Elizabeth Moritz (Bethesda, Maryland);  R. Benjamin Free (Bethesda, Maryland);  Joseph P. Steiner (Bethesda, Maryland);  Noel Terrence Southall (Rockville, Maryland);  Marc Ferrer (Rockville, Maryland);  Xin Hu (Rockville, Maryland);  Warren S. Weiner (Boston, Massachusetts);  Jeffrey Aubé (Chapel Hill, North Carolina);  Kevin Frankowski (Chapel Hill, North Carolina)
ABSTRACT The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.
FILED Friday, April 14, 2017
APPL NO 16/093365
CURRENT CPC
Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 25/28 (20180101)

Heterocyclic Compounds
C07D 209/42 (20130101)
C07D 213/65 (20130101)
C07D 213/81 (20130101)
C07D 235/24 (20130101)
C07D 295/185 (20130101)
C07D 307/85 (20130101)
C07D 317/64 (20130101)
C07D 333/70 (20130101)
C07D 401/12 (20130101) Original (OR) Class
C07D 405/12 (20130101)
C07D 409/12 (20130101)
C07D 471/04 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210323949 Fields et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
APPLICANT(S) FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES (BOCA RATON, Florida);  H. Lee Moffitt Cancer Center and Research Institute, Inc. (Tampa, Florida)
ASSIGNEE(S) FLORIDA ATLANTIC UNIVERSITY BOARD OF TRUSTEES (Boca Raton, Florida);  H. Lee Moffitt Cancer Center and Research Institute, Inc. (Tampa, Florida)
INVENTOR(S) Gregg B. Fields (Palm Beach Gardens, Florida);  Conor Lynch (Tampa, Florida)
ABSTRACT Novel compounds (small molecules) that potently and selectively inhibit MMP-13 (i.e., MMP-13 inhibitors) are used for treatment of multiple myeloma. The MMP-13 inhibitors described herein are highly selective for MMP-13 and when administered to an individual in need thereof, the compounds selectively kill multiple myeloma cells, reduce growth of multiple myeloma cells, inhibit multiple myeloma-induced osteoclastogenesis, and increase survival time in the individual.
FILED Friday, June 28, 2019
APPL NO 17/272135
CURRENT CPC
Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

Heterocyclic Compounds
C07D 405/12 (20130101)
C07D 405/14 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210323987 Garg et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) The Regents of the University of California (Oakland, California)
ASSIGNEE(S) The Regents of the University of California (Oakland, California)
INVENTOR(S) Neil K. Garg (Oakland, California);  Evan R. Darzi (Oakland, California);  Joyann S. Barber (Oakland, California);  Robert Susick (Oakland, California);  Jason Chari (Oakland, California);  Katie Spence (Oakland, California)
ABSTRACT Methods for the synthesis of polycyclic aromatic hydrocarbons and synthesis platforms for performing such syntheses are provided. Methods and platforms are provided that allow for the synthesis of aza-polycyclic aromatic hydrocarbons by an expedient ring assembly. Methods and platforms allow for a modular approach to synthesis that provide multiple new C—C bonds in sequential pericyclic reactions, thus giving access to compounds with multiple axes of substitution.
FILED Tuesday, August 20, 2019
APPL NO 17/269224
CURRENT CPC
Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus
B01J 31/2226 (20130101)
B01J 31/2291 (20130101)
B01J 31/2419 (20130101)
B01J 2231/4272 (20130101)
B01J 2531/824 (20130101)

Heterocyclic Compounds
C07D 209/58 (20130101)
C07D 209/90 (20130101)
C07D 217/04 (20130101)
C07D 273/04 (20130101)
C07D 333/38 (20130101)
C07D 409/04 (20130101)
C07D 413/04 (20130101)
C07D 417/14 (20130101)
C07D 471/04 (20130101)
C07D 471/14 (20130101)
C07D 491/052 (20130101)

Acyclic, Carbocyclic or Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium or Tellurium
C07F 15/0053 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210323996 Chang et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) CORNELL UNIVERSITY (Ithaca, New York)
ASSIGNEE(S)
INVENTOR(S) Pamela Chang (Ithaca, New York);  Bibudha Parasar (Ithaca, New York);  Lin Han (Ithaca, New York)
ABSTRACT A composition having the following structure: wherein: R1 is OH, ester group, ether group, amine, thiol, thioether, halide, or a group containing an alkynyl or azido functionality; R2 is H, OH, ester group, ether group, amine, thiol, thioether, halide, or a group containing an alkynyl or azido functionality; R3 is a group containing a reactive functionality capable of covalent binding to a thiol or amine; and R4 is H, OH, ester group, ether group, amine, thiol, thioether, halide, or a group containing an alkynyl or azido functionality; wherein one of R1, R2 and R4 is a group containing an alkynyl or azido functionality. Also disclosed is a method for profiling changes in BSH enzyme activity by attaching active BSH enzymes in a sample to the probe shown above, attaching a tag to the probe, and detecting the active BSH enzymes to obtain an activity profile.
FILED Thursday, April 15, 2021
APPL NO 17/231432
CURRENT CPC
Steroids
C07J 43/003 (20130101) Original (OR) Class

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/6848 (20130101)
G01N 2333/98 (20130101)
G01N 2800/065 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210323998 Micalizio et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) Trustees of Dartmouth College (Hanover, New Hampshire)
ASSIGNEE(S)
INVENTOR(S) Glenn C. Micalizio (Norwich, Vermont);  Arti B. Gaur (Hanover, New Hampshire)
ABSTRACT The present disclosure relates to stereodefined polycyclic (e.g., tetracyclic) compounds that contain quaternary centers at one or multiple ring fusions, synthetic methods for preparing such compounds, and methods of using such compounds to treat a disease, such as a brain tumor and, particularly, a glioma.
FILED Thursday, September 05, 2019
APPL NO 17/272091
CURRENT CPC
Steroids
C07J 1/0055 (20130101)
C07J 7/002 (20130101)
C07J 75/005 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324003 ANDRABI et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
APPLICANT(S) The Scripps Research Institute (La Jolla, California)
ASSIGNEE(S)
INVENTOR(S) Raiees ANDRABI (La Jolla, California);  Dennis BURTON (La Jolla, California)
ABSTRACT The present application relates to epitope-targeted SIV and HIV vaccines. The invention provides novel envelope glycoproteins which may be utilized as HIV-1 vaccine immunogens, antigens for crystallization, and for identification of broadly neutralizing antibodies. The invention encompasses preparation and purification of immunogenic compositions which are formulated into vaccines of the present invention.
FILED Thursday, April 15, 2021
APPL NO 17/231415
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/51 (20130101)
A61K 9/127 (20130101)
A61K 39/21 (20130101)
A61K 39/39 (20130101)
A61K 47/08 (20130101)
A61K 47/10 (20130101)
A61K 2039/545 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 31/18 (20180101)

Peptides
C07K 5/08 (20130101) Original (OR) Class

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 7/00 (20130101)
C12N 15/86 (20130101)
C12N 2740/15022 (20130101)
C12N 2750/14143 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/56988 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324004 PAHAN
FUNDED BY
Department of Veterans Affairs (DVA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Center for Complementary and Integrative Health (NCCIH)
National Institute on Aging (NIA)
National Institute of Neurological Disorders and Stroke (NINDS)
APPLICANT(S) Rush University Medical Center (Chicago, Illinois)
ASSIGNEE(S) Rush University Medical Center (Chicago, Illinois)
INVENTOR(S) Kalipada PAHAN (Skokie, Illinois)
ABSTRACT Compositions for inhibiting the binding between ACE2 and SARS-CoV-2 spike S1 are disclosed. Methods of treating COVID-19 are disclosed. Methods of making an in vivo model of COVID-19 are also disclosed.
FILED Wednesday, December 23, 2020
APPL NO 17/133035
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/0043 (20130101)
A61K 38/00 (20130101)
A61K 38/08 (20130101)
A61K 38/10 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 31/14 (20180101)

Peptides
C07K 7/06 (20130101) Original (OR) Class
C07K 7/08 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324014 McFADDEN et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) Arizona Board of Regents on behalf of Arizona State University (Scottsdale, Arizona);  Oncomyx Therapeutics, Inc. (Phoenix, Arizona)
ASSIGNEE(S)
INVENTOR(S) Douglas Grant McFADDEN (Tempe, Arizona);  Mohammed Masmudur RAHMAN (Chandler, Arizona);  Nancy VILLA (Tempe, Arizona);  Lino TORRES-DOMINGUEZ (Tempe, Arizona);  Lina FRANCO ACHURY (Tempe, Arizona);  Leslie Lynne SHARP (Rancho Santa Fe, California)
ABSTRACT Disclosed herein, in certain embodiments, are recombinant myxoma viruses (MYXVs) and nucleic acid constructs encoding the recombinant MYXVs. In some embodiments, the MYXVs are engineered to inactivate or attenuate an activity or expression level of an M153 protein. In some embodiments, the MYXVs are engineered to express one or more transgenes such as a tumor necrosis factor (TNF), interleukin-12 (IL-12), or decorin. Also disclosed herein, in certain embodiments, are methods of using the MYXVs. Some embodiments include providing a MYXV as described herein to a subject in need thereof.
FILED Thursday, June 24, 2021
APPL NO 17/357624
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 39/275 (20130101)
A61K 45/06 (20130101)
A61K 2039/572 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/04 (20180101)

Peptides
C07K 14/005 (20130101) Original (OR) Class
C07K 14/525 (20130101)
C07K 14/5434 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 7/00 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324017 HARDING et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
APPLICANT(S) VaxNewMo LLC (St. Louis, Missouri)
ASSIGNEE(S)
INVENTOR(S) Christian HARDING (St. Louis, Missouri);  Mario FELDMAN (St. Louis, Missouri)
ABSTRACT Provided herein are glycosylated ComP proteins, fragments and fusion proteins thereof, and methods of making, for example, for use in the production of conjugate vaccines. Also provided herein are conjugate vaccines against diseases including bacterial diseases.
FILED Friday, June 14, 2019
APPL NO 17/251994
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 39/05 (20130101)
A61K 39/092 (20130101)
A61K 39/0266 (20130101)
A61K 2039/6037 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 31/04 (20180101)

Peptides
C07K 14/195 (20130101) Original (OR) Class
C07K 2319/55 (20130101)
C07K 2319/91 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324023 Barber
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
APPLICANT(S) Glen N. Barber (Miami, Florida)
ASSIGNEE(S)
INVENTOR(S) Glen N. Barber (Miami, Florida)
ABSTRACT Modulators of STING are able to upregulate or down regulate immune responses. Administration of such modulators can be used to treat diseases or other undesirable conditions in a subject either directly or in combination with other agents.
FILED Thursday, June 24, 2021
APPL NO 17/357822
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/136 (20130101)
A61K 31/196 (20130101)
A61K 31/517 (20130101)
A61K 31/711 (20130101)
A61K 31/713 (20130101)
A61K 31/4748 (20130101)
A61K 31/7048 (20130101)
A61K 38/1709 (20130101)
A61K 45/06 (20130101)
A61K 2300/00 (20130101)

Peptides
C07K 14/4702 (20130101) Original (OR) Class

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/113 (20130101)
C12N 15/1138 (20130101)
C12N 2310/11 (20130101)
C12N 2310/14 (20130101)

Technical Subjects Covered by Former US Classification
Y10T 436/143333 (20150115)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324024 BRISCOE et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
APPLICANT(S) THE CHIDLREN'S MEDICAL CENTER CORPORATION (Boston, Massachusetts)
ASSIGNEE(S) THE CHILDREN'S MEDICAL CENTER CORPORATION (Boston, Massachusetts)
INVENTOR(S) David M. BRISCOE (Sharon, Massachusetts);  Diane R. BIELENBERG (Andover, Massachusetts);  Johannes WEDEL (Jamaica Plain, Massachusetts)
ABSTRACT Provided herein are methods and compositions comprising or using mutant semaphorin polypeptides.
FILED Tuesday, August 27, 2019
APPL NO 17/271380
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 38/00 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 37/06 (20180101)

Peptides
C07K 14/4703 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324032 Burnett, Jr.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
APPLICANT(S) Mayo Foundation for Medical Education and Research (Rochester, Minnesota)
ASSIGNEE(S) Mayo Foundation for Medical Education and Research (Rochester, Minnesota)
INVENTOR(S) John C. Burnett, Jr. (Rochester, Minnesota)
ABSTRACT Analogues of an alternatively spliced form of atrial natriuretic peptide (MANP) that exhibit pGC-A gain of function and can be used to treat cardiorenal and metabolic disease are described herein.
FILED Friday, June 25, 2021
APPL NO 17/359088
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 38/00 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 9/12 (20180101)
A61P 13/12 (20180101)

Peptides
C07K 14/58 (20130101) Original (OR) Class
C07K 14/582 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324035 Witte et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) The Regents of the University of California (Oakland, California);  California Institute of Technology (Pasadena, California);  The Olivia Newton-John Cancer Research Institute (Victoria, Australia)
ASSIGNEE(S) The Regents of the University of California (Oakland, California);  California Institute of Technology (Pasadena, California);  The Olivia Newton-John Cancer Research Institute (Victoria, Australia)
INVENTOR(S) Owen N. Witte (Sherman Oaks, California);  Jami McLaughlin Witte (Sherman Oaks, California);  Antoni Ribas (Los Angeles, California);  Lili Yang (Los Angeles, California);  Michael T. Bethune (Castro Valley, California);  Jonathan Cebon (New York, New York);  Katherine Woods (New York, New York);  Ashley J. Knights (Chadstone, Australia);  David Baltimore (Pasadena, California)
ABSTRACT Tumor-specific T cell receptor (TCR) gene transfer enables specific and potent immune targeting of tumor antigens. The canonical cancer-testis antigen, NY-ESO-1, is not expressed in normal tissues but is aberrantly expressed across a broad array of cancer types. It has also been targeted with A2-restricted TCR gene therapy without adverse events or notable side effects. To enable the targeting of NY-ESO-1 in a broader array of HLA haplotypes, we isolated TCRs specific for NY-ESO-1 epitopes presented by four MHC molecules: HLA-A2, -B07, -B18, and -C03. Using these TCRs, we have developed an approach to extend TCR gene therapies targeting NY-ESO-1 to patient populations beyond those expressing HLA-A2.
FILED Wednesday, September 04, 2019
APPL NO 17/273192
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 35/17 (20130101)
A61K 48/00 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

Peptides
C07K 14/7051 (20130101) Original (OR) Class

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 5/0636 (20130101)
C12N 15/86 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324043 REMALEY et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
APPLICANT(S) THE UNITED STATES OF AMERICA, as represented by the Secretary, Dept of Health and Human Services (Bethesda, Maryland);  Novo Nordisk A/S (Bagsværd, Germany)
ASSIGNEE(S)
INVENTOR(S) Alan Thomas REMALEY (Bethesda, Maryland);  Soumitra Shanker GHOSH (San Diego, California);  Madhav N. DEVALARAJA (Acton, Massachusetts);  Chih-Hung LO (Rockville, Maryland);  Denis O. SVIRIDOV (Rockville, Maryland);  Anna WOLSKA (Washington, District of Columbia)
ABSTRACT The disclosure provides apolipoprotein C-II (apoC-II) mimetic peptides and methods for treating hypertriglyceridemia in a patient with an effective amount of an apoC-II mimetic peptide.
FILED Tuesday, March 09, 2021
APPL NO 17/195766
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/0019 (20130101)
A61K 38/1709 (20130101)
A61K 38/1722 (20130101)

Peptides
C07K 14/775 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324044 Esteves et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
APPLICANT(S) University of Massachusetts (Boston, Massachusetts)
ASSIGNEE(S) University of Massachusetts (Boston, Massachusetts)
INVENTOR(S) Miguel Sena Esteves (Westford, Massachusetts);  Sourav Roy Choudhury (Newton, Massachusetts)
ABSTRACT The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.
FILED Thursday, April 22, 2021
APPL NO 17/237095
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 48/0025 (20130101)
A61K 48/0058 (20130101)

Peptides
C07K 7/00 (20130101)
C07K 7/04 (20130101)
C07K 14/00 (20130101)
C07K 14/005 (20130101)
C07K 14/075 (20130101)
C07K 14/775 (20130101) Original (OR) Class
C07K 19/00 (20130101)
C07K 2319/01 (20130101)
C07K 2319/30 (20130101)
C07K 2319/33 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/79 (20130101)
C12N 15/86 (20130101)
C12N 2750/14145 (20130101)
C12N 2810/85 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324050 Crowe, Jr. et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) Vanderbilt University (Nashville, Tennessee);  BAYLOR COLLEGE OF MEDICINE (Houston, Texas)
ASSIGNEE(S)
INVENTOR(S) James E. Crowe, Jr. (Nashville, Tennessee);  Mary Estes (Houston, Texas)
ABSTRACT The present disclosure is directed to antibodies binding to and neutralizing norovirus and methods for use thereof. Thus, in accordance with the present disclosure, there is provided a method of detecting a norovirus infection in a subject comprising (a) contacting a sample from the subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences; and (b) detecting norovirus in the sample by binding of the antibody or antibody fragment to a norovirus antigen in the sample.
FILED Tuesday, August 27, 2019
APPL NO 17/271843
CURRENT CPC
Peptides
C07K 16/10 (20130101) Original (OR) Class
C07K 2317/21 (20130101)
C07K 2317/33 (20130101)
C07K 2317/55 (20130101)
C07K 2317/76 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/56983 (20130101)
G01N 2333/08 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324051 CROWE, Jr. et al.
FUNDED BY
Department of Defense (DOD)
Defense Threat Reduction Agency (DTRA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
APPLICANT(S) VANDERBILT UNIVERSITY (Nashville, Tennessee);  BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (Austin, Texas)
ASSIGNEE(S)
INVENTOR(S) James E. CROWE, Jr. (Nashville, Tennessee);  Andrew I. FLYAK (Nashville, Tennessee);  Alexander BUKREYEV (Galveston, Texas);  Philipp ILINYKH (Galveston, Texas)
ABSTRACT The present disclosure is directed to antibodies binding to Marburg virus (MARV) glycoprotein (GP) and methods of use therefore.
FILED Thursday, July 01, 2021
APPL NO 17/365429
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 2039/505 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 31/14 (20180101)

Peptides
C07K 16/10 (20130101) Original (OR) Class
C07K 16/468 (20130101)

Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/701 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324053 Connors et al.
FUNDED BY
Department of Health and Human Services (HHS)
APPLICANT(S) The United States of America, as represented by the Secretary, Department of Health and Human (Bethesda, Maryland)
ASSIGNEE(S) The United States of America, as represented by the Secretary, Department of Health and Human (Bethesda, Maryland)
INVENTOR(S) Mark Connors (Bethesda, Maryland);  Jinghe Huang (Derwood, Maryland);  Byong Ha Kang (Rockville, Maryland);  John Mascola (Rockville, Maryland);  Elise Ishida (Chevy Chase, Maryland);  Tongqing Zhou (Boyds, Maryland);  Peter Kwong (Washington, District of Columbia);  Anqi Zheng (Boyds, Maryland)
ABSTRACT Antibodies and antigen binding fragments that specifically bind to gp120 and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.
FILED Friday, June 25, 2021
APPL NO 17/358522
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 2039/505 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 31/18 (20180101)

Peptides
C07K 16/468 (20130101)
C07K 16/1063 (20130101) Original (OR) Class
C07K 16/2809 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/56988 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324057 CHOU et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
APPLICANT(S) THE CHILDREN'S MEDICAL CENTER CORPORATION (Boston, Massachusetts)
ASSIGNEE(S) THE CHILDREN'S MEDICAL CENTER CORPORATION (Boston, Massachusetts)
INVENTOR(S) Janet S. CHOU (Cambridge, Massachusetts);  Raif S. GEHA (Belmont, Massachusetts)
ABSTRACT Described herein are methods and compositions for treating graft versus host disease. Additionally, described herein are methods and compositions for treating diabetes. Aspects of the invention relates to administering to a subject an agent that inhibits LRRC8A as a monotherapy or in combination with additional therapeutics.
FILED Friday, October 25, 2019
APPL NO 17/288600
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 38/28 (20130101)
A61K 45/06 (20130101)

Peptides
C07K 14/70521 (20130101)
C07K 16/18 (20130101) Original (OR) Class
C07K 2319/30 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/113 (20130101)
C12N 2310/141 (20130101)
C12N 2310/531 (20130101)
C12N 2320/31 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324058 Alba et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
APPLICANT(S) The Brigham and Women`s Hospital, Inc. (Boston, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) George A. Alba (Boston, Massachusetts);  Joseph Loscalzo (Dover, Massachusetts);  Bradley A. Maron (Sharon, Massachusetts)
ABSTRACT Anti-NEDD9 antibodies and methods of making and using said antibodies.
FILED Tuesday, November 05, 2019
APPL NO 17/290960
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 2039/505 (20130101)

Peptides
C07K 16/18 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324060 SIERKS et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute on Aging (NIA)
APPLICANT(S) ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (SCOTTSDALE, Arizona)
ASSIGNEE(S)
INVENTOR(S) Michael SIERKS (Ft. McDowell, Arizona);  Huilai TIAN (Tempe, Arizona)
ABSTRACT The invention relates to antibodies, antibody fragments and binding agents that specifically recognize oligomeric tau but do not bind to monomeric tau, fibrillar tau or non-disease associated forms of tau.
FILED Friday, May 21, 2021
APPL NO 17/327462
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 2039/505 (20130101)

Peptides
C07K 16/005 (20130101)
C07K 16/18 (20130101) Original (OR) Class
C07K 2317/21 (20130101)
C07K 2317/30 (20130101)
C07K 2317/622 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/1037 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/6896 (20130101)
G01N 2800/2821 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324065 KEANE et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
APPLICANT(S) UNIVERSITY OF MIAMI (Miami, Florida)
ASSIGNEE(S)
INVENTOR(S) Robert W. KEANE (Miami, Florida);  W. Dalton DIETRICH (Miami, Florida);  Nadine KERR (Miami, Florida);  Shu WU (Miami, Florida);  Juan Pablo DE RIVERO VACCARI (Miami, Florida)
ABSTRACT The present invention provides compositions and methods for reducing inflammation in the lungs of a mammal that is afflicted by a condition that leads to inflammation in the lungs. The compositions and methods described herein include agents that inhibit inflammasome signaling in the mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s).
FILED Friday, June 25, 2021
APPL NO 17/358582
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/727 (20130101)
A61K 39/3955 (20130101)
A61K 39/39541 (20130101)
A61K 2039/505 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 11/00 (20180101)
A61P 25/00 (20180101)
A61P 25/14 (20180101)
A61P 25/28 (20180101)
A61P 29/00 (20180101)
A61P 37/06 (20180101)

Peptides
C07K 16/18 (20130101)
C07K 16/24 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324074 Dimitrov et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) The U.S.A., as represented by the Secretary, Department of Health and Human Services (Bethesda, Maryland)
ASSIGNEE(S) The U.S.A., as represented by the Secretary, Department of Health and Human Services (Bethesda, Maryland)
INVENTOR(S) Dimiter S. Dimitrov (Pittsburgh, Pennsylvania);  Zhongyu Zhu (Frederick, Maryland);  Sneha Ramakrishna (Bethesda, Maryland);  Terry J. Fry (Aurora, Colorado)
ABSTRACT An affinity matured anti-CD22 human monoclonal antibody exhibiting significantly higher affinity (less than 50 pM) compared to the parental antibody (affinity of about 2 nM) is described. The anti-CD22 variant antibody or a fragment thereof, such as a single-chain variable fragment (scFv), can be used as the antigen-binding portion of chimeric antigen receptors (CARs), antibody-drug conjugates (ADCs), immunotoxins or multi-specific antibodies for the treatment of B-cell malignancies.
FILED Thursday, July 11, 2019
APPL NO 17/259334
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/365 (20130101)
A61K 35/17 (20130101)
A61K 47/6803 (20170801)
A61K 47/6851 (20170801)
A61K 2039/505 (20130101)

Peptides
C07K 14/705 (20130101)
C07K 16/2803 (20130101) Original (OR) Class
C07K 2317/31 (20130101)
C07K 2317/53 (20130101)
C07K 2317/94 (20130101)
C07K 2317/565 (20130101)
C07K 2319/02 (20130101)
C07K 2319/03 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/574 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324078 Diaz et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) The Johns Hopkins University (Baltimore, Maryland)
ASSIGNEE(S)
INVENTOR(S) Luis Diaz (Ellicot City, Maryland);  Bert Vogelstein (Baltimore, Maryland);  Kenneth W. Kinzler (Baltimore, Maryland);  Nickolas Papadopoulos (Towson, Maryland);  Dung Le (Lutherville, Maryland);  Drew M. Pardoll (Brookville, Maryland);  Suzanne L. Topalian (Brookville, Maryland)
ABSTRACT Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.
FILED Tuesday, June 22, 2021
APPL NO 17/354656
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 2039/505 (20130101)

Peptides
C07K 16/30 (20130101)
C07K 16/40 (20130101)
C07K 16/2803 (20130101) Original (OR) Class
C07K 16/2818 (20130101)
C07K 16/2827 (20130101)

Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6886 (20130101)
C12Q 2600/106 (20130101)
C12Q 2600/156 (20130101)

Enzymes
C12Y 113/11052 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324086 NDHLOVU et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Mental Health (NIMH)
APPLICANT(S) University of Hawaii (Honolulu, Hawaii)
ASSIGNEE(S)
INVENTOR(S) Lishomwa C. NDHLOVU (Honolulu, Hawaii);  Toshiro NIKI (Honolulu, Hawaii)
ABSTRACT An antibody targeting Galectin-9 is provided as are methods of using the same treatment of chronic immune conditions such as infections, inflammatory diseases and cancer, in particular malignant mesothelioma.
FILED Friday, July 12, 2019
APPL NO 17/260077
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 45/06 (20130101)
A61K 2039/505 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

Peptides
C07K 16/2851 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324090 Khan et al.
FUNDED BY
Department of Health and Human Services (HHS)
APPLICANT(S) The U.S.A., as represented by the Secretary, Department of Health and Human Services (Bethesda, Maryland)
ASSIGNEE(S) The U.S.A., as represented by the Secretary, Department of Health and Human Services (Bethesda, Maryland)
INVENTOR(S) Javed Khan (Derwood, Maryland);  Sivasubramanian Baskar (Ellicott City, Maryland);  Rimas J. Orentas (Seattle, Washington);  Dimiter S. Dimitrov (Pittsburgh, Pennsylvania);  Zhongyu Zhu (Frederick, Maryland);  Tai Chi Cheuk (Germantown, Maryland)
ABSTRACT Monoclonal antibodies selected from immunized mice, immunized rabbits and a human scFv library that specifically bind fibroblast growth factor receptor 4 (FGFR4) are described. Chimeric antigen receptors, antibody-drug conjugates, immunoconjugates, bispecific antibodies and immunoliposomes comprising the disclosed FGFR4-specific antibodies are also described. The antibody compositions can be used to diagnose or treat a FGFR4-positive cancer, such as rhabdomyosarcoma, lung cancer, liver cancer, breast cancer, pancreatic cancer or prostate cancer.
FILED Wednesday, June 23, 2021
APPL NO 17/355703
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 39/39558 (20130101)
A61K 47/6803 (20170801)
A61K 47/6849 (20170801)
A61K 47/6911 (20170801)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

Peptides
C07K 16/2863 (20130101) Original (OR) Class
C07K 2317/77 (20130101)
C07K 2317/92 (20130101)
C07K 2317/622 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324110 WISNIEWSKI et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
APPLICANT(S) NEW YORK UNIVERSITY (New York, New York)
ASSIGNEE(S)
INVENTOR(S) Thomas M. WISNIEWSKI (Staten Island, New York);  Fernando GONI (New York, New York)
ABSTRACT The present invention relates to antibodies and binding fragments thereof that bind the β-sheet secondary structure of a pathological monomeric or oligomeric non-fibrillar proteins without binding to the non-toxic, non-pathological forms of these proteins or peptides. These antibodies and binding fragments thereof are suitable for the diagnosis, prevention, and treatment of protein conformational disorders including all amyloid diseases.
FILED Friday, November 13, 2020
APPL NO 17/098026
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 2039/505 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 25/28 (20180101)

Peptides
C07K 7/06 (20130101)
C07K 14/00 (20130101)
C07K 16/18 (20130101)
C07K 16/44 (20130101) Original (OR) Class
C07K 2317/30 (20130101)
C07K 2317/33 (20130101)
C07K 2317/34 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324311 Skardal et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
Air Force Space Command (AFSPC)
Space Systems Command (SSC)
Department of the Army (DOA)
U.S. Army Medical Research and Materiel Command (USAMRMC)
Department of the Navy (DON)
Space and Naval Warfare Systems (SPAWAR)
Defense Threat Reduction Agency (DTRA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
APPLICANT(S) Wake Forest University Health Sciences (Winston-Salem, North Carolina)
ASSIGNEE(S)
INVENTOR(S) Aleksander Skardal (Clemmons, North Carolina);  Thomas Shupe (Mocksville, North Carolina);  Anthony Atala (Winston-Salem, North Carolina)
ABSTRACT Described herein are apparatus, including multi-tissue body-on-a-chip apparatus. In some embodiments, described are apparatus including at least a first, second, and third chamber in fluid communication with one another and with at least one tissue in each chamber, such as, for example, liver tissue in said first chamber; cardiac muscle tissue in said second chamber; and lung tissue in said third chamber; and a common aqueous growth media in said first, second, and third chamber. In some embodiments, the apparatus includes a fourth chamber including testicular or ovarian tissue in said fourth chamber. In some embodiments, the apparatus includes an optional fifth or sixth chamber; each said chamber includes different additional tissue selected from the group consisting of vascular endothelial, skeletal muscle, kidney, nerve, brain, and intestinal tissue (e.g., small intestine tissue and/or colon tissue). Also described are methods of using an apparatus of the present invention.
FILED Tuesday, October 10, 2017
APPL NO 16/341521
CURRENT CPC
Apparatus for Enzymology or Microbiology;
C12M 21/08 (20130101) Original (OR) Class
C12M 23/16 (20130101)
C12M 23/44 (20130101)
C12M 29/10 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/5082 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324313 Allbritton et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Human Genome Research Institute (NHGRI)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
APPLICANT(S) The University of North Carolina at Chapel Hill (Chapel Hill, North Carolina)
ASSIGNEE(S)
INVENTOR(S) Nancy L. Allbritton (Seattle, None);  Christopher E. Sims (Seattle, None);  Yuli Wang (Lynnwood, None);  Pavak Kirit Shah (Carrboro, None)
ABSTRACT An apparatus for collecting or culturing cells or cell colonies includes: a common substrate formed from a flexible resilient polymeric material and having a plurality of wells formed therein; and a plurality of rigid cell carriers releasably connected to said common substrate, with said carriers arranged in the form of an array, and with each of the carriers resiliently received in one of the wells. A method of collecting or culturing cells or cell colonies with such an apparatus is carried out by depositing a liquid media carrying cells on the apparatus so that said cells settle on or adhere to said the carriers; and then (c) releasing at least one selected carrier having said cells thereon by gradual application of release energy to each carrier from the cavity in which it is received (e.g., by pushing with a probe).
FILED Monday, June 28, 2021
APPL NO 17/361039
CURRENT CPC
Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus
B01J 19/0046 (20130101)
B01J 2219/00452 (20130101)
B01J 2219/00743 (20130101)

Apparatus for Enzymology or Microbiology;
C12M 23/12 (20130101) Original (OR) Class
C12M 23/20 (20130101)
C12M 23/22 (20130101)
C12M 25/04 (20130101)
C12M 25/16 (20130101)
C12M 47/02 (20130101)
C12M 47/04 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324329 Schulz
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Center for Research Resources (NCRR)
APPLICANT(S) ViaCyte, Inc. (San Diego, California)
ASSIGNEE(S)
INVENTOR(S) Thomas C. Schulz (Athens, Georgia)
ABSTRACT The present invention relates to methods for production of undifferentiated or differentiated embryonic stem cell aggregate suspension cultures from undifferentiated or differentiated embryonic stem cell single cell suspensions and methods of differentiation thereof.
FILED Monday, May 24, 2021
APPL NO 17/328980
CURRENT CPC
Apparatus for Enzymology or Microbiology;
C12M 27/12 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 5/0603 (20130101)
C12N 5/0606 (20130101) Original (OR) Class
C12N 5/0676 (20130101)
C12N 2501/11 (20130101)
C12N 2501/15 (20130101)
C12N 2501/16 (20130101)
C12N 2501/41 (20130101)
C12N 2501/105 (20130101)
C12N 2501/115 (20130101)
C12N 2501/117 (20130101)
C12N 2501/195 (20130101)
C12N 2501/415 (20130101)
C12N 2501/998 (20130101)
C12N 2506/02 (20130101)
C12N 2509/00 (20130101)
C12N 2511/00 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324351 Kranzusch et al.
FUNDED BY
Department of Energy (DOE)
Argonne National Laboratory (ANL)
UChicago Argonne, LLC (UCHICAGO)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Center for Research Resources (NCRR)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) Presodent and Fellows of Harvard College (Cambridge, Massachusetts);  Dana-Farber Cancer Institute, Inc. (Boston, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Philip J. Kranzusch (Bringhton, Massachusetts);  John J. Mekalanos (Newton, Massachusetts);  Aaron T. Whiteley (Brookline, Massachusetts);  Wen Zhou (Boston, Massachusetts)
ABSTRACT The present invention is based, in part, on the discovery of the human-specific regulatory control of cGAS and the structure of the active human cGAS-DNA complex, as well as compositions comprising the modified hcGAS polypeptide, hcGAS-DNA complex, hcGAS-DNA-ATP complex, and methods of screening for modulators of the structure, expression, and/or activity of such polypeptides and complexes.
FILED Wednesday, June 26, 2019
APPL NO 17/252454
CURRENT CPC
Animal Husbandry; Care of Birds, Fishes, Insects; Fishing; Rearing or Breeding Animals, Not Otherwise Provided For; New Breeds of Animals
A01K 67/0278 (20130101)

Preparations for Medical, Dental, or Toilet Purposes
A61K 38/00 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

General Methods of Organic Chemistry; Apparatus Therefor
C07B 2200/13 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 9/1241 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324357 CHOUDHARY et al.
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
Department of the Army (DOA)
Department of the Navy (DON)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
APPLICANT(S) THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (BOSTON, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Amit CHOUDHARY (Boston, Massachusetts);  Qingxuan ZHOU (BOSTON, Massachusetts);  Praveen KOKKONDA (BOSTON, Massachusetts)
ABSTRACT The disclosure includes non-naturally occurring or engineered CRISPR Cas variant proteins comprising one or more functional domains and degrader compositions specifically targeting the CRISPR Cas variant proteins; compositions, systems and methods of using the CRISPR Cas variant proteins comprising one or more functional domains and degrader compounds for spatio-temporal control are also provided.
FILED Tuesday, August 20, 2019
APPL NO 17/270358
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/454 (20130101)
A61K 31/506 (20130101)
A61K 31/7088 (20130101)
A61K 38/465 (20130101)
A61K 48/00 (20130101)

Peptides
C07K 2319/95 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 9/22 (20130101) Original (OR) Class
C12N 15/11 (20130101)
C12N 2310/20 (20170501)
C12N 2800/80 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324360 CHEN et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
NIH Office of the Director (NIHOD)
National Science Foundation (NSF)
APPLICANT(S) The Regents of the University of California (Oakland, California)
ASSIGNEE(S)
INVENTOR(S) Yvonne Y. CHEN (Los Angeles, California);  Patrick HO (Fremont, California)
ABSTRACT Compositions and methods are provided for the cell-mediated targeted killing of diseased cells based on the presence of an intracellular antigen, rather than a surface-bound marker. The targeting cells are modified to express a cytotoxic protein that is delivered into a targeted cell, and after delivery is selectively activated by the presence of a cytoplasmic protein of interest. In one embodiment of the invention, the cytotoxic molecule is a Granzyme B (GrB) polypeptide. In the compositions of the invention, GrB is modified to render its cytotoxic enzymatic functions inactive, until the presence of an intracellular antigen unlocks the GrB molecule to enable enzymatic activities.
FILED Thursday, June 24, 2021
APPL NO 17/357704
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 35/17 (20130101)
A61K 38/482 (20130101)

Peptides
C07K 14/47 (20130101)
C07K 14/4702 (20130101)
C07K 16/40 (20130101)
C07K 2317/622 (20130101)
C07K 2319/00 (20130101)
C07K 2319/95 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 5/0636 (20130101)
C12N 9/64 (20130101)
C12N 9/6467 (20130101) Original (OR) Class
C12N 15/85 (20130101)
C12N 2510/00 (20130101)

Enzymes
C12Y 304/21079 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324370 Yin et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) Massachusetts Institute of Technology (Cambridge, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Hao Yin (Cambridge, Massachusetts);  Wen Xue (Cambridge, Massachusetts);  Daniel G. Anderson (Framingham, Massachusetts);  Joseph R. Dorkin (Somerville, Massachusetts);  Tyler E. Jacks (Newton, Massachusetts)
ABSTRACT The present disclosure relates to compositions and methods for modifying a gene sequence, and for systems for deliverying such compositions. For example, the disclosure relates to modifying a gene sequence using a CRISPR-Cas9 or other nucleic acid editing system, and methods and delivery systems for achieving such gene modification, such as viral or non-viral delivery systems.
FILED Monday, March 08, 2021
APPL NO 17/195625
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 48/005 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 7/00 (20130101)
C12N 15/85 (20130101)
C12N 15/86 (20130101)
C12N 15/88 (20130101)
C12N 15/102 (20130101) Original (OR) Class
C12N 15/111 (20130101)
C12N 2310/20 (20170501)
C12N 2750/14143 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324376 Dhara et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) Trustees of Dartmouth College (Hanover, New Hampshire);  Memorial Sloan Kettering Cancer Center (New York, New York)
ASSIGNEE(S)
INVENTOR(S) Surajit Dhara (Hanover, New Hampshire);  Steven D. Leach (Hanover, New Hampshire);  Sagar Chhangawala (New York, New York);  Christina Leslie (New York, New York)
ABSTRACT The present disclosure relates to an array-based assay for transposase-accessible chromatin and prognostic molecular markers of treatment-resistant/early recurrent cancer.
FILED Tuesday, August 13, 2019
APPL NO 17/268195
CURRENT CPC
Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/1065 (20130101) Original (OR) Class

Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6806 (20130101)
C12Q 1/6874 (20130101)
C12Q 1/6886 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324380 DE ABREU RIBEIRO et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Center for Advancing Translational Sciences (NCATS)
APPLICANT(S) Cairn Biosciences, Inc. (San Francisco, California)
ASSIGNEE(S)
INVENTOR(S) M. Susana G. DE ABREU RIBEIRO (San Francisco, California);  Catherine I. LACAYO (Fremont, California);  Mary J. C. LUDLAM (San Francisco, California);  Salome Calado BOTELHO (San Francisco, California)
ABSTRACT The present invention provides multicistronic reporter vectors, acceptor stem cells for receiving multicistronic reporter vectors, and multireporter cells for use in assays for profiling two or more polypeptides in live cells, wherein the vectors comprise a reporter polypeptide under the control of a lineage specific promoter to act as a barcode for a specific cell type. Methods of making multicistronic reporter vectors, acceptor cells for receiving multicistronic reporter vectors, and multireporter cells are provided. Libraries and kits comprising multicistronic reporter vectors, acceptor cells for receiving multicistronic reporter vectors, and multireporter cells are provided. Methods of profiling/assaying the multireporter cells and multireporter cell libraries are provided.
FILED Friday, August 16, 2019
APPL NO 17/269223
CURRENT CPC
Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/67 (20130101)
C12N 15/1086 (20130101) Original (OR) Class
C12N 2830/20 (20130101)
C12N 2840/20 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324383 Jaffee et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) The Johns Hopkins University (Baltimore, Maryland)
ASSIGNEE(S)
INVENTOR(S) Elizabeth A. Jaffee (Baltimore, Maryland);  Nina Chu (Baltimore, Maryland);  Jacquelyn Winifred Zimmerman (Baltimore, Maryland)
ABSTRACT In one aspect, compositions are provided for the early diagnosis and treatment of pancreatic ductal adenocarcinoma and include microRNAs, e.g. miR-21 and inhibitors thereof. The treatment compositions can be useful for early detection, and for intercepting developing premalignant pancreatic lesions and other KRAS-driven premalignancies.
FILED Friday, April 16, 2021
APPL NO 17/233378
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/7088 (20130101)
A61K 45/06 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/113 (20130101) Original (OR) Class

Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6886 (20130101)
C12Q 2600/178 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324385 Taylor
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Child Health and Human Development (NICHD)
APPLICANT(S) YALE UNIVERSITY (New Haven, Connecticut)
ASSIGNEE(S)
INVENTOR(S) Hugh Taylor (Easton, Connecticut)
ABSTRACT The invention includes compositions and methods for the treating or preventing endometriosis in a subject in need thereof. In one aspect, the invention relates to compositions and methods for modulating let-7 microRNA.
FILED Friday, July 12, 2019
APPL NO 17/258879
CURRENT CPC
Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 15/00 (20180101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/1137 (20130101) Original (OR) Class
C12N 2310/141 (20130101)
C12N 2310/531 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324387 Lewin et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Eye Institute (NEI)
APPLICANT(S) University of Florida Research Foundation, Incorporated (Gainesville, Florida);  The Trustees of the University of Pennsylvania (Philadelphia, Pennsylvania)
ASSIGNEE(S) Univeristy of Florida Research Foundation, Incorporated (Gainesville, Florida);  The Trustees of the University of Pennsylvania (Philadelphia, Pennsylvania)
INVENTOR(S) Alfred S. Lewin (Gainesville, Florida);  William W. Hauswirth (Gainesville, Florida);  Michael T. Massengill (Gainesville, Florida);  William Beltran (Wynnewood, Pennsylvania);  Gustavo D. Aguirre (Media, Pennsylvania);  Artur Cideciyan (Lafayette Hill, Pennsylvania);  Samuel Jacobson (Penn Valley, Pennsylvania)
ABSTRACT Aspects of the disclosure relate to methods and compositions for treating retinitis pigmentosa. In some aspects, the disclosure provides compositions and methods for delivering an interfering nucleic acid (for example an interfering RNA) to a subject in order to reduce expression of one or both alleles of an endogenous rho gene (for example a mutant rho allele associated with retinitis pigmentosa) in the subject. In some embodiments, a replacement rho gene that is resistant to the interfering nucleic acid also is delivered to the subject.
FILED Friday, May 21, 2021
APPL NO 17/327609
CURRENT CPC
Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 27/02 (20180101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 7/00 (20130101)
C12N 15/86 (20130101)
C12N 15/113 (20130101)
C12N 15/1138 (20130101) Original (OR) Class
C12N 2310/14 (20130101)
C12N 2310/122 (20130101)
C12N 2310/141 (20130101)
C12N 2310/531 (20130101)
C12N 2330/51 (20130101)
C12N 2750/14143 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324396 Daniell
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Eye Institute (NEI)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (Philadelphia, Pennsylvania)
ASSIGNEE(S)
INVENTOR(S) Henry Daniell (Media, Pennsylvania)
ABSTRACT Compositions and methods for producing marker free biopharmaceutical proteins in the plastids of edible plants are disclosed. Also provided are methods for oral administration of such proteins to subjects in need thereof for the treatment of disease.
FILED Thursday, August 22, 2019
APPL NO 17/270368
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 38/00 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 19/00 (20180101)

Peptides
C07K 14/65 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/8214 (20130101)
C12N 15/8257 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324411 BAILEY et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
APPLICANT(S) THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (Austin, Texas)
ASSIGNEE(S) THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (Austin, Texas)
INVENTOR(S) Rachel M. BAILEY (Trophy Club, Texas);  Steven J. GRAY (Southlake, Texas)
ABSTRACT The present disclosure provides methods and compositions for the treatment of diseases and/or disorders in a subject, including, but not limited to neurological disorders such as giant axonal neuropathy. The methods described herein include direct administration of a gene therapy (e.g. an rAAV viral vector) to a subject via injection into a vagus nerve (e.g. the left vagus nerve) of the subject.
FILED Wednesday, April 14, 2021
APPL NO 17/230484
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 48/005 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 25/02 (20180101)

Peptides
C07K 14/01 (20130101)
C07K 16/081 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/86 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324412 GNEDEVA et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute on Deafness and Other Communication Disorders (NIDCD)
APPLICANT(S) UNIVERSITY OF SOUTHERN CALIFORNIA (Los Angeles, California)
ASSIGNEE(S)
INVENTOR(S) Ksenia GNEDEVA (Malibu, California);  Neil I. SEGIL (Altadena, California);  Xizi WANG (Arcadia, California)
ABSTRACT A method for inducing sensory receptor regeneration includes a step of identifying a subject in need of regeneration of inner ear sensory epithelia. Yap/Tead signaling in the subject is then activated. Typically, Yap/Tead signaling is activated by introducing an expression vector into the subject such that the expression vector contacts inner ear sensory epithelia in a sufficient amount to induce regeneration thereof. Characteristically, the expression vector encodes a constitutively active YAP gene.
FILED Thursday, April 15, 2021
APPL NO 17/231328
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/0046 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 27/16 (20180101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 7/00 (20130101)
C12N 15/86 (20130101) Original (OR) Class
C12N 2750/14143 (20130101)
C12N 2750/14171 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324413 Irvine et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
APPLICANT(S) Massachusetts Institute of Technology (Cambridge, Massachusetts)
ASSIGNEE(S) Massachusetts Institute of Technology (Cambridge, Massachusetts)
INVENTOR(S) Darrell J. Irvine (Arlington, Massachusetts);  Ron Weiss (Newton, Massachusetts);  Yingzhong Li (Quincy, Massachusetts);  Jan Lonzaric (Arlington, Massachusetts);  Parisa Yousefpour (Cambridge, Massachusetts)
ABSTRACT Genetic circuits have been developed to regulate behaviors of replicon RNA in responses to small molecules, which has broader applications, such as for quantitative expression of cargo genes, temporary expression of immunomodulatory cytokines or antigens for better cancer immunotherapy or vaccination, and for increased safety in use of self-replicating vectors or in combination with other viral-delivery vectors. Described herein are genetic circuits suitable for systems that either require a tight off state or a slow off state, which can serve for instance where either a kill switch or prolonged protein expression (e.g., of vaccine antigens) are needed.
FILED Thursday, April 15, 2021
APPL NO 17/231588
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/505 (20130101)
A61K 31/713 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/86 (20130101) Original (OR) Class
C12N 2720/12322 (20130101)
C12N 2720/12343 (20130101)
C12N 2820/60 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324414 Weiss et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
APPLICANT(S) Massachusetts Institute of Technology (Cambridge, Massachusetts);  University of Massachusetts (Boston, Massachusetts)
ASSIGNEE(S) Massachusetts Institute of Technology (Cambridge, Massachusetts);  University of Massachusetts (Boston, Massachusetts)
INVENTOR(S) Ron Weiss (Newton, Massachusetts);  Jin Huh (Watertown, Massachusetts);  Yingzhong Li (Quincy, Massachusetts);  Eric Goldstein (Cambridge, Massachusetts);  Hava Siegelmann (Amherst, Massachusetts)
ABSTRACT This disclosure provides engineered genetic systems for sequestering and/or destroying viruses, compositions and cells comprising the genetic systems, and methods of treating viral infections, reducing viral load, and/or reducing viral spread. The disclosure also provides libraries comprising elements to be incorporated into the engineered genetic systems.
FILED Friday, April 16, 2021
APPL NO 17/232676
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/5123 (20130101)
A61K 35/28 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 31/14 (20180101)

Peptides
C07K 16/10 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 9/22 (20130101)
C12N 15/11 (20130101)
C12N 15/86 (20130101) Original (OR) Class
C12N 15/1093 (20130101)
C12N 15/1137 (20130101)
C12N 2310/14 (20130101)
C12N 2310/20 (20170501)
C12N 2310/141 (20130101)
C12N 2320/31 (20130101)
C12N 2320/32 (20130101)
C12N 2710/16643 (20130101)
C12N 2800/80 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324450 Church et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Human Genome Research Institute (NHGRI)
National Heart, Lung, and Blood Institute (NHLBI)
APPLICANT(S) President and Fellows of Harvard College (Cambridge, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) George M. Church (Brookline, Massachusetts);  Je-Hyuk Lee (Allston, Massachusetts);  Richard C. Terry (Carlisle, Massachusetts);  Evan R. Daugharthy (Cambridge, Massachusetts)
ABSTRACT Methods of making a three-dimensional matrix of nucleic acids within a cell is provided.
FILED Wednesday, June 30, 2021
APPL NO 17/363097
CURRENT CPC
Fermentation or Enzyme-using Processes to Synthesise a Desired Chemical Compound or Composition or to Separate Optical Isomers From a Racemic Mixture
C12P 19/34 (20130101)

Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6806 (20130101) Original (OR) Class
C12Q 1/6844 (20130101)
C12Q 1/6869 (20130101)
C12Q 1/6874 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324456 Cunningham et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Chemical, Bioengineering, Environmental and Transport Systems (CBET)
APPLICANT(S) The Board of Trustees of the University of Illinois (Urbana, Illinois)
ASSIGNEE(S)
INVENTOR(S) Brian T. Cunningham (Champaign, Illinois);  Yue Zhuo (Champaign, Illinois);  Brendan Harley (Urbana, Illinois);  Ji Sun Choi (Urbana, Illinois);  Thibault Marin (Champaign, Illinois);  Yi Lu (Champaign, Illinois)
ABSTRACT A digital assay for a micro RNA (miRNA) or other target analyte in a sample makes use of nanoparticles that absorb light at the resonant wavelength of a photonic crystal (PC). Such nanoparticles locally quench the resonant reflection of light from the PC when present on the surface of the PC. The nanoparticles are functionalized to specifically bind to the target analyte, and the PC surface is functionalized to specifically bind to the nanoparticles that have bound to the target analyte. The sample is exposed to the functionalized nanoparticles, and the individual nanoparticles bound to the PC surface can be identified and counted based on reduced intensity values in the reflected light from the PC. The number of bound nanoparticles that are counted in this way can be correlated to the abundance of the target analyte in the sample.
FILED Monday, May 24, 2021
APPL NO 17/328752
CURRENT CPC
Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6825 (20130101) Original (OR) Class
C12Q 1/6886 (20130101)
C12Q 2600/178 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 21/554 (20130101)
G01N 21/774 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324469 Xie et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Human Genome Research Institute (NHGRI)
APPLICANT(S) President and Fellows of Harvard College (Cambridge, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Xiaoliang Sunney Xie (Lexington, Massachusetts);  Katsuyuki Shiroguchi (Arlington, Massachusetts);  Peter A. Sims (Cambridge, Massachusetts);  Tony Z. Jia (Cambridge, Massachusetts)
ABSTRACT Methods and compositions for digital profiling of nucleic acid sequences present in a sample are provided.
FILED Wednesday, June 30, 2021
APPL NO 17/363053
CURRENT CPC
Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/1065 (20130101)

Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6853 (20130101)
C12Q 1/6874 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324470 Salk et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Institute on Aging (NIA)
APPLICANT(S) UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (Seattle, Washington)
ASSIGNEE(S)
INVENTOR(S) Jesse Salk (Seattle, Washington);  Lawrence A. Loeb (Bellevue, Washington);  Michael Schmitt (Seattle, Washington)
ABSTRACT Next Generation DNA sequencing promises to revolutionize clinical medicine and basic research. However, while this technology has the capacity to generate hundreds of billions of nucleotides of DNA sequence in a single experiment, the error rate of approximately 1% results in hundreds of millions of sequencing mistakes. These scattered errors can be tolerated in some applications but become extremely problematic when “deep sequencing” genetically heterogeneous mixtures, such as tumors or mixed microbial populations. To overcome limitations in sequencing accuracy, a method Duplex Consensus Sequencing (DCS) is provided. This approach greatly reduces errors by independently tagging and sequencing each of the two strands of a DNA duplex. As the two strands are complementary, true mutations are found at the same position in both strands. In contrast, PCR or sequencing errors will result in errors in only one strand. This method uniquely capitalizes on the redundant information stored in double-stranded DNA, thus overcoming technical limitations of prior methods utilizing data from only one of the two strands.
FILED Monday, June 28, 2021
APPL NO 17/361245
CURRENT CPC
Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6806 (20130101)
C12Q 1/6869 (20130101)
C12Q 1/6876 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324478 Stegmaier
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) Dana-Farber Cancer Institute, Inc. (Boston, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Kimberly Stegmaier (Jamaica Plain, Massachusetts)
ABSTRACT The present invention is based, in part, on the identification of TP53 dependency biomarkers, including MDM2, MDM4, USP7, and Wip1/PPM1D, as well as modulators and methods of use thereof, for identifying, assessing, preventing, and treating Ewing sarcoma.
FILED Wednesday, July 17, 2019
APPL NO 17/260824
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 38/12 (20130101)
A61K 45/06 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)

Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6886 (20130101) Original (OR) Class
C12Q 2600/112 (20130101)
C12Q 2600/158 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/5011 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325280 Matula et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Institute of General Medical Sciences (NIGMS)
APPLICANT(S) University of Washington (Seattle, Washington)
ASSIGNEE(S)
INVENTOR(S) Thomas J. Matula (Kirkland, Washington);  Karol Bomsztyk (Mercer Island, Washington);  Brian MacConaghy (Kent, Washington);  Justin Reed (Seattle, Washington);  Adam D. Maxwell (Woodinville, Washington)
ABSTRACT A system for processing biological or other samples includes an array of transducer elements that are positioned to align with sample wells in a microplate. Each transducer element produces ultrasound energy that is focused towards a well of the microplate with sufficient acoustic pressure to cause inertial cavitation. In one embodiment, the transducers are configured to direct ultrasound energy into cylindrical wells. In other embodiments, the transducer elements are configured to direct ultrasound energy into non-cylindrical wells of a microplate.
FILED Friday, April 23, 2021
APPL NO 17/239387
CURRENT CPC
Chemical or Physical Laboratory Apparatus for General Use
B01L 3/5085 (20130101)

Methods or Apparatus for Generating or Transmitting Mechanical Vibrations of Infrasonic, Sonic, or Ultrasonic Frequency, for Performing Mechanical Work in General
B06B 1/0215 (20130101)
B06B 1/0629 (20130101)
B06B 2201/55 (20130101)
B06B 2201/70 (20130101)

Apparatus for Enzymology or Microbiology;
C12M 47/06 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 1/286 (20130101) Original (OR) Class

Sound-producing Devices; Methods or Devices for Protecting Against, or for Damping, Noise or Other Acoustic Waves in General; Acoustics Not Otherwise Provided for
G10K 11/30 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325324 YU et al.
FUNDED BY
Department of Health and Human Services (HHS)
Food and Drug Administration (FDA)
APPLICANT(S) UNIVERSITY OF MARYLAND, BALTIMORE (Baltimore, Maryland)
ASSIGNEE(S)
INVENTOR(S) Yihua (Bruce) YU (Baltimore, Maryland);  Marc B. TARABAN (Baltimore, Maryland);  Katharine T. BRIGGS (Baltimore, Maryland)
ABSTRACT A method of using the relaxation rate (R1 and/or R2) of solvent NMR signal to assess whether drug products have undergone substantial chemical degradation during manufacturing, transport and/or storage. The monitoring can be performed under both static and flow conditions, in real-time and in a contact-free manner.
FILED Friday, March 19, 2021
APPL NO 17/206373
CURRENT CPC
Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 24/088 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325329 Bandara et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Chemical, Bioengineering, Environmental and Transport Systems (CBET)
Division of Civil, Mechanical and Manufacturing Innovation (CMMI)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Chemistry (CHE)
APPLICANT(S) Southern Methodist University (Dallas, Texas);  University of Rhode Island Board of Trustees (Kingston, Rhode Island)
ASSIGNEE(S)
INVENTOR(S) Y.M. Nuwan D.Y. Bandara (Canberra, Australia);  Buddini I. Karawdeniya (Canberra, Australia);  Jugal Saharia (Dallas, Texas);  Min Jun Kim (Plano, Texas);  Jason Rodger Dwyer (Providence, Rhode Island)
ABSTRACT The present invention includes one or more nanopores in a SixNy membrane comprising a monoprotic surface termination, methods of making, and methods of using the one or more nanopores, where the one or more nanopores are a chemically-tuned controlled dielectric breakdown (CT-CDB) nanopore membrane, wherein the CT-CDB allows for long-term stability of measurements in the presence of only electrolyte (open pore current stability) and ability to support many molecular detection events. In addition, the CT-CBD has pore that unclog spontaneously, in response to voltage cessation or application, or both.
FILED Friday, April 16, 2021
APPL NO 17/232624
CURRENT CPC
Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 27/127 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325368 Lane et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) Dana-Farber Cancer Institute, Inc. (Boston, Massachusetts);  The Brigham and Women's Hospital, Inc. (Boston, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Andrew Lane (Needham, Massachusetts);  Jon Aster (Lexington, Massachusetts)
ABSTRACT The present invention is based in part on the identification of DPH1 and other members of the diphthamide synthesis pathway as biomarkers of resistance to an ADP-ribosylating toxin in a cell, and methods for identification, assessment, and treatment of a condition that is resistant to an ADP-ribosylating toxin.
FILED Tuesday, October 30, 2018
APPL NO 16/756545
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 45/06 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/5011 (20130101) Original (OR) Class
G01N 33/57426 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325379 Lindsay et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Human Genome Research Institute (NHGRI)
APPLICANT(S) ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (SCOTTSDALE, Arizona);  RECOGNITION ANALYTIX INC. (Phoenix, Arizona)
ASSIGNEE(S)
INVENTOR(S) Stuart Lindsay (SCOTTSDALE, Arizona);  Karen Anderson (SCOTTSDALE, Arizona);  Mark Knappenberger (SCOTTSDALE, Arizona);  Sepideh Afsari Mamaghani (SCOTTSDALE, Arizona);  Jacob L. Swett (TEMPE, Arizona)
ABSTRACT The present disclosure provides devices, systems, and methods related to single molecule detection. In particular, the present disclosure provides devices and methods for sequence-specific detection of a nucleic acid target using current fluctuations as a readout for protein binding to the nucleic acid target. As described herein, certain aspects of the bioelectronic devices and method can be used to detect and identify any nucleic acid target for the purpose of diagnosis and/or treatment.
FILED Friday, April 16, 2021
APPL NO 17/232631
CURRENT CPC
Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 9/22 (20130101)
C12N 15/11 (20130101)
C12N 2310/20 (20170501)
C12N 2800/80 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 27/021 (20130101)
G01N 33/5308 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325387 Shalek et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Human Genome Research Institute (NHGRI)
National Institute of Allergy and Infectious Diseases (NIAID)
NIH Office of the Director (NIHOD)
APPLICANT(S) The Broad Institute, Inc. (Cambridge, Massachusetts);  Massachusetts Institute of Technology (Cambridge, Massachusetts);  The General Hospital Corporation (Boston, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Alexander K. Shalek (Cambridge, Massachusetts);  Christopher Smillie (Cambridge, Massachusetts);  Rebecca H. Herbst (Cambridge, Massachusetts);  Moshe Biton (Cambridge, Massachusetts);  Aviv Regev (Cambridge, Massachusetts);  Jose Ordovas-Montanes (Cambridge, Massachusetts);  Ramnik Xavier (Cambridge, Massachusetts)
ABSTRACT The present invention provides for a human cell atlas of the colon from healthy and diseased subjects. The atlas was obtained by single sequencing of about 117,000 cells. The present invention discloses novel markers for cell types. Moreover, genes associated with disease are identified in the colon and colon specific cell types. The invention provides for diagnostic assays based on gene markers and cell composition, as well as target cell types that express genes associated with disease. Finally, disclosed are novel cell types and methods of quantitating, detecting and isolating the cell types.
FILED Tuesday, July 17, 2018
APPL NO 16/632018
CURRENT CPC
Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6883 (20130101)
C12Q 2600/158 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/56966 (20130101) Original (OR) Class
G01N 2800/065 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325392 Buranda et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of General Medical Sciences (NIGMS)
National Institute of Neurological Disorders and Stroke (NINDS)
National Science Foundation (NSF)
Directorate for Biological Sciences (BIO)
Division of Molecular and Cellular Biosciences (MCB)
APPLICANT(S) UNM RAINFOREST INNOVATIONS (Albuquerque, New Mexico)
ASSIGNEE(S)
INVENTOR(S) Tione Buranda (Albuquerque, New Mexico);  Jacob Ongudi Agola (Albuquerque, New Mexico);  Soumik BasuRay (Dallas, Texas);  Scarlett Swanson (Albuquerque, New Mexico);  Angela Wandinger-Ness (Albuquerque, New Mexico);  Peter C. Simons (Albuquerque, New Mexico);  Virginie Bondu (Albuquerque, New Mexico)
ABSTRACT In one embodiment, the invention provides a method of diagnosing sepsis or a virus-related infection (often a viral hemorrhagic fever infection) in a subject by detecting and measuring the level of a set of sepsis and virus infection-associated-GTPase biomarkers in a sample obtained from the subject using multiplexed flow cytometry. Related kits are also provided. In a preferred embodiment, the invention provides point of care diagnostic methods for determining an early stage sepsis or the severity of a virus infection, especially in a hospital or other setting.
FILED Tuesday, February 23, 2021
APPL NO 17/182859
CURRENT CPC
Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/86 (20130101)
G01N 33/573 (20130101) Original (OR) Class
G01N 2333/914 (20130101)
G01N 2800/26 (20130101)
G01N 2800/224 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325403 Mrksich et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) NORTHWESTERN UNIVERSITY (Evanston, Illinois)
ASSIGNEE(S)
INVENTOR(S) Milan Mrksich (Hinsdale, Illinois);  Eric J. Berns (Park Ridge, Illinois);  Maria D. Cabezas (Evanston, Illinois)
ABSTRACT The disclosure provides a cell-based, label-free assay compatible with high-throughput screening (HTS) that can report quantitatively on enzyme activities by measuring mass changes of substrates with MALDI-mass spectrometry.
FILED Tuesday, June 29, 2021
APPL NO 17/362600
CURRENT CPC
Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/00 (20130101)
C12Q 1/26 (20130101)
C12Q 1/37 (20130101)
C12Q 1/42 (20130101)
C12Q 1/44 (20130101)
C12Q 1/46 (20130101)
C12Q 1/48 (20130101)
C12Q 1/485 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/6851 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325405 Padmanabhan et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Small Business Administration (SBA)
Small Business Innovation Research (SBIR)
APPLICANT(S) RETHAM TECHNOLOGIES, LLC (Wauwatosa, Wisconsin)
ASSIGNEE(S)
INVENTOR(S) Anand Padmanabhan (Rochester, Minnesota);  Curtis G. Jones (Wauwatosa, Wisconsin)
ABSTRACT Described is a method for identifying pathogenic platelet-activating antibodies in a subject's blood and particularly antibodies implicated in heparin-induced thrombocytopenia (HIT) which comprises the preparation of a platelet releasate from a normal subject's platelets, the combination of the platelet release with a normal subject's platelets, a test subject's blood sample, and analyzing the sample for platelet activation.
FILED Monday, April 19, 2021
APPL NO 17/234182
CURRENT CPC
Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 5/0644 (20130101)
C12N 2500/42 (20130101)
C12N 2501/30 (20130101)
C12N 2501/998 (20130101)
C12N 2523/00 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 1/28 (20130101)
G01N 33/545 (20130101)
G01N 33/6857 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325652 Tang et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
APPLICANT(S) University of Central Florida Research Foundation, Inc. (Orlando, Florida)
ASSIGNEE(S)
INVENTOR(S) Jialei Tang (Orlando, Florida);  Vahid Ebrahimi (Orlando, Florida);  Kyu Young Han (Orlando, Florida)
ABSTRACT An illumination system may include an illumination source, a line-projection system to simultaneously illuminate a pupil plane with a static distribution of a plurality of one-dimensional (1D) coherent beams. Each of the 1D coherent beams of the plurality of 1D coherent beams may extend lengthwise along a coherent direction between boundaries of the pupil plane, have a width along an incoherent direction perpendicular to the coherent direction, and are distributed in a parallel distribution along the incoherent direction. Each of the 1D coherent beams of the plurality of 1D coherent beams is also spatially coherent along the coherent direction and spatially incoherent along the incoherent direction. The system may further include an objective lens to form a light sheet in an imaging plane based on an incoherent superposition of the plurality of 1D coherent beams.
FILED Wednesday, April 21, 2021
APPL NO 17/236941
CURRENT CPC
Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 21/6458 (20130101)
G01N 2021/6469 (20130101)
G01N 2021/6478 (20130101)
G01N 2201/061 (20130101)

Optical Elements, Systems, or Apparatus
G02B 3/06 (20130101)
G02B 21/02 (20130101)
G02B 21/06 (20130101) Original (OR) Class
G02B 21/16 (20130101)
G02B 21/26 (20130101)
G02B 21/367 (20130101)
G02B 27/48 (20130101)
G02B 27/0927 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325656 Liu et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
Congressionally Directed Medical Research Programs (CDMRP)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Science Foundation (NSF)
APPLICANT(S) University of Washington (Seattle, Washington)
ASSIGNEE(S) University of Washington (Seattle, Washington)
INVENTOR(S) Jonathan T.C. Liu (Seattle, Washington);  Lindsey A. Barner (Seattle, Washington);  Adam K. Glaser (Seattle, Washington)
ABSTRACT Apparatuses, systems, and methods for solid immersion meniscus lenses (SIMlenses). An optical system may include a sample holder with a first side which supports a sample, and a second side opposite the first side. The second side of the sample holder may be in contact with an immersion fluid. Light passing between the sample and an objective lens may pass through the sample holder, immersion fluid, and a SIMlens positioned between the immersion fluid and objective. The SIMlens may have a first curved surface and a second curved surface, each of which may be shaped to match a wavefront of the light as it passes through the SIMlens. The immersion fluid, SIMlens, and environment containing the objective may all have different refractive indices.
FILED Wednesday, June 23, 2021
APPL NO 17/356135
CURRENT CPC
Optical Elements, Systems, or Apparatus
G02B 21/26 (20130101)
G02B 21/0032 (20130101)
G02B 21/33 (20130101) Original (OR) Class
G02B 21/248 (20130101)
G02B 21/367 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210326653 Zhou et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
APPLICANT(S) Arizona Board of Regents on Behalf of Arizona State University (Scottsdale, Arizona)
ASSIGNEE(S)
INVENTOR(S) Zongwei Zhou (Tempe, Arizona);  Vatsal Sodha (San Jose, California);  Jiaxuan Pang (Tempe, Arizona);  Jianming Liang (Scottsdale, Arizona)
ABSTRACT Described herein are means for generation of self-taught generic models, named Models Genesis, without requiring any manual labeling, in which the Models Genesis are then utilized for the processing of medical imaging. For instance, an exemplary system is specially configured for learning general-purpose image representations by recovering original sub-volumes of 3D input images from transformed 3D images. Such a system operates by cropping a sub-volume from each 3D input image; performing image transformations upon each of the sub-volumes cropped from the 3D input images to generate transformed sub-volumes; and training an encoder-decoder architecture with skip connections to learn a common image representation by restoring the original sub-volumes cropped from the 3D input images from the transformed sub-volumes generated via the image transformations. A pre-trained 3D generic model is thus provided, based on the trained encoder-decoder architecture having learned the common image representation which is capable of identifying anatomical patterns in never before seen 3D medical images having no labeling and no annotation. More importantly, the pre-trained generic models lead to improved performance in multiple target tasks, effective across diseases, organs, datasets, and modalities.
FILED Wednesday, April 07, 2021
APPL NO 17/224886
CURRENT CPC
Recognition of Data; Presentation of Data; Record Carriers; Handling Record Carriers
G06K 9/6259 (20130101) Original (OR) Class
G06K 9/6261 (20130101)
G06K 2209/05 (20130101)

Computer Systems Based on Specific Computational Models
G06N 3/088 (20130101)
G06N 3/0454 (20130101)

Image Data Processing or Generation, in General
G06T 3/00 (20130101)

Healthcare Informatics, i.e Information and Communication Technology [ICT] Specially Adapted for the Handling or Processing of Medical or Healthcare Data
G16H 30/40 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210326704 George
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
Department of the Navy (DON)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
NIH Office of the Director (NIHOD)
National Science Foundation (NSF)
APPLICANT(S) UNIVERISTY OF UTAH RESEARCH FOUNDATION (Salt Lake City, Utah)
ASSIGNEE(S)
INVENTOR(S) Jacob Anthony George (Salt Lake City, Utah)
ABSTRACT A method for training an artificial intelligence (AI) model for allowing a user to intuitively control an electronic device includes positioning a plurality of sensors at a plurality of particular positions on a human body for sensing electric signals. The method also includes recording a first set of electric signals from each of the plurality of sensors in a continuous manner. At the same time, a first set of motion intents associated with a first sequence of body movement is also recorded in a continuous manner. An AI regression model is trained using a neural network to map the first set of electric signals to the first set of motion intents. In response to receiving a second set of electric signals from the plurality of sensors in a continuous manner, the AI regression model predicts a motion intent, causing the electronic device to perform an action.
FILED Wednesday, April 14, 2021
APPL NO 17/230446
CURRENT CPC
Electric Digital Data Processing
G06F 3/014 (20130101)
G06F 3/015 (20130101)

Computer Systems Based on Specific Computational Models
G06N 3/04 (20130101)
G06N 3/08 (20130101) Original (OR) Class
G06N 3/063 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210327535 ZHOU et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
APPLICANT(S) The Regents of the University of California (Oakland, California);  EarlyDiagnostics, Inc. (Los Angeles, California)
ASSIGNEE(S)
INVENTOR(S) Xianghong Jasmine ZHOU (Los Angeles, California);  Wenyuan LI (Los Angeles, California);  Shuo LI (Los Angeles, California);  Chun-Chi LIU (Los Angeles, California);  Xiaohui NI (Los Angeles, California)
ABSTRACT The present disclosure provides methods and systems for detecting or inferring levels of Copy Number Variants (CNVs) in cell-free nucleic acid samples to detect or assess cancer and prenatal diseases. Cell-free nucleic acid methylation sequencing data may be utilized to distinguish tumor-derived or fetal-derived sequencing reads from normal cfDNA sequencing reads. Each cell-free nucleic acid sequencing read (e.g., containing tumor or fetal methylation markers) may be classified as corresponding to a tumor/fetal-derived or a normal-plasma cell-free nucleic acid, based on the methylation cfDNA sequencing data (e.g., obtained using Bisulfite sequencing or bisulfite-free sequencing methods) and tumor/fetal methylation markers. Next, a profile of the tumor/fetal-derived sequencing read counts may be constructed and then normalized. The CNV status (e.g., gain or loss) of each genomic region may be inferred, and a diagnosis or prognosis can be made based on a subjects inferred CNV profile.
FILED Thursday, August 22, 2019
APPL NO 17/269983
CURRENT CPC
Bioinformatics, i.e Information and Communication Technology [ICT] Specially Adapted for Genetic or Protein-related Data Processing in Computational Molecular Biology
G16B 20/10 (20190201) Original (OR) Class
G16B 30/00 (20190201)
G16B 40/30 (20190201)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210327537 Califano et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) The Trustees of Columbia University in the City of New York (New York, New York)
ASSIGNEE(S)
INVENTOR(S) Andrea Califano (New York, New York);  Mariano Javier Alvarez (Cortlandt Manor, New York)
ABSTRACT Methods for determining regulon enrichment in gene expression signatures are disclosed herein. An example method can include obtaining a set of transcriptional targets of a regulon. The method can include obtaining a gene expression signature by comparing a gene expression profile of a test sample to gene expression profiles of a plurality of samples representing control phenotypes. The method can include calculating a regulon enrichment score for each regulon in the gene expression signature. The method can including determining whether a number of control samples in the control phenotypes is above a predetermined threshold to support evaluation of statistical significance using permutation analysis. The method can include, in response to determining that the number of control samples is above the predetermined threshold, calculating a significance value by comparing each regulon enrichment score to a null model.
FILED Friday, September 25, 2020
APPL NO 17/033312
CURRENT CPC
Bioinformatics, i.e Information and Communication Technology [ICT] Specially Adapted for Genetic or Protein-related Data Processing in Computational Molecular Biology
G16B 5/00 (20190201)
G16B 5/20 (20190201)
G16B 20/00 (20190201)
G16B 20/20 (20190201) Original (OR) Class
G16B 25/00 (20190201)
G16B 25/10 (20190201)
VIEW PATENT @ USPTO:  Full Text   PDF 

Department of Defense (DOD) 

US 20210321975 Sikdar et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
U.S. Army Medical Research and Materiel Command (USAMRMC)
National Science Foundation (NSF)
APPLICANT(S) George Mason University (Fairfax, Virginia)
ASSIGNEE(S)
INVENTOR(S) Siddhartha Sikdar (Washginton, District of Columbia);  Parag Chitnis (Burke, Virginia);  Biswarup Mukherjee (Fairfax, Virginia);  Joseph Majdi (Fairfax, Virginia)
ABSTRACT A low-power (e.g., battery-operated, etc.) wearable ultrasound system may be used to monitor the musculoskeletal function of a subject and provide information that may be used for electrical stimulation.
FILED Wednesday, April 21, 2021
APPL NO 17/236752
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 8/08 (20130101) Original (OR) Class
A61B 8/488 (20130101)
A61B 8/5223 (20130101)

Electrotherapy; Magnetotherapy; Radiation Therapy; Ultrasound Therapy
A61N 1/36003 (20130101)

Computer Systems Based on Specific Computational Models
G06N 20/00 (20190101)

Healthcare Informatics, i.e Information and Communication Technology [ICT] Specially Adapted for the Handling or Processing of Medical or Healthcare Data
G16H 20/30 (20180101)
G16H 30/40 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322025 Greene et al.
FUNDED BY
Department of Defense (DOD)
Department of the Navy (DON)
Secretary of the Navy (SECNAV)
APPLICANT(S) MicroVention, Inc. (Tustin, California);  University of Virginia Patent Foundation (Charlottesville, Virginia);  United States of America as Represented by the Secretary of the Navy (Silver Spring, Maryland);  Emergency Scientific LLC (Salt Lake City, Utah)
ASSIGNEE(S) MicroVention, Inc. (Tustin, California);  University of Virginia Patent Foundation (Charlottesville, Virginia);  United States of America as Represented by the Secretary of the Navy (Silver Spring, Maryland);  Emergency Scientific LLC (Salt Lake City, Utah)
INVENTOR(S) George R. Greene (Costa Mesa, California);  Ivan Sepetka (Los Altos, California);  Cathy Lei (Chino Hills, California);  Rupal Nguyen (Costa Mesa, California);  Matthew J. Bradley (Silver Spring, Maryland);  Stephen T. Ahlers (Silver Spring, Maryland);  Carl S. Goforth (Silver Spring, Maryland);  James R. Stone (Charlottesville, Virginia);  Timothy Ray Nieman (North Salt Lake City, Utah);  Shawn Fojtik (Park City, Utah)
ABSTRACT Blood vessel occlusion devices, systems and methods, in particular embodiments of devices for aortic occlusion. The device includes one or more locator portions and an occluder portion. The device is delivered via transcatheter delivery. The locator portion may be radially expanded using a handle and actuator at the proximal end of the delivery catheter. Tactile feedback from the locator portion is used to determine proper location of the occluder portion, for example within the abdominal aorta. The occluder is then radially expanded to occlude the vessel.
FILED Friday, June 25, 2021
APPL NO 17/359304
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 17/1204 (20130101)
A61B 17/12109 (20130101) Original (OR) Class
A61B 17/12136 (20130101)
A61B 2017/1205 (20130101)

Devices for Introducing Media Into, or Onto, the Body; Devices for Transducing Body Media or for Taking Media From the Body; Devices for Producing or Ending Sleep or Stupor
A61M 25/1011 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322026 JOHNSON et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
Air Force Materiel Command (AFMC)
United States Air Force (USAF)
APPLICANT(S) Certus Critical Care, Inc. (Sacramento, California);  Wake Forest University Health Sciences (Winston-Salem, North Carolina)
ASSIGNEE(S)
INVENTOR(S) Michael Austin JOHNSON (Holladay, Utah);  David POISNER (Carmichael, California);  Melanie MCWADE (Portland, Oregon);  Timothy WILLIAMS (Winston-Salem, North Carolina);  Lucas NEFF (Winston-Salem, North Carolina)
ABSTRACT Systems and methods for blood flow control are described herein. In some variations, a blood flow control system may comprise a blood flow control device. The blood flow control device may be placed within a body of a patient and may comprise an expandable member and a sensor. The sensor may be configured to measure at least one of a physiologic condition of the patient and a pressure associated with the expandable member. The blood flow control system may include at least one controller communicably coupled to the sensor to: receive data indicative of at least one of the physiologic condition of the patient and the pressure associated with the expandable member from the sensor, compare the received data with target data, identify at least one error based on the comparison, and in response to identifying the error, inhibit at least one function of the blood flow control system.
FILED Tuesday, March 16, 2021
APPL NO 17/203742
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 5/02158 (20130101)
A61B 5/4836 (20130101)
A61B 17/12109 (20130101)
A61B 17/12136 (20130101) Original (OR) Class
A61B 34/25 (20160201)
A61B 2017/00557 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322300 CHEN et al.
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
APPLICANT(S) CALIFORNIA INSTITUTE OF TECHNOLOGY (Pasadena, California)
ASSIGNEE(S)
INVENTOR(S) Samson CHEN (Pasadena, California);  Axel SCHERER (Pasadena, California);  Richard Daniel SMITH, JR. (Pasadena, California)
ABSTRACT An implantable device contains a drug or biosensing compound, protected from the external environment within a human body by several barriers which are broken upon activation of the device through electrothermal, chemical, and mechanical processes. The device allows accurate and repeated dosing within a human body, thus reducing the number of implantation procedures required. This device extends the lifetime of a biosensor, reducing the number of implantation procedures required.
FILED Friday, May 14, 2021
APPL NO 17/321296
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 5/686 (20130101)
A61B 5/4839 (20130101)
A61B 5/14532 (20130101)

Containers Specially Adapted for Medical or Pharmaceutical Purposes; Devices or Methods Specially Adapted for Bringing Pharmaceutical Products into Particular Physical or Administering Forms; Devices for Administering Food or Medicines Orally; Baby Comforters; Devices for Receiving Spittle
A61J 1/1412 (20130101)
A61J 1/1468 (20150501)

Preparations for Medical, Dental, or Toilet Purposes
A61K 9/0009 (20130101) Original (OR) Class
A61K 9/0024 (20130101)
A61K 9/0097 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322559 Kessler et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
U.S. Army Medical Research and Materiel Command (USAMRMC)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
APPLICANT(S) University of Utah Research Foundation (Salt Lake City, Utah)
ASSIGNEE(S)
INVENTOR(S) Julian Kessler (Salt Lake City, Utah);  Michael S. Yu (Salt Lake City, Utah);  Yang Li (Salt Lake City, Utah)
ABSTRACT Disclosed are peptide conjugates comprising an active agent, a spacer moiety, and a dimeric collagen hybridizing peptide comprising a first and second collagen hybridizing peptide, a linker; and a branch point, wherein the first and second collagen hybridizing peptides comprise the sequence of at least (GXY)n, wherein G is glycine, wherein X and Y are any amino acid, and wherein n is any number between 3 and 12. Also disclosed are methods of detecting denatured collagen in a sample comprising contacting a composition comprising any one of the disclosed peptide conjugates to a sample, wherein the active agent comprises a therapeutic agent, and detecting the presence or absence of binding of the peptide conjugate to denatured collagen, the presence of binding indicating the presence of denatured collagen in the sample. Also disclosed are methods of treating a disease or injury involving collagen damage comprising administering to a subject having a disease or injury involving collagen damage any one of the disclosed peptide conjugates.
FILED Wednesday, February 24, 2021
APPL NO 17/184289
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 47/64 (20170801)
A61K 47/65 (20170801)
A61K 47/641 (20170801) Original (OR) Class

Peptides
C07K 14/78 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/6887 (20130101)
G01N 2333/78 (20130101)
G01N 2500/20 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322689 Hoekman et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
Small Business Administration (SBA)
Small Business Innovation Research (SBIR)
APPLICANT(S) Impel Neuropharma, Inc. (Seattle, Washington)
ASSIGNEE(S)
INVENTOR(S) John D. Hoekman (Seattle, Washington);  Michael Hite (Normandy Park, Washington);  Alan Brunelle (Woodinville, Washington);  Joel Relethford (Everett, Washington)
ABSTRACT A nozzle for use in delivering a mixture of aerosol propellant and drug formulation. The nozzle includes a drug product inlet configured to receive a mixture of aerosolized propellant and an intranasal dosage form. The inlet is disposed at the proximal end. A nozzle body is secured to the drug product inlet. Two or more channels are disposed within the body. Two or more orifice apertures are disposed at the distal end of the nozzle.
FILED Monday, February 01, 2021
APPL NO 17/164371
CURRENT CPC
Devices for Introducing Media Into, or Onto, the Body; Devices for Transducing Body Media or for Taking Media From the Body; Devices for Producing or Ending Sleep or Stupor
A61M 15/08 (20130101) Original (OR) Class
A61M 15/0021 (20140204)
A61M 16/127 (20140204)
A61M 16/208 (20130101)
A61M 2210/0612 (20130101)
A61M 2210/0618 (20130101)
A61M 2210/1067 (20130101)
A61M 2210/1475 (20130101)

Spraying Apparatus; Atomising Apparatus; Nozzles
B05B 1/14 (20130101)
B05B 7/08 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322771 Wagner et al.
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
Department of the Army (DOA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
APPLICANT(S) Highland Instruments, Inc. (Somerville, Massachusetts)
ASSIGNEE(S) Highland Instruments, Inc. (Somerville, Massachusetts)
INVENTOR(S) Timothy Andrew Wagner (Somerville, Massachusetts);  Uri Tzvi Eden (Somerville, Massachusetts)
ABSTRACT The invention generally relates to methods of stimulating tissue based upon filtering properties of the tissue. In certain aspects, the invention provides methods for stimulating tissue that involve analyzing at least one filtering property of a region of at least one tissue, and providing a dose of energy to the at least one region of tissue based upon results of the analyzing step.
FILED Monday, April 19, 2021
APPL NO 17/233762
CURRENT CPC
Physical Therapy Apparatus, e.g Devices for Locating or Stimulating Reflex Points in the Body; Artificial Respiration; Massage; Bathing Devices for Special Therapeutic or Hygienic Purposes or Specific Parts of the Body
A61H 23/0236 (20130101)
A61H 23/0245 (20130101)

Electrotherapy; Magnetotherapy; Radiation Therapy; Ultrasound Therapy
A61N 1/36025 (20130101) Original (OR) Class
A61N 1/36082 (20130101)
A61N 5/02 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322951 Medina et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
Secretary of the Army (SECARMY)
APPLICANT(S) United States of America as Represented by The Secretary of The Army (Alexandria, Virginia)
ASSIGNEE(S)
INVENTOR(S) Victor F Medina (Clinton, Mississippi);  Scott A Waisner (Vicksburg, Mississippi);  Charles C Ellison (Vicksburg, Mississippi);  Jose Mattei-Sosa (Vicksburg, Mississippi);  Jacob M Lalley (Vicksburg, Mississippi);  Christopher S Griggs (Vicksburg, Mississippi)
ABSTRACT In one embodiment, a system of PFAS (Per-Poly-fluorinated alkyl substances) effluent liquid treatment includes: a pump to pump a liquid received via an intake; a sediment filter to filter sediment from the liquid; a granular activated carbon (GAC) device, disposed downstream of the sediment filter, to remove organic contaminants from the liquid; one (preferably two) or more ion exchange resin columns, disposed downstream of the GAC device, to remove PFAS constituents from the liquid; and a plurality of control valves being controlled to direct the liquid to flow along one or more liquid flow paths through the ion exchange resin columns so as to adjust a rate of processing the liquid by the ion exchange resin columns. Directing the flow takes into consideration factors including any minimum rate of processing, any maximum amount of waste generation, and any target remaining PFAS contamination in the liquid after processing.
FILED Tuesday, April 21, 2020
APPL NO 16/854874
CURRENT CPC
Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus
B01J 20/20 (20130101) Original (OR) Class

Treatment of Water, Waste Water, Sewage, or Sludge
C02F 1/283 (20130101)
C02F 2101/36 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322976 NG Pitti et al.
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
Department of Health and Human Services (HHS)
Food and Drug Administration (FDA)
APPLICANT(S) President and Fellows of Harvard College (Cambridge, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Carlos Francisco NG Pitti (Jamaica Plain, Massachusetts);  Ulri Nicole Lee (Seattle, Washington);  Richard Novack (Boston, Massachusetts);  Olivier Yves Frederic Henry (Brookline, Massachusetts);  Remco Franciscus Peter Van Erp (Sint Anthonis, Netherlands);  Donald E. Ingber (Boston, Massachusetts)
ABSTRACT A fluidic device includes a fluidic layer, a capture material, and an electronics layer, the fluidic layer includes a main channel and a pair of sample channels fluidly coupled to the main channel. The pair of sample channels is configured to receive and introduce a sample material into the device. The sample material includes an analyte. The capture material is positioned in a portion of the main channel that is spaced from the pair of sample channels. The capture material has a three-dimensional matrix of receptors therein configured to bond with the analyte. The capture material has a length that is associated with a dynamic range of the fluidic device and a cross-sectional area that is associated with a sensitivity of the fluidic device. The electronics layer includes electrodes configured to measure an electrical resistance through a portion of the capture material.
FILED Wednesday, March 14, 2018
APPL NO 16/494230
CURRENT CPC
Chemical or Physical Laboratory Apparatus for General Use
B01L 3/502707 (20130101) Original (OR) Class
B01L 3/502715 (20130101)
B01L 2300/069 (20130101)
B01L 2300/0645 (20130101)
B01L 2300/0867 (20130101)
B01L 2300/0896 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 27/08 (20130101)
G01N 33/48707 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210323257 O'Keefe
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
U.S. Air Force
APPLICANT(S) Massachusetts Institute of Technology (Cambridge, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Cheryl O'Keefe (North Billerica, Massachusetts)
ABSTRACT Techniques are disclosed for modifying the acoustic signature of plastic structures. An example structure implementing the techniques includes an inner wall forming an inner shell of the structure, the inner wall having a first edge and a second edge opposing the first edge, and an outer wall forming an outer shell of the structure, the outer wall having a first edge and a second edge opposing the first edge. The structure also includes an upper wall member joining the first edge of the inner wall to the first edge of the outer wall and a lower wall member joining the second edge of the inner wall to the second edge of the outer wall to form a wall cavity, an infill structure within the wall cavity, and at least two holes in the structure providing an opening from an exterior of the structure to the wall cavity.
FILED Wednesday, March 31, 2021
APPL NO 17/218835
CURRENT CPC
Producing Particular Articles From Plastics or From Substances in a Plastic State
B29D 99/0089 (20130101) Original (OR) Class

Additive Manufacturing, i.e Manufacturing of Three-dimensional [3-D] Objects by Additive Deposition, Additive Agglomeration or Additive Layering, e.g by 3-d Printing, Stereolithography or Selective Laser Sintering
B33Y 70/00 (20141201)
B33Y 80/00 (20141201)

Radio Direction-finding; Radio Navigation; Determining Distance or Velocity by Use of Radio Waves; Locating or Presence-detecting by Use of the Reflection or Reradiation of Radio Waves; Analogous Arrangements Using Other Waves
G01S 7/521 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210323352 Manesh et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
Army Research Laboratory (ARL)
Army Research Office (ARO)
United States Army (USA)
APPLICANT(S) Bridgestone Americas Tire Operations, LLC (Nashville, Tennessee)
ASSIGNEE(S)
INVENTOR(S) Ali Manesh (Chicago, Illinois);  Mike Tercha (Weston, Wisconsin);  Brian Anderson (Wausau, Wisconsin);  Karen Schlei (Wausau, Wisconsin);  Brian Meliska (Weston, Wisconsin);  Louis Stark (Kronenwetter, Wisconsin);  Benjamin Knospe (Merrill, Wisconsin);  Fidelis Ceranski (Marathon, Wisconsin);  Glenn Howland (Kronenwetter, Wisconsin)
ABSTRACT A non-pneumatic tire and hub assembly includes an inner ring having an axis of rotation, a deformable outer ring, and a flexible web extending between the inner ring and the deformable outer ring. The assembly further includes a hollow, metal cylinder coupled to the inner ring. The hollow, metal cylinder has a flanged portion extending towards an interior portion of the hollow, metal cylinder.
FILED Tuesday, April 20, 2021
APPL NO 17/235250
CURRENT CPC
Vehicle Tyres Tyre Inflation; Tyre Changing or Repairing; Repairing, or Connecting Valves To, Inflatable Elastic Bodies in General; Devices or Arrangements Related to Tyres
B60C 7/00 (20130101)
B60C 7/14 (20130101) Original (OR) Class
B60C 7/18 (20130101)
B60C 7/24 (20130101)
B60C 2007/107 (20130101)

Technical Subjects Covered by Former US Classification
Y10T 152/10378 (20150115)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210323645 Price et al.
FUNDED BY
Department of Defense (DOD)
Department of the Navy (DON)
Secretary of the Navy (SECNAV)
APPLICANT(S) The United States of America, as represented by the Secretary of the Navy (Arlington, Virginia)
ASSIGNEE(S)
INVENTOR(S) Christopher M. Price (Monterey, California);  Paul R. Leary (Monterey, California);  Brian S. Bingham (Pacific Grove, California)
ABSTRACT The invention relates to a payload frame for deploying a payload underwater. The payload frame includes at least three lead screws, each lead screw connected near a top end of the lead screw to the payload by a corresponding spherical bearing; at least three motors, each motor connected to a bottom end of one of the lead screws, the motor to rotate the lead screw through the corresponding spherical bearing; at least three feet, each foot attached to one of the motors, the feet to support and secure the payload frame on a water body bed; an accelerometer attached to the payload, the accelerometer to measure gravity vectors of the payload; and a microcontroller connected to the accelerometer and the motors. The microcontroller to receive the gravity vectors from the accelerometer and control each of the motors based on the gravity vectors to position the payload in a target orientation.
FILED Wednesday, April 21, 2021
APPL NO 17/236975
CURRENT CPC
Offensive or Defensive Arrangements on Vessels; Mine-laying; Mine-sweeping; Submarines; Aircraft Carriers
B63G 8/001 (20130101) Original (OR) Class
B63G 8/20 (20130101)
B63G 2008/004 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210323689 Pan et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
Air Force Materiel Command (AFMC)
Air Force Research Laboratory (AFRL)
APPLICANT(S) MICROLINK DEVICES, INC. (Niles, Illinois)
ASSIGNEE(S)
INVENTOR(S) Noren Pan (Wilmette, Illinois);  Raymond Chan (Hoffman Estates, Illinois);  Haruki Miyamoto (Arlington Heights, Illinois);  Andree Wibowo (Itasca, Illinois);  Mark Osowski (Vernon Hills, Illinois);  Christopher Youtsey (Libertyville, Illinois);  David McCallum (West Chicago, Illinois)
ABSTRACT Some embodiments include a high efficiency, lightweight solar sheet. Some embodiments include a solar sheet configured for installation on a surface of a UAV or on a surface of a component of a UAV. The solar sheet includes a plurality of solar cells and a polymer layer to which the plurality of solar cells are attached. Some embodiments include a kit for supplying solar power in a battery-powered or fuel cell powered unmanned aerial vehicle (UAV) by incorporating flexible solar cells into a component of a UAV, affixing flexible solar cells to a surface of a UAV, or affixing flexible solar cells to a surface of a component of a UAV. The kit also includes a power conditioning system configured to operate the solar cells within a desired power range and configured to provide power having a voltage compatible with an electrical system of the UAV.
FILED Wednesday, June 23, 2021
APPL NO 17/356017
CURRENT CPC
Propulsion of Electrically-propelled Vehicles; Supplying Electric Power for Auxiliary Equipment of Electrically-propelled Vehicles; Electrodynamic Brake Systems for Vehicles in General; Magnetic Suspension or Levitation for Vehicles; Monitoring Operating Variables of Electrically-propelled Vehicles; Electric Safety Devices for Electrically-propelled Vehicles
B60L 8/003 (20130101)
B60L 53/00 (20190201)
B60L 2200/10 (20130101)

Aeroplanes; Helicopters
B64C 39/024 (20130101)
B64C 2201/021 (20130101)
B64C 2201/042 (20130101)

Equipment for Fitting in or to Aircraft; Flying Suits; Parachutes; Arrangements or Mounting of Power Plants or Propulsion Transmissions in Aircraft
B64D 27/24 (20130101) Original (OR) Class
B64D 2221/00 (20130101)

Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for
H01L 31/046 (20141201)

Generation of Electric Power by Conversion of Infra-red Radiation, Visible Light or Ultraviolet Light, e.g Using Photovoltaic [PV] Modules
H02S 10/40 (20141201)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210323868 Wadley et al.
FUNDED BY
Department of Defense (DOD)
Department of the Navy (DON)
Office of Naval Research (ONR)
APPLICANT(S) University of Virginia Patent Foundation (Charlottesville, Virginia)
ASSIGNEE(S) University of Virginia Patent Foundation (Charlottesville, Virginia)
INVENTOR(S) Haydn N. G. Wadley (Keswick, Virginia);  Jeroen A. Deijkers (Charlottesville, Virginia)
ABSTRACT A new class of multi-component rare earth multi-silicate materials has been created for use in harsh environments such as gas turbine engines. Moreover, by combining two-or-more rare earth disilicates the properties (for example, thermal expansion, thermal conductivity, etc.) can be tailored to fit specific applications, such as having a matching thermal expansion with that of silicon-based composites and a low thermal conductivity close to that of 1 W/m K. Applications can be extended for use with other material classes such as MCrAlY, MAX-phase, and refractory metal alloys, utilizing a thermal expansion of up to about 15−10−6 /° C. By mixing of specific sets of rare earth disilicates it is possible to obtain a high entropy or entropy stabilized mixture, and utilize features such as “sluggish diffusion”, and more.
FILED Thursday, August 29, 2019
APPL NO 17/271773
CURRENT CPC
Lime, Magnesia; Slag; Cements; Compositions Thereof, e.g Mortars, Concrete or Like Building Materials; Artificial Stone; Ceramics; Refractories; Treatment of Natural Stone
C04B 28/006 (20130101) Original (OR) Class
C04B 41/009 (20130101)
C04B 41/87 (20130101)
C04B 41/89 (20130101)
C04B 41/522 (20130101)
C04B 41/5024 (20130101)
C04B 2111/00482 (20130101)

Non-positive Displacement Machines or Engines, e.g Steam Turbines
F01D 5/288 (20130101)

Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy
H01M 8/04067 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324010 Tsao et al.
FUNDED BY
Department of Defense (DOD)
Defense Threat Reduction Agency (DTRA)
APPLICANT(S) University of Washington (Seattle, Washington)
ASSIGNEE(S) University of Washington (Seattle, Washington)
INVENTOR(S) Caroline Tsao (Seattle, Washington);  Sijin Luozhong (Seattle, Washington);  Trevor Corrigan (Seattle, Washington);  Shaoyi Jiang (Seattle, Washington);  Erik Liu (Seattle, Washington);  Patrick McMullen (Seattle, Washington)
ABSTRACT Charged polypeptides, their conjugates, and fusion proteins comprising such polypeptides are disclosed. Inclusion of such a polypeptide in a fusion protein increases the protein's properties such as stability and circulation half-life, which results in a better therapeutic efficacy compared to an active protein alone. Thus, a fusion protein or a conjugate of the disclosure can be useful in developing a protein or peptide drug, treating or preventing diseases, disorders, or conditions, or improving a subjects health or wellbeing.
FILED Thursday, October 10, 2019
APPL NO 17/283708
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 47/645 (20170801)

Peptides
C07K 14/00 (20130101) Original (OR) Class
C07K 14/56 (20130101)
C07K 14/535 (20130101)
C07K 14/43595 (20130101)
C07K 2319/00 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324011 SHEN et al.
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
Department of the Army (DOA)
Army Research Office (ARO)
APPLICANT(S) UNIVERSITY OF WASHINGTON (Seattle, Washington)
ASSIGNEE(S)
INVENTOR(S) Hao SHEN (Seattle, Washington);  Jorge FALLAS (Seattle, Washington);  David BAKER (Seattle, Washington)
ABSTRACT Disclosed herein are polypeptides having the amino acid sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the full length of the amino acid sequence selected from the group consisting of SEQ ID NO: 1-33 and 36, wherein the polypeptides include at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% of the identified interface residues, and wherein the polypeptides are capable of end-to-end homo-polymerization, homo-polymers of the polypeptides, and related capping and anchor proteins to facilitate homo-polymer formation.
FILED Thursday, October 24, 2019
APPL NO 17/285057
CURRENT CPC
Peptides
C07K 1/00 (20130101)
C07K 14/001 (20130101) Original (OR) Class
C07K 2319/00 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324051 CROWE, Jr. et al.
FUNDED BY
Department of Defense (DOD)
Defense Threat Reduction Agency (DTRA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
APPLICANT(S) VANDERBILT UNIVERSITY (Nashville, Tennessee);  BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (Austin, Texas)
ASSIGNEE(S)
INVENTOR(S) James E. CROWE, Jr. (Nashville, Tennessee);  Andrew I. FLYAK (Nashville, Tennessee);  Alexander BUKREYEV (Galveston, Texas);  Philipp ILINYKH (Galveston, Texas)
ABSTRACT The present disclosure is directed to antibodies binding to Marburg virus (MARV) glycoprotein (GP) and methods of use therefore.
FILED Thursday, July 01, 2021
APPL NO 17/365429
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 2039/505 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 31/14 (20180101)

Peptides
C07K 16/10 (20130101) Original (OR) Class
C07K 16/468 (20130101)

Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/701 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324071 COOPER et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
U.S. Army Medical Research and Materiel Command (USAMRMC)
APPLICANT(S) BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (Cambridge, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Laurence J.N. COOPER (Houston, Texas);  Ana Beatriz KORNGOLD (Houston, Texas);  Brian A. RABINOVICH (Houston, Texas);  Harjeet SINGH (Houston, Texas);  Simon OLIVARES (Houston, Texas)
ABSTRACT Provided are methods of generating chimeric antigen receptors (CAR). In some embodiments, library screening of CAR is performed by generating a vector encoding the CAR from random attachment of vectors from libraries of vectors encoding antigen-binding domains (e.g., scFv regions), hinge regions, and endodomains. In some embodiments, the vectors contain a transposon.
FILED Friday, February 26, 2021
APPL NO 17/187074
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 35/17 (20130101)
A61K 2035/124 (20130101)

Peptides
C07K 14/4746 (20130101)
C07K 14/4748 (20130101)
C07K 14/7051 (20130101)
C07K 14/70517 (20130101)
C07K 14/70521 (20130101)
C07K 14/70578 (20130101)
C07K 16/2803 (20130101) Original (OR) Class
C07K 2317/622 (20130101)
C07K 2319/00 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 9/1241 (20130101)
C12N 15/85 (20130101)

Enzymes
C12Y 207/07 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324121 Liebfarth et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
Army Research Office (ARO)
National Science Foundation (NSF)
APPLICANT(S) The University of North Carolina at Chapel Hill (Chapel Hill, North Carolina)
ASSIGNEE(S)
INVENTOR(S) Frank Liebfarth (Carrboro, North Carolina);  Aaron Teator (Chapel Hill, North Carolina)
ABSTRACT Disclosed herein are isotactic polyvinyl ethers and improved methods of making same. The method disclosed herein can produce polyvinyl ethers having a higher isotacticity as compared to polyvinyl ethers prepared with conventional methods.
FILED Thursday, August 15, 2019
APPL NO 17/269247
CURRENT CPC
Macromolecular Compounds Obtained by Reactions Only Involving Carbon-to-carbon Unsaturated Bonds
C08F 216/20 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324205 Walters et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
Air Force Materiel Command (AFMC)
United States Air Force (USAF)
APPLICANT(S) PPG Industries Ohio, Inc. (Cleveland, Ohio)
ASSIGNEE(S) PPG Industries Ohio, Inc. (Cleveland, Ohio)
INVENTOR(S) David N. Walters (Slippery Rock, Pennsylvania);  John R. Schneider (Sharpsburg, Pennsylvania)
ABSTRACT Coating compositions are disclosed that include corrosion resisting particles such that the coating composition can exhibit corrosion resistance properties. Also disclosed are substrates at least partially coated with a coating deposited from such a composition and multi-component composite coatings, wherein at least one coating later is deposited from such a coating composition. Methods and apparatus for making ultrafine solid particles are also disclosed.
FILED Wednesday, April 21, 2021
APPL NO 17/236576
CURRENT CPC
Macromolecular Compounds Obtained by Reactions Only Involving Carbon-to-carbon Unsaturated Bonds
C08F 283/006 (20130101)
C08F 290/06 (20130101)
C08F 299/06 (20130101)

Macromolecular Compounds Obtained Otherwise Than by Reactions Only Involving Unsaturated Carbon-to-carbon Bonds
C08G 18/672 (20130101)
C08G 18/3206 (20130101)

Compositions of Macromolecular Compounds
C08L 23/26 (20130101)
C08L 27/00 (20130101)

Coating Compositions, e.g Paints, Varnishes or Lacquers; Filling Pastes; Chemical Paint or Ink Removers; Inks; Correcting Fluids; Woodstains; Pastes or Solids for Colouring or Printing; Use of Materials Therefor
C09D 4/06 (20130101)
C09D 5/002 (20130101)
C09D 5/084 (20130101) Original (OR) Class
C09D 7/67 (20180101)
C09D 123/26 (20130101)
C09D 175/16 (20130101)

Technical Subjects Covered by Former US Classification
Y10T 428/258 (20150115)
Y10T 428/31522 (20150401)
Y10T 428/31529 (20150401)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324269 Boyd et al.
FUNDED BY
Department of Defense (DOD)
Department of the Navy (DON)
Secretary of the Navy (SECNAV)
APPLICANT(S) The Government of the United States of America, as represented by the Secretary of the Navy (Arlington, Virginia)
ASSIGNEE(S) The Government of the United States of America, as represented by the Secretary of the Navy (Arlington, Virginia)
INVENTOR(S) Darryl A. Boyd (Alexandria, Virginia);  Michael H. Stewart (Springfield, Virginia);  Kimihiro Susumu (Alexandria, Virginia);  Eunkeu Oh (Alexandria, Virginia);  James P. Wissman (Hyattsville, Maryland)
ABSTRACT This disclosure concerns a method of making a ligand for Quantum Dot functionalization, a method of making a functionalized Quantum Dot (QD) with a ligand, and a method of making a transparent luminescent quantum dot thiol-yne nanocomposite with tailorable optical, thermal, and mechanical properties. The prepolymer solution and functionalized Quantum Dot can be used in additive manufacturing.
FILED Wednesday, June 30, 2021
APPL NO 17/363526
CURRENT CPC
Heterocyclic Compounds
C07D 339/04 (20130101)

Materials for Miscellaneous Applications, Not Provided for Elsewhere
C09K 11/02 (20130101)
C09K 11/886 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324311 Skardal et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
Air Force Space Command (AFSPC)
Space Systems Command (SSC)
Department of the Army (DOA)
U.S. Army Medical Research and Materiel Command (USAMRMC)
Department of the Navy (DON)
Space and Naval Warfare Systems (SPAWAR)
Defense Threat Reduction Agency (DTRA)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
APPLICANT(S) Wake Forest University Health Sciences (Winston-Salem, North Carolina)
ASSIGNEE(S)
INVENTOR(S) Aleksander Skardal (Clemmons, North Carolina);  Thomas Shupe (Mocksville, North Carolina);  Anthony Atala (Winston-Salem, North Carolina)
ABSTRACT Described herein are apparatus, including multi-tissue body-on-a-chip apparatus. In some embodiments, described are apparatus including at least a first, second, and third chamber in fluid communication with one another and with at least one tissue in each chamber, such as, for example, liver tissue in said first chamber; cardiac muscle tissue in said second chamber; and lung tissue in said third chamber; and a common aqueous growth media in said first, second, and third chamber. In some embodiments, the apparatus includes a fourth chamber including testicular or ovarian tissue in said fourth chamber. In some embodiments, the apparatus includes an optional fifth or sixth chamber; each said chamber includes different additional tissue selected from the group consisting of vascular endothelial, skeletal muscle, kidney, nerve, brain, and intestinal tissue (e.g., small intestine tissue and/or colon tissue). Also described are methods of using an apparatus of the present invention.
FILED Tuesday, October 10, 2017
APPL NO 16/341521
CURRENT CPC
Apparatus for Enzymology or Microbiology;
C12M 21/08 (20130101) Original (OR) Class
C12M 23/16 (20130101)
C12M 23/44 (20130101)
C12M 29/10 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/5082 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324357 CHOUDHARY et al.
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
Department of the Army (DOA)
Department of the Navy (DON)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
APPLICANT(S) THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (BOSTON, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Amit CHOUDHARY (Boston, Massachusetts);  Qingxuan ZHOU (BOSTON, Massachusetts);  Praveen KOKKONDA (BOSTON, Massachusetts)
ABSTRACT The disclosure includes non-naturally occurring or engineered CRISPR Cas variant proteins comprising one or more functional domains and degrader compositions specifically targeting the CRISPR Cas variant proteins; compositions, systems and methods of using the CRISPR Cas variant proteins comprising one or more functional domains and degrader compounds for spatio-temporal control are also provided.
FILED Tuesday, August 20, 2019
APPL NO 17/270358
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/454 (20130101)
A61K 31/506 (20130101)
A61K 31/7088 (20130101)
A61K 38/465 (20130101)
A61K 48/00 (20130101)

Peptides
C07K 2319/95 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 9/22 (20130101) Original (OR) Class
C12N 15/11 (20130101)
C12N 2310/20 (20170501)
C12N 2800/80 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324382 Jakimo et al.
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
APPLICANT(S) Massachusetts Institute of Technology (Cambridge, Massachusetts)
ASSIGNEE(S) Massachusetts Institute of Technology (Cambridge, Massachusetts)
INVENTOR(S) Noah Jakimo (Boston, Massachusetts);  Pranam Chatterjee (Cambridge, Massachusetts);  Joseph M. Jacobson (Newton, Massachusetts)
ABSTRACT A chimeric DNA:RNA guide for very high accuracy Cas9 genome editing employs nucleotide-type substitutions in nucleic acid-guided endonucleases for enhanced specificity. The CRISPR-Cas9 gene editing system is manipulated to generate chimeric DNA:RNA guide strands to minimize the off-target cleavage events of the S. pyogenes Cas9 endonuclease. A DNA:RNA chimeric guide strand is sufficient to guide Cas9 to a specified target sequence for indel formation and minimize off-target cleavage events due to the specificity conferred by DNA-DNA interactions. Use of chimeric mismatch-evading lowered-thermostability guides (“melt-guides”) demonstrate that nucleotide-type substitutions in the spacer can reduce cleavage of sequences mismatched by as few as a single base pair. The chimeric mismatch-evading lowered-thermostability guides replace most gRNA spacer positions with DNA bases to suppress mismatched targets under Cas9's catalytic threshold.
FILED Friday, January 22, 2021
APPL NO 17/156492
CURRENT CPC
Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 9/22 (20130101)
C12N 9/96 (20130101)
C12N 15/11 (20130101) Original (OR) Class
C12N 15/111 (20130101)
C12N 15/907 (20130101)
C12N 15/1136 (20130101)
C12N 2310/20 (20170501)
C12N 2310/335 (20130101)
C12N 2310/343 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324389 Abedi et al.
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
APPLICANT(S) California Institute of Technology (Pasadena, California)
ASSIGNEE(S)
INVENTOR(S) Mohamad H. Abedi (Pasadena, California);  Mikhail Shapiro (Pasadena, California);  Dan I. Piraner (Pasadena, California);  Justin Lee (Pasadena, California)
ABSTRACT Disclosed herein include methods, compositions, and kits suitable for use in spatiotemporal regulation of therapeutic T-cells through a combination of molecular and physical actuation. There are provided, in some embodiments, thermal bioswitches that allow T-cells to sense small changes in temperature and use them as inputs for the actuation of genetic circuits. Also disclosed herein are T cell activity sensors. Genetic circuits capable of inducing expression of a payload upon thermal stimulation and/or immune cell stimulation are provided. There are provided, in some embodiments, thermally actuated immune cells and methods of using are provided. Oscillator circuits and methods of preventing T cell exhaustion are also disclosed.
FILED Thursday, April 15, 2021
APPL NO 17/230998
CURRENT CPC
Peptides
C07K 14/7051 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 15/635 (20130101) Original (OR) Class
C12N 2830/008 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324512 Wu et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
Army Research Office (ARO)
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Materials Research (DMR)
APPLICANT(S) University of Kansas (Lawrence, Kansas)
ASSIGNEE(S)
INVENTOR(S) Judy Z. Wu (Lawrence, Kansas);  Qingfeng Liu (Nanjing, China PRC)
ABSTRACT A method of making a plasmonic metal/graphene heterostructure comprises heating an organometallic complex precursor comprising a metal at a first temperature T1 for a first period of time t1 to deposit a layer of the metal on a surface of a heated substrate, the heated substrate in fluid communication with the precursor; and heating, in situ, the precursor at a second temperature T2 for a second period of time t2 to simultaneously form on the layer of the metal, a monolayer of graphene and a plurality of carbon-encapsulated metal nanostructures comprising the metal, thereby providing the plasmonic metal/graphene heterostructure. The heated substrate is characterized by a third temperature T3. The plasmonic metal/graphene heterostructures, devices incorporating the heterostructures, and methods of using the heterostructures are also provided.
FILED Wednesday, July 03, 2019
APPL NO 17/255817
CURRENT CPC
Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures
B82Y 40/00 (20130101)

Coating Metallic Material; Coating Material With Metallic Material; Surface Treatment of Metallic Material by Diffusion into the Surface, by Chemical Conversion or Substitution; Coating by Vacuum Evaporation, by Sputtering, by Ion Implantation or by Chemical Vapour Deposition, in General
C23C 16/30 (20130101) Original (OR) Class
C23C 16/448 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 21/658 (20130101)

Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for
H01L 31/028 (20130101)
H01L 31/0232 (20130101)
H01L 31/02161 (20130101)
H01L 31/02363 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325303 Ancona et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
United States Army (USA)
Department of the Navy (DON)
Naval Research Laboratory (NRL)
Secretary of the Navy (SECNAV)
APPLICANT(S) The Government of the United States of America, as represented by the Secretary of the Navy (Arlington, Virginia)
ASSIGNEE(S)
INVENTOR(S) Mario Ancona (Alexandria, Virginia);  Hieu Bui (Alexandria, Virginia)
ABSTRACT The stiffness and topology of ultra-small circular DNAs and DNA/peptide hybrids are exploited to create a transducer of enzyme activity with low error rates. The modularity and flexibility of the concept are illustrated by demonstrating various transducers that respond to either specific restriction endonucleases or to specific proteases. In all cases the output is a DNA oligo signal that, as we show, can readily be converted directly to an optical readout, or can serve as input for further processing, for example, using DNA logic or amplification. By exploiting the DNA hairpin (or stem-loop) structure and the phenomenon of strand displacement, an enzyme signal is converted into a DNA signal, in the manner of a transducer. This is valuable because a DNA signal can be readily amplified, combined, and processed as information.
FILED Wednesday, June 16, 2021
APPL NO 17/348824
CURRENT CPC
Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/005 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 21/6428 (20130101) Original (OR) Class
G01N 33/52 (20130101)
G01N 33/542 (20130101)
G01N 2021/6432 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325333 Glaven et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
United States Army (USA)
Department of the Navy (DON)
Naval Research Laboratory (NRL)
Secretary of the Navy (SECNAV)
APPLICANT(S) The Government of the United States of Amerrica, as represented by the Secretary of the Navy (Arlington, Virginia)
ASSIGNEE(S)
INVENTOR(S) Sarah M. Glaven (Washington, District of Columbia);  Daniel A. Phillips (Washington, District of Columbia);  Matthew D. Yates (Washington, District of Columbia);  Leonard M. Tender (Bethesda, Maryland)
ABSTRACT A biocompatible electrochemical flow cell (eFC) for high resolution imaging of anode and cathode biofilms using laser scanning confocal microscopy employs optically transparent indium tin oxide (ITO)-coated electrode configured to allow observation of the flow chamber. This enables correlation of electrochemical signatures with biofilm development in real-time.
FILED Monday, April 19, 2021
APPL NO 17/233617
CURRENT CPC
Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 27/48 (20130101)
G01N 27/327 (20130101) Original (OR) Class
G01N 27/4161 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325355 Rubenstein et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
Secretary of the Air Force (SECAF)
APPLICANT(S) Government of the United States, as represented by the Secretary of the Air Force (Wright-Patterson AFB, Ohio)
ASSIGNEE(S) Government of the United States, as represented by the Secretary of the Air Force (Wright-Patterson AFB, Ohio)
INVENTOR(S) Mitchell H. Rubenstein (Beavercreek, Ohio);  Patrick Lewis (Alburquerque, New Mexico)
ABSTRACT A system for solventless calibration of volatile or semi-volatile compounds and methods thereof. The system includes a fluid path having a first end configured to be operably coupled to a fluid source and a second end configured to be operably coupled to the analytical instrument. A solid sorbent is disposed along the fluid path and is configured to absorb an analyte. The flow of fluid along the fluid path from the first end to the second end causes absorbed analyte to be desorbed from the solid sorbent at a desired concentration to the instrument.
FILED Thursday, June 24, 2021
APPL NO 17/356822
CURRENT CPC
Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus
B01J 20/103 (20130101)
B01J 20/262 (20130101)
B01J 2220/54 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 30/12 (20130101)
G01N 30/93 (20130101)
G01N 30/482 (20130101)
G01N 30/8665 (20130101) Original (OR) Class
G01N 2030/328 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325553 HAMEED et al.
FUNDED BY
Department of Defense (DOD)
Department of the Navy (DON)
Secretary of the Navy (SECNAV)
APPLICANT(S) The United States of America, as represnted by the Secratray of the Navy (Arlington, Virginia)
ASSIGNEE(S)
INVENTOR(S) Zishan HAMEED (Norfolk, Virginia);  John GATS (Seattle, Washington);  Jin-Woo HAN (San Jose, California);  Meyya Meyyappan (San Jose, California)
ABSTRACT A MEMS nanotube based radiation sensor that is low cost, low power, compact, reliable and is applicable across many fields and a method for fabricating such a sensor are described. Each sensor may be connected to an array of similar but distinct sensors that leverage different materials and nanotube technology to detect radiation.
FILED Saturday, April 17, 2021
APPL NO 17/233441
CURRENT CPC
Microstructural Devices or Systems, e.g Micromechanical Devices
B81B 7/0058 (20130101)

Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures
B82Y 30/00 (20130101)

Measurement of Nuclear or X-radiation
G01T 3/08 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325577 Kildishev et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
Air Force Office of Scientific Research (AFOSR)
Defense Advanced Research Projects Agency (DARPA)
APPLICANT(S) Purdue Research Foundation (West Lafayette, Indiana)
ASSIGNEE(S) Purdue Research Foundation (West Lafayette, Indiana)
INVENTOR(S) Alexander V. Kildishev (West Lafayette, Indiana);  Di Wang (West Lafayette, Indiana);  Zhaxylyk A. Kudyshev (West Lafayette, Indiana);  Maowen Song (West Lafayette, Indiana);  Alexandra Boltasseva (West Lafayette, Indiana);  Vladimir M. Shalaev (West Lafayette, Indiana)
ABSTRACT A plasmonic system is disclosed. The system includes at least one polarizer that is configured to provide at least one linearly polarized broadband light beam, an anisotropic plasmonic metasurface (APM) assembly having a plurality of nanoantennae each having a predetermined orientation with respect to a global axis representing encoded digital data, the APM assembly configured to receive the at least one linearly polarized broadband light beam and by applying localized surface plasmon resonance reflect light with selectable wavelengths associated with the predetermined orientations of the nanoantennae, and at least one analyzer that is configured to receive the reflected light with selectable wavelength, wherein the relative angles between each of the at least one analyzers and each of the at least one polarizers are selectable with respect to the global axis, thereby allowing decoding of the digital data.
FILED Wednesday, April 07, 2021
APPL NO 17/224338
CURRENT CPC
Optical Elements, Systems, or Apparatus
G02B 5/008 (20130101) Original (OR) Class

Information Storage Based on Relative Movement Between Record Carrier and Transducer
G11B 7/125 (20130101)
G11B 7/1381 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325656 Liu et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
Congressionally Directed Medical Research Programs (CDMRP)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Science Foundation (NSF)
APPLICANT(S) University of Washington (Seattle, Washington)
ASSIGNEE(S) University of Washington (Seattle, Washington)
INVENTOR(S) Jonathan T.C. Liu (Seattle, Washington);  Lindsey A. Barner (Seattle, Washington);  Adam K. Glaser (Seattle, Washington)
ABSTRACT Apparatuses, systems, and methods for solid immersion meniscus lenses (SIMlenses). An optical system may include a sample holder with a first side which supports a sample, and a second side opposite the first side. The second side of the sample holder may be in contact with an immersion fluid. Light passing between the sample and an objective lens may pass through the sample holder, immersion fluid, and a SIMlens positioned between the immersion fluid and objective. The SIMlens may have a first curved surface and a second curved surface, each of which may be shaped to match a wavefront of the light as it passes through the SIMlens. The immersion fluid, SIMlens, and environment containing the objective may all have different refractive indices.
FILED Wednesday, June 23, 2021
APPL NO 17/356135
CURRENT CPC
Optical Elements, Systems, or Apparatus
G02B 21/26 (20130101)
G02B 21/0032 (20130101)
G02B 21/33 (20130101) Original (OR) Class
G02B 21/248 (20130101)
G02B 21/367 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325952 Ardanaz et al.
FUNDED BY
Department of Defense (DOD)
National Security Agency (NSA)
APPLICANT(S) INTEL CORPORATION (Santa Clara, California)
ASSIGNEE(S) INTEL CORPORATION (SANTA CLARA, California)
INVENTOR(S) Federico Ardanaz (Hillsboro, Oregon);  Jonathan M. Eastep (Portland, Oregon);  Richard J. Greco (West Linn, Oregon);  Ramkumar Nagappan (Chandler, Arizona);  Alan B. Kyker (Winters, California)
ABSTRACT Apparatus, systems, and methods provide an interface between a plurality of hardware resources of a node and a power manager. The interface is configured to define one or more resource groups to expose to the power manager for power measurement and control, assign the plurality of hardware resources to the one or more resource groups, and provide a power allowance to each resource group.
FILED Thursday, June 24, 2021
APPL NO 17/357479
CURRENT CPC
Electric Digital Data Processing
G06F 1/325 (20130101) Original (OR) Class
G06F 1/3287 (20130101)
G06F 1/3293 (20130101)

Climate Change Mitigation Technologies in Information and Communication Technologies [ICT] i.e Information and Communication Technologies Aiming at the Reduction of Their Own Energy Use
Y02D 10/00 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210326464 ZHU
FUNDED BY
Department of Defense (DOD)
Defense Logistics Agency (DLA)
APPLICANT(S) NIRA, INC. (McLean, Virginia)
ASSIGNEE(S)
INVENTOR(S) Wen ZHU (McLean, Virginia)
ABSTRACT A method for document authorization and distribution is provided. The method is based on a system including a repository server, communicating with or hosting a repository; a blockchain network, including a plurality of peers; and a plurality of user devices, each communicating with the repository server or the blockchain network. The repository contains a plurality of published documents. A plurality of document publication records, a plurality of document dissemination records, and an access control smart contract are distributed over the peers. The method includes: when an access request for a published document is submitted by a user from a user device, retrieving the published document; verifying the document access right; encrypting the published document with a document password encrypted using the user's public key; signing and posting a document dissemination record, including the document password; and placing the document contents and a signed document hash value in a container document.
FILED Tuesday, April 21, 2020
APPL NO 16/854685
CURRENT CPC
Electric Digital Data Processing
G06F 16/93 (20190101)
G06F 16/954 (20190101)
G06F 21/602 (20130101)
G06F 21/6209 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210326664 Dasgupta et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
United States Army (USA)
Department of the Navy (DON)
Naval Research Laboratory (NRL)
Secretary of the Navy (SECNAV)
APPLICANT(S) The Government of the United States of America, as represented by the Secretary of the Navy (Arlington, Virginia)
ASSIGNEE(S)
INVENTOR(S) Prithviraj Dasgupta (Springfield, Virginia);  Joseph B. Collins (McLean, Virginia)
ABSTRACT Methods and systems are provided for automatic classification of information in an adversarial machine learning setting. For example, a learner that includes multiple classifiers may perform data classification automatically. Each classifier may be trained with adversarial data of a different strength. For a given query to be classified, the learner is configured to intelligently select a classifier that is commensurate with the adversarial strength of the data inside the query, without explicit knowledge of that data or its adversarial strength.
FILED Monday, March 01, 2021
APPL NO 17/188923
CURRENT CPC
Recognition of Data; Presentation of Data; Record Carriers; Handling Record Carriers
G06K 9/628 (20130101)
G06K 9/6278 (20130101) Original (OR) Class

Computer Systems Based on Specific Computational Models
G06N 20/20 (20190101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210326704 George
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
Department of the Navy (DON)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
NIH Office of the Director (NIHOD)
National Science Foundation (NSF)
APPLICANT(S) UNIVERISTY OF UTAH RESEARCH FOUNDATION (Salt Lake City, Utah)
ASSIGNEE(S)
INVENTOR(S) Jacob Anthony George (Salt Lake City, Utah)
ABSTRACT A method for training an artificial intelligence (AI) model for allowing a user to intuitively control an electronic device includes positioning a plurality of sensors at a plurality of particular positions on a human body for sensing electric signals. The method also includes recording a first set of electric signals from each of the plurality of sensors in a continuous manner. At the same time, a first set of motion intents associated with a first sequence of body movement is also recorded in a continuous manner. An AI regression model is trained using a neural network to map the first set of electric signals to the first set of motion intents. In response to receiving a second set of electric signals from the plurality of sensors in a continuous manner, the AI regression model predicts a motion intent, causing the electronic device to perform an action.
FILED Wednesday, April 14, 2021
APPL NO 17/230446
CURRENT CPC
Electric Digital Data Processing
G06F 3/014 (20130101)
G06F 3/015 (20130101)

Computer Systems Based on Specific Computational Models
G06N 3/04 (20130101)
G06N 3/08 (20130101) Original (OR) Class
G06N 3/063 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210326756 Khaleghi et al.
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
APPLICANT(S) The Regents of the University of California (Oakland, California)
ASSIGNEE(S)
INVENTOR(S) Behnam Khaleghi (La Jolla, California);  Tajana Simunic Rosing (San Diego, California);  Mohsen Imani (San Diego, California);  Sahand Salamat (San Diego, California)
ABSTRACT A method of providing a trained machine learning model can include providing a trained non-binary hyperdimensional machine learning model that includes a plurality of trained hypervector classes, wherein each of the trained hypervector classes includes N elements, and then, eliminating selected ones of the N elements from the trained non-binary hyperdimensional machine learning model based on whether the selected element has a similarity with other ones of the N elements, to provide a sparsified trained non-binary hyperdimensional machine learning model.
FILED Wednesday, April 07, 2021
APPL NO 17/224306
CURRENT CPC
Recognition of Data; Presentation of Data; Record Carriers; Handling Record Carriers
G06K 9/628 (20130101)
G06K 9/6256 (20130101)

Computer Systems Based on Specific Computational Models
G06N 20/00 (20190101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210327061 Clymer et al.
FUNDED BY
Department of Defense (DOD)
Department of the Navy (DON)
Office of Naval Research (ONR)
APPLICANT(S) Carnegie Mellon University (Pittsburgh, Pennsylvania);  UNIVERSITY OF PITTSBURGH – OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (Pittsburgh, Pennsylvania)
ASSIGNEE(S)
INVENTOR(S) Daniel Clymer (Pittsburgh, Pennsylvania);  Jonathan Cagan (Pittsburgh, Pennsylvania);  Philip LeDuc (Pittsburgh, Pennsylvania);  Liron Pantanowitz (Pittsburgh, Pennsylvania);  Janet Catov (Pittsburgh, Pennsylvania)
ABSTRACT A hierarchical deep-learning object detection framework provides a method for identifying objects of interest in high-resolution, high pixel count images, wherein the objects of interest comprise a relatively a small pixel count when compared to the overall image. The method uses first deep-learning model to analyze the high pixel count images, in whole or as a patchwork, at a lower resolution to identify objects, and a second deep-learning model to analyze the objects at a higher resolution to classify the objects.
FILED Friday, May 21, 2021
APPL NO 17/326541
CURRENT CPC
Recognition of Data; Presentation of Data; Record Carriers; Handling Record Carriers
G06K 9/6247 (20130101)
G06K 9/6268 (20130101)
G06K 2209/051 (20130101)

Image Data Processing or Generation, in General
G06T 7/0012 (20130101) Original (OR) Class
G06T 2207/10056 (20130101)
G06T 2207/20021 (20130101)
G06T 2207/20081 (20130101)
G06T 2207/30101 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210327403 Huang et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
Air Force Office of Scientific Research (AFOSR)
United States Air Force (USAF)
APPLICANT(S) The Curators of the University of Missouri (Columbia, Missouri)
ASSIGNEE(S)
INVENTOR(S) Guoliang Huang (Columbia, Missouri);  Yangyang Chen (Columbia, Missouri);  Xiaopeng Li (Columbia, Missouri)
ABSTRACT A programmable metasurface and method is described having a plurality of parallel slits in an elastic substrate plate defining a plurality of unit cells, each having an actuator beam and a sensing beam with a slit therebetween. Each sensing beam has a pair of sensors for sensing flexural waves in the substrate. The actuator beam has a piezoelectric actuator that is controlled by a control circuit where the control circuit generates an actuator signal and where the control circuit compares the preceding actuator signal to the difference between the sensors and an electrical transfer function to result in the metasurface being able to perform a desired function.
FILED Monday, September 16, 2019
APPL NO 17/262475
CURRENT CPC
Sound-producing Devices; Methods or Devices for Protecting Against, or for Damping, Noise or Other Acoustic Waves in General; Acoustics Not Otherwise Provided for
G10K 11/346 (20130101) Original (OR) Class
G10K 11/348 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210327486 van 't Erve et al.
FUNDED BY
Department of Defense (DOD)
Department of the Navy (DON)
Secretary of the Navy (SECNAV)
APPLICANT(S) The Government of the United States of America, as represented by the Secretary of the Navy (Arlington, Virginia)
ASSIGNEE(S) The Government of the United States of America, as represented by the Secretary of the Navy (Arlington, Virginia)
INVENTOR(S) Olaf M.J. van 't Erve (Falls Church, Virginia);  Steven P. Bennett (Alexandria, Virginia);  Adam L. Friedman (Silver Spring, Maryland)
ABSTRACT A metamagnetic tunneling-based spin valve device for multistate magnetic memory comprising an electronic memory logic element with four stable resistance states. A metamagnetic tunneling-based spin valve device for multistate magnetic memory comprising a layer of a metamagnetic material, a layer of a nonmagnetic material on the layer of a metamagnetic material, and a layer of a ferromagnetic material on the layer of a nonmagnetic material. A method of making a metamagnetic tunneling-based spin valve device for multistate magnetic memory.
FILED Tuesday, June 29, 2021
APPL NO 17/362355
CURRENT CPC
Static Stores
G11C 11/161 (20130101) Original (OR) Class
G11C 11/5607 (20130101)

Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for
H01L 43/08 (20130101)
H01L 43/10 (20130101)
H01L 43/12 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210327496 Snider et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
Air Force Research Laboratory (AFRL)
United States Air Force (USAF)
APPLICANT(S) Indiana Integrated Circuits, LLC (South Bend, Indiana);  University of Notre Dame du Lac (Notre Dame, Indiana)
ASSIGNEE(S)
INVENTOR(S) Gregory Snider (Niles, Michigan);  Rene Celis-Cordova (South Bend, Indiana);  Alexei Orlov (South Bend, Indiana);  Tian Lu (Osceola, Indiana);  Jason M. Kulick (South Bend, Indiana)
ABSTRACT In a method computer storage element operation, first and second rising (or falling) clock edges are applied to first and second power inputs of the computer storage element having a transistor array between the first and second power inputs over time T1 whereupon a logic value applied to an input of the transistor array is stored therein. Thereafter, first and second falling (or rising) clock edges are applied to the first and second power inputs over time T2, whereupon part of an electrical charge or energy associated with the logic value stored in the transistor array is provided to circuitry that generates the first and/or second clock edge(s), wherein the value(s) of time T1 and/or time T2 is/are greater than a product of RC, where R is resistance associated with the computer storage element, and C is a load capacitance associated with the computer storage element.
FILED Friday, February 19, 2021
APPL NO 17/179478
CURRENT CPC
Static Stores
G11C 11/412 (20130101) Original (OR) Class

Pulse Technique
H03K 3/0372 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210327540 Schobel et al.
FUNDED BY
Department of Defense (DOD)
Uniformed Services University of the Health Sciences (USUHS)
Henry M Jackson Foundation for the Advancement of Military Medicine, Inc (HJF)
APPLICANT(S) Henry M. Jackson Foundation for the Advancement of Military Medicine (Bethesda, Maryland);  Naval Medical Research Center (Silver Spring, Maryland);  Duke University Medical Center (Durham, North Carolina);  Emory University (Atlanta, Georgia)
ASSIGNEE(S) Henry M. Jackson Foundation for the Advancement of Military Medicine (Bethesda, Maryland);  Naval Medical Research Center (Silver Spring, Maryland);  Duke University Medical Center (Durham, North Carolina);  Emory University (Atlanta, Georgia)
INVENTOR(S) Seth A Schobel (Bethesda, Maryland);  Vivek Khatri (Bethesda, Maryland);  Felipe Lisboa (Bethesda, Maryland);  Matthew J. Bradley (Silver Spring, Maryland);  Christopher J. Dente (Atlanta, Georgia);  Timothy Buchman (Atlanta, Georgia);  Allan D. Kirk (Durham, North Carolina);  Jonathan A. Forsberg (Silver Spring, Maryland);  Todd V. Brennan (Durham, North Carolina);  Eric A. Elster (Bethesda, Maryland)
ABSTRACT The present disclosure describes methods and systems for predicting if a subject has an increased risk of having or developing one or more clinical outcomes, including prior to the detection of symptoms thereof and/or prior to onset of any detectable symptoms thereof. The present disclosure also describes a method of generating a model for predicting one or more clinical outcomes.
FILED Friday, August 16, 2019
APPL NO 17/268882
CURRENT CPC
Computer Systems Based on Specific Computational Models
G06N 20/00 (20190101)

Bioinformatics, i.e Information and Communication Technology [ICT] Specially Adapted for Genetic or Protein-related Data Processing in Computational Molecular Biology
G16B 5/20 (20190201)
G16B 40/00 (20190201) Original (OR) Class

Healthcare Informatics, i.e Information and Communication Technology [ICT] Specially Adapted for the Handling or Processing of Medical or Healthcare Data
G16H 10/40 (20180101)
G16H 10/60 (20180101)
G16H 50/20 (20180101)
G16H 50/30 (20180101)
G16H 50/70 (20180101)
G16H 70/20 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210327604 Russo et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
Army Research Laboratory (ARL)
APPLICANT(S) U.S. DEVCOM Army Research Laboratory (Adelphi, Maryland)
ASSIGNEE(S)
INVENTOR(S) John A. Russo (Spencerville, Maryland);  Marc S. Litz (Columbia, Maryland);  William B. Ray, II (Lubbock, Texas)
ABSTRACT An electrode for beta-photovoltaic cells includes: a substrate formed of a conductive layer with a thickness ranging between about 10 nm to 1 micron; a composite layer of radioluminescent phosphor with radioisotope particles homogeneously dispersed therein formed on conductive substrate with a thickness ranging between about 1 and 25 microns; and a semiconductor comprising a P-i-N/P-u-N junction or a N-i-P-P junction. The radioisotope may be a beta-emitter, such as Ni-63, H-3, Pm-147, or Sr-90/Y-90.
FILED Wednesday, June 30, 2021
APPL NO 17/363886
CURRENT CPC
Processes for the Electrolytic or Electrophoretic Production of Coatings; Electroforming; Apparatus Therefor
C25D 13/02 (20130101)
C25D 13/22 (20130101)

Obtaining Energy From Radioactive Sources; Applications of Radiation From Radioactive Sources, Not Otherwise Provided For; Utilising Cosmic Radiation
G21H 3/02 (20130101) Original (OR) Class

Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for
H01L 31/055 (20130101)
H01L 31/075 (20130101)
H01L 31/1884 (20130101)
H01L 31/03046 (20130101)
H01L 31/03048 (20130101)
H01L 31/022475 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210327694 Houlahan, JR. et al.
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
APPLICANT(S) Starfire Industries LLC (Champaign, Illinois)
ASSIGNEE(S)
INVENTOR(S) Thomas J. Houlahan, JR. (Urbana, Illinois);  Daniel P. Menet (Urbana, Illinois);  Ian F. Haehnlein (Champaign, Illinois);  Ivan A. Shchelkanov (Pleasanton, California);  Robert A. Stubbers (Savoy, Illinois);  Brian E. Jurczyk (Champaign, Illinois)
ABSTRACT A system and associated method are described for depositing high-quality films for providing a coating on a three-dimensional surface such as an internal surface of a bellows structure. The system includes a magnetic array comprising multiple sets of magnets arranged to have Hall-Effect regions that run lengthwise along a sputter target. The system further includes an elongated sputtering electrode material tube surrounding the magnetic array comprising multiple sets of magnets arranged to have Hall-Effect regions that run lengthwise along the sputter target. During operation, the system generates and controls ion flux for direct current high-power impulse magnetron sputtering. During operation logic circuitry issues a control signal to control a kick pulse property of a sustained positive voltage kick pulse taken from the group consisting of: onset delay, amplitude and duration.
FILED Monday, May 17, 2021
APPL NO 17/322600
CURRENT CPC
Coating Metallic Material; Coating Material With Metallic Material; Surface Treatment of Metallic Material by Diffusion into the Surface, by Chemical Conversion or Substitution; Coating by Vacuum Evaporation, by Sputtering, by Ion Implantation or by Chemical Vapour Deposition, in General
C23C 14/35 (20130101)
C23C 14/3485 (20130101)

Electric Discharge Tubes or Discharge Lamps
H01J 37/3405 (20130101)
H01J 37/3417 (20130101)
H01J 37/3467 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210328087 BURGER et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
U.S. Army
Army Research Office (ARO)
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Industrial Innovation and Partnerships (IIP)
APPLICANT(S) THE REGENTS OF THE UNIVERSITY OF MICHIGAN (Ann Arbor, Michigan)
ASSIGNEE(S) THE REGENTS OF THE UNIVERSITY OF MICHIGAN (Ann Arbor, Michigan)
INVENTOR(S) Tobias BURGER (Ann Arbor, Michigan);  Byungjun LEE (Ann Arbor, Michigan);  Dejiu FAN (Ann Arbor, Michigan);  Andrej LENERT (Ann Arbor, Michigan);  Stephen R. FORREST (Ann Arbor, Michigan)
ABSTRACT To reach high efficiencies, thermophotovoltaic cells must utilize the broad spectrum of a radiative thermal source. One promising approach to overcome this challenge is to have low-energy photons reflected and reabsorbed by the thermal emitter, where their energy can have another chance at contributing toward photogeneration in the cell. However, current methods for photon recuperation are limited by insufficient bandwidth or parasitic absorption, resulting in large efficiency losses relative to theoretical limits. This work demonstrates nearly perfect reflection of low-energy photons (˜99%) by embedding an air layer within the TPV cell. This result represents a four-fold reduction in parasitic absorption relative to existing TPV cells. As out-of-band reflectance approaches unity, TPV efficiency becomes nearly insensitive to cell bandgap and emitter temperature. Accessing this regime unlocks a range of possible materials and heat sources that were previously inaccessible to TPV energy conversion.
FILED Friday, April 16, 2021
APPL NO 17/232243
CURRENT CPC
Single-crystal-growth; Unidirectional Solidification of Eutectic Material or Unidirectional Demixing of Eutectoid Material; Refining by Zone-melting of Material; Production of a Homogeneous Polycrystalline Material With Defined Structure; Single Crystals or Homogeneous Polycrystalline Material With Defined Structure; After-treatment of Single Crystals or a Homogeneous Polycrystalline Material With Defined Structure; Apparatus Therefor
C30B 25/04 (20130101)
C30B 25/22 (20130101)

Photomechanical Production of Textured or Patterned Surfaces, e.g for Printing, for Processing of Semiconductor Devices; Materials Therefor; Originals Therefor; Apparatus Specially Adapted Therefor;
G03F 7/0005 (20130101)

Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for
H01L 31/043 (20141201)
H01L 31/0264 (20130101)
H01L 31/0687 (20130101) Original (OR) Class
H01L 31/0735 (20130101)
H01L 31/1852 (20130101)
H01L 31/1896 (20130101)
H01L 31/02327 (20130101)
H01L 33/0093 (20200501)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210328093 Pan et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
Air Force Research Laboratory (AFRL)
Department of Energy (DOE)
National Renewable Energy Laboratory (NREL)
APPLICANT(S) MICROLINK DEVICES, INC. (Niles, Illinois)
ASSIGNEE(S)
INVENTOR(S) Noren Pan (Wilmette, Illinois);  Glen Hillier (Spring Grove, Illinois);  Duy Phach Vu (San Jose, California);  Rao Tatavarti (Mount Prospect, Illinois);  Christopher Youtsey (Libertyville, Illinois);  David McCallum (West Chicago, Illinois);  Genevieve Martin (Chicago, Illinois)
ABSTRACT The present invention utilizes epitaxial lift-off in which a sacrificial layer is included in the epitaxial growth between the substrate and a thin film III-V compound solar cell. To provide support for the thin film III-V compound solar cell in absence of the substrate, a backing layer is applied to a surface of the thin film III-V compound solar cell before it is separated from the substrate. To separate the thin film III-V compound solar cell from the substrate, the sacrificial layer is removed as part of the epitaxial lift-off. Once the substrate is separated from the thin film III-V compound solar cell, the substrate may then be reused in the formation of another thin film III-V compound solar cell.
FILED Monday, February 08, 2021
APPL NO 17/170133
CURRENT CPC
Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for
H01L 31/1844 (20130101)
H01L 31/1852 (20130101) Original (OR) Class
H01L 31/1896 (20130101)
H01L 31/06875 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210328207 Eskra et al.
FUNDED BY
Department of Defense (DOD)
Defense Logistics Agency (DLA)
APPLICANT(S) Eskra Technical Products, Inc. (Saukville, Wisconsin)
ASSIGNEE(S)
INVENTOR(S) Michael David Eskra (Saukville, Wisconsin);  Paula Margaret Ralston (Frederick, Maryland);  Rodney Mortensen LaFollette (South Jordan, Utah);  James Bernard Nowakowski (Washburn, Wisconsin)
ABSTRACT A solventless system for fabricating electrodes includes a mechanism for feeding a substrate through the system, a first application region comprised of a first device for applying a first layer to the substrate, wherein the first layer is comprised of an active material mixture and a binder, and the binder includes at least one of a thermoplastic material and a thermoset material, and the system includes a first heater positioned to heat the first layer.
FILED Monday, May 17, 2021
APPL NO 17/302944
CURRENT CPC
Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy
H01M 4/0404 (20130101) Original (OR) Class
H01M 4/0419 (20130101)
H01M 4/622 (20130101)
H01M 4/623 (20130101)
H01M 4/625 (20130101)
H01M 4/1391 (20130101)
H01M 4/1393 (20130101)
H01M 4/1395 (20130101)
H01M 10/0565 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210328253 Zhang et al.
FUNDED BY
Department of Defense (DOD)
Department of the Navy (DON)
United States Navy (USN)
Small Business Administration (SBA)
Small Business Innovation Research (SBIR)
APPLICANT(S) Navitas Systems, LLC (Lisle, Illinois)
ASSIGNEE(S)
INVENTOR(S) Pu Zhang (Ann Arbor, Michigan);  Michael Wixom (Ann Arbor, Michigan);  Qingliu Wu (Ann Arbor, Michigan)
ABSTRACT Provided are electrode active materials with a porous structure and including a metal, that when loaded with sulfur serve as electrochemically superior cathode active materials. The metal structures are optionally used on their own, are coated with another material, or coats another porous structure such as a porous carbon structure that allows for excellent retention of both sulfur and polysulfides, are conductive themselves, and show long term stability and excellent cycle life.
FILED Monday, June 28, 2021
APPL NO 17/360687
CURRENT CPC
Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy
H01M 4/13 (20130101)
H01M 4/38 (20130101)
H01M 4/134 (20130101)
H01M 4/0402 (20130101)
H01M 4/624 (20130101)
H01M 4/625 (20130101)
H01M 4/663 (20130101)
H01M 4/808 (20130101)
H01M 4/5815 (20130101)
H01M 10/052 (20130101) Original (OR) Class
H01M 2004/027 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210328323 Kho et al.
FUNDED BY
Department of Defense (DOD)
Department of the Navy (DON)
Naval Information Warfare Center (NIWC)
Secretary of the Navy (SECNAV)
APPLICANT(S) United States Government as represented by the Secretary of the Navy (San Diego, California)
ASSIGNEE(S)
INVENTOR(S) Yong An Kho (Chula Vista, California);  Steven E. Mancewicz (San Diego, California)
ABSTRACT A planar antenna clamp system comprising: a base; a connector mounted to the base; a clamp arm mounted to the base such that, when in an open configuration, an air gap exists between the top surface of the base and the bottom surface of the clamp arm's distal end, and wherein the clamp arm and the base are oriented with respect to one another such that conductors of a planar antenna may be positioned in the air gap when in the open configuration; a matching circuit disposed on the top surface of the base and electrically connected to the connector; and a clamp configured to compress the conductors of the planar antenna between the top surface of the base and the bottom surface of the clamp arm such that the conductors of the planar antenna are operatively coupled with the matching circuit, when in a closed configuration.
FILED Friday, April 17, 2020
APPL NO 16/851554
CURRENT CPC
Antennas, i.e Radio Aerials
H01Q 1/1235 (20130101) Original (OR) Class
H01Q 9/045 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210328768 Ganje et al.
FUNDED BY
Department of Defense (DOD)
Department of the Air Force (DAF)
Air Force Life Cycle Management Center (AFLCMC)
United States Air Force (USAF)
APPLICANT(S) Rockwell Collins, Inc. (Cedar Rapids, Iowa)
ASSIGNEE(S) Rockwell Collins, Inc. (Cedar Rapids, Iowa)
INVENTOR(S) Stephen A. Ganje (Frisco, Texas);  Christopher M. Trebisovsky (Wylie, Texas)
ABSTRACT A receiver apparatus and method for optimized decryption and despreading of a very low frequency (VLF) bitstream is disclosed. In embodiments, the receiver includes antenna elements for receiving a transmission security (TRANSEC) encoded bitstream associated with an uncertainty window size and a spread factor. The receiver includes cryptographic processors that, when the spread factor is sufficiently large, select key section numbers A and data section numbers B based on the window size and spread factor. The cryptographic processors generate an output sequence of correlation windows, each correlation window associated with a symbol of the bitstream, via pipelined sectional mirrored-key convolution based on a key section number A and data section number B chosen to optimize performance (e.g., processor performance, memory performance).
FILED Thursday, April 08, 2021
APPL NO 17/225926
CURRENT CPC
Electric Digital Data Processing
G06F 17/142 (20130101)
G06F 21/72 (20130101)

Transmission of Digital Information, e.g Telegraphic Communication
H04L 9/065 (20130101) Original (OR) Class
H04L 9/0825 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210328943 Jones et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
U.S. Army
U.S. Army Tank-Automotive and Armaments Command (TACOM)
APPLICANT(S) BAE Systems Information and Electronic Systems Integration Inc. (Nashua, New Hampshire)
ASSIGNEE(S) BAE Systems Information and Electronic Systems Integration Inc. (Nashua, New Hampshire)
INVENTOR(S) Christopher L. Jones (Georgetown, Texas);  Paul W. Davis (Austin, Texas);  Dylan George (Austin, Texas);  Jonathon E. Kruger (Pflugerville, Texas)
ABSTRACT Methods and structures are disclosed for self-automating a process of determining a device's location based on its network address. A computing device includes a network interface configured to communicate with a physical port of a network switch and a memory configured to store a plurality of different initialization protocols each associated with a corresponding network address of a plurality of network addresses. Each of the initialization protocols may be associated with a different physical location. The computing device also includes a processor configured to attempt to connect to the network switch via the network interface using a network address from the stored plurality of network addresses. In response to connecting with the network switch using the network address, the processor identifies a corresponding initialization protocol associated with the network address and executes the corresponding initialized procedure.
FILED Wednesday, April 15, 2020
APPL NO 16/849446
CURRENT CPC
Electric Digital Data Processing
G06F 9/4401 (20130101)

Transmission of Digital Information, e.g Telegraphic Communication
H04L 45/745 (20130101)
H04L 49/351 (20130101) Original (OR) Class
H04L 61/25 (20130101)
H04L 61/6022 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210329026 Bogdan et al.
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
Department of the Navy (DON)
National Science Foundation (NSF)
APPLICANT(S) UNIVERSITY OF SOUTHERN CALIFORNIA (Los Angeles, California)
ASSIGNEE(S)
INVENTOR(S) Paul Bogdan (Los Angeles, California);  Yuankun Xue (Los Angeles, California)
ABSTRACT Methods, systems, devices and apparatuses for reconstructing a network. The network reconstruction system includes a processor. The processor is configured to determine an unknown sub-network of a network. The unknown sub-network includes multiple unknown nodes and multiple unknown links. The processor is configured to determine the unknown sub-network based on a known sub-network that has multiple known nodes and multiple known links, a network model and an attacker's statistical behavior to reconstruct the network. The processor is configured to determine one or more network parameters of the network. The network processor is configured to provide a probability of an outcome of an input or observation into the network or into a second network that has the one or more network parameters of the network.
FILED Monday, April 12, 2021
APPL NO 17/227966
CURRENT CPC
Computer Systems Based on Specific Computational Models
G06N 7/005 (20130101)

Transmission of Digital Information, e.g Telegraphic Communication
H04L 41/145 (20130101)
H04L 41/147 (20130101)
H04L 41/0866 (20130101)
H04L 63/1425 (20130101)
H04L 63/1441 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 

National Science Foundation (NSF) 

US 20210321954 Iasemidis et al.
FUNDED BY
National Science Foundation (NSF)
Office of Integrative Activities (OIA)
APPLICANT(S) LOUISIANA TECH RESEARCH CORPORATION (Ruston, Louisiana)
ASSIGNEE(S)
INVENTOR(S) Leonidis Iasemidis (Ruston, Louisiana);  Timothy N. Hutson (Ruston, Louisiana)
ABSTRACT Network analysis of a patient's neuro-cardio-respiratory system can be performed to detect an impending crisis, diagnose an abnormality, and/or provide informative feedback about a treatment regime. A system can receive data recorded by one or more recording devices from a patient. The data is time varying and related to two or more organs of the patient's neuro-cardio-respiratory system that are monitored. The system can estimate directional interactions between the two or more organs within the patient's body over time via a mathematical analysis of the data to identify one or more pathologies in a network of the neuro-cardio-respiratory system. When the one or more pathologies are identified, the system can provide the advance warning of the impending crisis, the diagnosis of the abnormality, or the informative feedback for the treatment regime.
FILED Tuesday, September 03, 2019
APPL NO 17/271961
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 5/021 (20130101)
A61B 5/0035 (20130101)
A61B 5/0245 (20130101)
A61B 5/4035 (20130101)
A61B 5/4064 (20130101)
A61B 5/4082 (20130101)
A61B 5/4094 (20130101)
A61B 5/4818 (20130101)
A61B 5/7275 (20130101) Original (OR) Class
A61B 5/7282 (20130101)
A61B 2560/02 (20130101)

Healthcare Informatics, i.e Information and Communication Technology [ICT] Specially Adapted for the Handling or Processing of Medical or Healthcare Data
G16H 50/20 (20180101)
G16H 50/30 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210321975 Sikdar et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
U.S. Army Medical Research and Materiel Command (USAMRMC)
National Science Foundation (NSF)
APPLICANT(S) George Mason University (Fairfax, Virginia)
ASSIGNEE(S)
INVENTOR(S) Siddhartha Sikdar (Washginton, District of Columbia);  Parag Chitnis (Burke, Virginia);  Biswarup Mukherjee (Fairfax, Virginia);  Joseph Majdi (Fairfax, Virginia)
ABSTRACT A low-power (e.g., battery-operated, etc.) wearable ultrasound system may be used to monitor the musculoskeletal function of a subject and provide information that may be used for electrical stimulation.
FILED Wednesday, April 21, 2021
APPL NO 17/236752
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 8/08 (20130101) Original (OR) Class
A61B 8/488 (20130101)
A61B 8/5223 (20130101)

Electrotherapy; Magnetotherapy; Radiation Therapy; Ultrasound Therapy
A61N 1/36003 (20130101)

Computer Systems Based on Specific Computational Models
G06N 20/00 (20190101)

Healthcare Informatics, i.e Information and Communication Technology [ICT] Specially Adapted for the Handling or Processing of Medical or Healthcare Data
G16H 20/30 (20180101)
G16H 30/40 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322004 Khanicheh et al.
FUNDED BY
National Science Foundation (NSF)
Small Business Administration (SBA)
Small Business Innovation Research (SBIR)
APPLICANT(S) EnVision Endoscopy, Inc. (Somerville, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Azadeh Khanicheh (Somerville, Massachusetts);  Isaac Ostrovsky (Wellesley, Massachusetts)
ABSTRACT Provided herein is an endoscopic suturing system configured for attachment to, and use with, an endoscope.
FILED Tuesday, June 22, 2021
APPL NO 17/354649
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 17/0469 (20130101) Original (OR) Class
A61B 17/0491 (20130101)
A61B 2017/047 (20130101)
A61B 2017/00473 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322333 Astete et al.
FUNDED BY
National Science Foundation (NSF)
Office of Experimental Program To Stimulate Competitive Research (EPSCOR)
APPLICANT(S) Board of Supervisors of Louisiana State University and Agricultural and Mechanical College (Baton Rouge, Louisiana)
ASSIGNEE(S) Board of Supervisors of Louisiana State University and Agricultural and Mechanical College (Baton Rouge, Louisiana)
INVENTOR(S) Carlos Astete (Baton Rouge, Louisiana);  Cristina Sabliov (Baton Rouge, Louisiana)
ABSTRACT Amphiphilic biopolymers have been synthesized by grafting lignin onto PLGA to form graft polymers, which can then be further assembled into polymeric nanoparticles without a requirement for surfactants. The nanoparticles have a typical diameter of 75 nm. The nanoparticles may be used, for example, for drug delivery, including efficient and effective drug delivery against cancers such as triple negative breast cancers.
FILED Wednesday, October 09, 2019
APPL NO 17/283730
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 9/5153 (20130101) Original (OR) Class
A61K 9/5192 (20130101)
A61K 31/437 (20130101)

Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures
B82Y 5/00 (20130101)

Macromolecular Compounds Obtained Otherwise Than by Reactions Only Involving Unsaturated Carbon-to-carbon Bonds
C08G 81/00 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322394 Zhang
FUNDED BY
National Science Foundation (NSF)
Directorate for Biological Sciences (BIO)
Division of Molecular and Cellular Biosciences (MCB)
APPLICANT(S) Purdue Research Foundation (West Lafayette, Indiana)
ASSIGNEE(S) Purdue Research Foundation (West Lafayette, Indiana)
INVENTOR(S) Chunhua Zhang (West Lafayette, Indiana)
ABSTRACT In one embodiment, the present application relates to methods and materials for weed control of a field of a crop plant using a cellulose biosynthesis inhibitor selected from the group consisting of ES20 and ES20-1 to ES20-9 of FIG. 1A. In another embodiment, the present disclosure relates to a method for treatment or prevention of an infection through inhibition of biofilm formation of microorganisms comprising the step of applying a therapeutic effective amount of a cellulose biosynthesis inhibitor selected from the group consisting of ES20 and ES20-1˜ES20-9 of FIG. 1A, or a salt thereof, in combination with one or more other commonly used antibiotics. A composition matter comprising said compounds and methods of use are within the scope of the present invention.
FILED Friday, April 02, 2021
APPL NO 17/220975
CURRENT CPC
Preservation of Bodies of Humans or Animals or Plants or Parts Thereof; Biocides, e.g as Disinfectants, as Pesticides or as Herbicides; Pest Repellants or Attractants; Plant Growth Regulators
A01N 47/30 (20130101)
A01N 47/34 (20130101)
A01N 47/36 (20130101)

Preparations for Medical, Dental, or Toilet Purposes
A61K 31/17 (20130101)
A61K 31/44 (20130101) Original (OR) Class
A61K 31/381 (20130101)
A61K 45/06 (20130101)

Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles
A61L 2/16 (20130101)
A61L 2/0082 (20130101)
A61L 2101/40 (20200801)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 31/04 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322557 Burdick et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Dental and Craniofacial Research (NIDCR)
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Materials Research (DMR)
APPLICANT(S) The Trustees of the University of Pennsylvania (Philadelphia, Pennsylvania)
ASSIGNEE(S)
INVENTOR(S) Jason Alan Burdick (Philadelphia, Pennsylvania);  Sujata Sahoo (Wilmington, Delaware);  Cindy Chung (Parsippany, New Jersey)
ABSTRACT Provided are polysaccharide compositions capable of controllable hydrolytic degradation and suitable for controlled release of therapeutic agents. Also provided are methods for synthesizing such compositions and a variety of applications in which the compositions may be used.
FILED Wednesday, June 23, 2021
APPL NO 17/355660
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 47/36 (20130101) Original (OR) Class

Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles
A61L 27/18 (20130101)
A61L 27/52 (20130101)
A61L 27/54 (20130101)
A61L 27/58 (20130101)
A61L 27/3834 (20130101)
A61L 2300/414 (20130101)
A61L 2300/426 (20130101)
A61L 2300/442 (20130101)
A61L 2300/604 (20130101)
A61L 2430/06 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 5/0012 (20130101)
C12N 5/0663 (20130101)
C12N 2533/40 (20130101)
C12N 2533/80 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322567 Yang et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Chemical, Bioengineering, Environmental and Transport Systems (CBET)
APPLICANT(S) VIRGINIA COMMONWEALTH UNIVERSITY INTELLECTUAL PROPERTY FOUNDATION (Richmond, Virginia)
ASSIGNEE(S)
INVENTOR(S) Hu Yang (Glen Allen, Virginia);  Shobha Ghosh (Glen Allen, Virginia);  Hongliang He (Richmond, Virginia);  Michael Lancina (Richmond, Virginia)
ABSTRACT The present disclosure relates to carbohydrate-functionalized nanoparticles and methods of treating cardiovascular disease (for example, atherosclerosis).
FILED Friday, October 27, 2017
APPL NO 16/345303
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/7105 (20130101)
A61K 38/465 (20130101)
A61K 47/26 (20130101)
A61K 47/60 (20170801)
A61K 47/6935 (20170801) Original (OR) Class

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 9/10 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322950 JIAO et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Civil, Mechanical and Manufacturing Innovation (CMMI)
APPLICANT(S) UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (PITTSBURGH, Pennsylvania)
ASSIGNEE(S) UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (PITTSBURGH, Pennsylvania)
INVENTOR(S) SHICHAO JIAO (PITTSBURGH, Pennsylvania);  JOSEPH JOHN MCCARTHY (GLENSHAW, Pennsylvania)
ABSTRACT The invention relates to novel composites for capture, e.g., absorption, of condensable gases and vapors from atmospheric sources, and gas or vapor streams, and the recovery of the condensed gases and vapors from the composites, as well as passive methods absent of external sources of energy for conducting the capturing and recovery processes. The composites include a hydrophilic matrix; hydrophilic solids embedded or immersed in the matrix, in close proximity to each other; and porogenic material embedded in the matrix, having a size larger than the hydrophilic solids; wherein selective removal of the porogenic material from the matrix forms a hierarchically porous matrix.
FILED Monday, October 28, 2019
APPL NO 17/271463
CURRENT CPC
Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus
B01J 20/10 (20130101) Original (OR) Class
B01J 20/28 (20130101)
B01J 20/261 (20130101)

Macromolecular Compounds Obtained by Reactions Only Involving Carbon-to-carbon Unsaturated Bonds
C08F 120/14 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210323045 Lujan et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
National Science Foundation (NSF)
APPLICANT(S) BOISE STATE UNIVERSITY (Boise, Idaho)
ASSIGNEE(S)
INVENTOR(S) Trevor Lujan (Boise, Idaho);  Sean Nelson (Meridian, Idaho);  Madison Wale (Boise, Idaho);  Danielle Siegel (Boise, Idaho);  Jaremy Creechley (Laramie, Wyoming)
ABSTRACT A system may include a blade die, a first clamping caul positioned on a first side of the blade die, and a second clamping caul positioned on a second side of the blade die. A molding surface of the blade die and a molding surface of the first clamping caul may be configured to bend a first interchangeable blade positioned therebetween into a first shape in response to a first compression force. A second molding surface of the blade die and a molding surface of the second clamping caul may be configured to bend a second interchangeable blade positioned therebetween into a second shape in response to a second compression force.
FILED Monday, April 19, 2021
APPL NO 17/234606
CURRENT CPC
Working or Processing of Sheet Metal or Metal Tubes, Rods or Profiles Without Essentially Removing Material; Punching Metal
B21D 28/34 (20130101) Original (OR) Class
B21D 43/003 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210323058 Sandhage
FUNDED BY
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Materials Research (DMR)
APPLICANT(S) Purdue Research Foundation (West Lafayette, Indiana)
ASSIGNEE(S)
INVENTOR(S) Kenneth Henry Sandhage (Lafayette, Indiana)
ABSTRACT Methods for producing final bodies that contain a fine-grained refractory complex concentrated alloy (RCCA), as well as RCCAs, intermediate materials and final bodies containing the RCCAs, and high-temperature devices formed by such final bodies. Such a method includes providing a precursor with one or more precursor compounds containing elements of an RCCA, reducing the precursor compounds in the precursor via reaction with a reducing agent so as to generate the RCCA and a compound comprising a product of the reaction between the reducing agent and the precursor compounds, generating a solid material that contains at least the RCCA, forming with the solid material a porous intermediate body, and consolidating the porous intermediate body so as to partially or completely remove the pore volume from the porous intermediate body, and in doing so yield either a denser final body or a denser film.
FILED Monday, March 22, 2021
APPL NO 17/208424
CURRENT CPC
Working Metallic Powder; Manufacture of Articles From Metallic Powder; Making Metallic Powder
B22F 3/001 (20130101) Original (OR) Class
B22F 3/14 (20130101)
B22F 3/16 (20130101)
B22F 3/1143 (20130101)
B22F 9/20 (20130101)
B22F 9/24 (20130101)
B22F 9/30 (20130101)
B22F 2003/145 (20130101)
B22F 2301/20 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210323983 Toutov et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Chemistry (CHE)
APPLICANT(S) California Institute Of Technology (Pasadena, California)
ASSIGNEE(S)
INVENTOR(S) Anton Toutov (Magnolia, Texas);  Wenbo Liu (Wuhan, China PRC);  David P. Schuman (Pasadena, California);  Brian M. Stoltz (San Marino, California);  Robert H. Grubbs (South Pasadena, California)
ABSTRACT The present disclosure is directed to methods of silylating organic substrates containing C—H or O—H bonds. In some embodiments, the methods use compositions that are derived from the preconditioning of mixtures of hydrosilanes or organodisilanes with bases, including metal hydroxide, metal alkoxide, metal silanoates, potassium amides, and/or graphitic potassium bases.
FILED Thursday, May 27, 2021
APPL NO 17/332394
CURRENT CPC
Acyclic, Carbocyclic or Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium or Tellurium
C07F 7/0814 (20130101) Original (OR) Class
C07F 7/0896 (20130101)
C07F 7/1804 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324121 Liebfarth et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
Army Research Office (ARO)
National Science Foundation (NSF)
APPLICANT(S) The University of North Carolina at Chapel Hill (Chapel Hill, North Carolina)
ASSIGNEE(S)
INVENTOR(S) Frank Liebfarth (Carrboro, North Carolina);  Aaron Teator (Chapel Hill, North Carolina)
ABSTRACT Disclosed herein are isotactic polyvinyl ethers and improved methods of making same. The method disclosed herein can produce polyvinyl ethers having a higher isotacticity as compared to polyvinyl ethers prepared with conventional methods.
FILED Thursday, August 15, 2019
APPL NO 17/269247
CURRENT CPC
Macromolecular Compounds Obtained by Reactions Only Involving Carbon-to-carbon Unsaturated Bonds
C08F 216/20 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324129 Youngblood et al.
FUNDED BY
National Science Foundation (NSF)
APPLICANT(S) Purdue Research Foundation (West Lafayette, Indiana)
ASSIGNEE(S) Purdue Research Foundation (West Lafayette, Indiana)
INVENTOR(S) Jeffrey Paul Youngblood (West Lafayette, Indiana);  Matthew Korey (Hamilton, Ohio);  John Alan Howarter (West Lafayette, Indiana);  Natalie Burgos (West Lafayette, Indiana)
ABSTRACT The present disclosure provides to a novel flame retardant resin, wherein the resin is a reaction product of an epoxy material, a curing agent, and a partially esterified tannic acid of formula I, wherein TA represents a tannic acid moiety, R1 represents an optionally substituted C1-C6 straight or branched alkyl, an optionally substituted C3-C6 cyclic ring, an optionally substituted phenyl group, or any combination thereof, and n is 2-10.
FILED Monday, February 15, 2021
APPL NO 17/175748
CURRENT CPC
Macromolecular Compounds Obtained by Reactions Only Involving Carbon-to-carbon Unsaturated Bonds
C08F 283/10 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324360 CHEN et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
NIH Office of the Director (NIHOD)
National Science Foundation (NSF)
APPLICANT(S) The Regents of the University of California (Oakland, California)
ASSIGNEE(S)
INVENTOR(S) Yvonne Y. CHEN (Los Angeles, California);  Patrick HO (Fremont, California)
ABSTRACT Compositions and methods are provided for the cell-mediated targeted killing of diseased cells based on the presence of an intracellular antigen, rather than a surface-bound marker. The targeting cells are modified to express a cytotoxic protein that is delivered into a targeted cell, and after delivery is selectively activated by the presence of a cytoplasmic protein of interest. In one embodiment of the invention, the cytotoxic molecule is a Granzyme B (GrB) polypeptide. In the compositions of the invention, GrB is modified to render its cytotoxic enzymatic functions inactive, until the presence of an intracellular antigen unlocks the GrB molecule to enable enzymatic activities.
FILED Thursday, June 24, 2021
APPL NO 17/357704
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 35/17 (20130101)
A61K 38/482 (20130101)

Peptides
C07K 14/47 (20130101)
C07K 14/4702 (20130101)
C07K 16/40 (20130101)
C07K 2317/622 (20130101)
C07K 2319/00 (20130101)
C07K 2319/95 (20130101)

Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 5/0636 (20130101)
C12N 9/64 (20130101)
C12N 9/6467 (20130101) Original (OR) Class
C12N 15/85 (20130101)
C12N 2510/00 (20130101)

Enzymes
C12Y 304/21079 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324366 DANIEL et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Chemical, Bioengineering, Environmental and Transport Systems (CBET)
APPLICANT(S) Cornell University (Ithaca, New York)
ASSIGNEE(S)
INVENTOR(S) Susan DANIEL (Ithaca, New York);  Martin STUEBLER (Ithaca, New York);  Han-Yuan LIU (Ithaca, New York)
ABSTRACT Provided herein are compositions comprising a plant plasma membrane supported on a surface of an object, wherein the plant plasma membrane is not associated with a plant cell.
FILED Thursday, July 11, 2019
APPL NO 17/258863
CURRENT CPC
Microorganisms or Enzymes; Compositions Thereof; Propagating, Preserving, or Maintaining Microorganisms; Mutation or Genetic Engineering; Culture Media
C12N 11/08 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324442 BUNDY et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Chemical, Bioengineering, Environmental and Transport Systems (CBET)
APPLICANT(S) Brigham Young University (Provo, Utah)
ASSIGNEE(S)
INVENTOR(S) Bradley C. BUNDY (Provo, Utah);  J. Porter HUNT (Provo, Utah)
ABSTRACT Disclosed herein are biosensors including transcription, translation, and coupled transcription/translation systems. The biosensors may be made from cell lysates, purified enzymes, or a combination thereof. The biosensors may include an inhibitor, and may include a reporter. The biosensor may be supplied in a kit for testing for a disease or condition. Methods of using the biosensor are also disclosed.
FILED Wednesday, January 06, 2021
APPL NO 17/142932
CURRENT CPC
Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/485 (20130101) Original (OR) Class

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 2333/9124 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324456 Cunningham et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Chemical, Bioengineering, Environmental and Transport Systems (CBET)
APPLICANT(S) The Board of Trustees of the University of Illinois (Urbana, Illinois)
ASSIGNEE(S)
INVENTOR(S) Brian T. Cunningham (Champaign, Illinois);  Yue Zhuo (Champaign, Illinois);  Brendan Harley (Urbana, Illinois);  Ji Sun Choi (Urbana, Illinois);  Thibault Marin (Champaign, Illinois);  Yi Lu (Champaign, Illinois)
ABSTRACT A digital assay for a micro RNA (miRNA) or other target analyte in a sample makes use of nanoparticles that absorb light at the resonant wavelength of a photonic crystal (PC). Such nanoparticles locally quench the resonant reflection of light from the PC when present on the surface of the PC. The nanoparticles are functionalized to specifically bind to the target analyte, and the PC surface is functionalized to specifically bind to the nanoparticles that have bound to the target analyte. The sample is exposed to the functionalized nanoparticles, and the individual nanoparticles bound to the PC surface can be identified and counted based on reduced intensity values in the reflected light from the PC. The number of bound nanoparticles that are counted in this way can be correlated to the abundance of the target analyte in the sample.
FILED Monday, May 24, 2021
APPL NO 17/328752
CURRENT CPC
Measuring or Testing Processes Involving Enzymes, Nucleic Acids or Microorganisms; Compositions or Test Papers Therefor; Processes of Preparing Such Compositions; Condition-responsive Control in Microbiological or Enzymological Processes
C12Q 1/6825 (20130101) Original (OR) Class
C12Q 1/6886 (20130101)
C12Q 2600/178 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 21/554 (20130101)
G01N 21/774 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324512 Wu et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
Army Research Office (ARO)
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Materials Research (DMR)
APPLICANT(S) University of Kansas (Lawrence, Kansas)
ASSIGNEE(S)
INVENTOR(S) Judy Z. Wu (Lawrence, Kansas);  Qingfeng Liu (Nanjing, China PRC)
ABSTRACT A method of making a plasmonic metal/graphene heterostructure comprises heating an organometallic complex precursor comprising a metal at a first temperature T1 for a first period of time t1 to deposit a layer of the metal on a surface of a heated substrate, the heated substrate in fluid communication with the precursor; and heating, in situ, the precursor at a second temperature T2 for a second period of time t2 to simultaneously form on the layer of the metal, a monolayer of graphene and a plurality of carbon-encapsulated metal nanostructures comprising the metal, thereby providing the plasmonic metal/graphene heterostructure. The heated substrate is characterized by a third temperature T3. The plasmonic metal/graphene heterostructures, devices incorporating the heterostructures, and methods of using the heterostructures are also provided.
FILED Wednesday, July 03, 2019
APPL NO 17/255817
CURRENT CPC
Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures
B82Y 40/00 (20130101)

Coating Metallic Material; Coating Material With Metallic Material; Surface Treatment of Metallic Material by Diffusion into the Surface, by Chemical Conversion or Substitution; Coating by Vacuum Evaporation, by Sputtering, by Ion Implantation or by Chemical Vapour Deposition, in General
C23C 16/30 (20130101) Original (OR) Class
C23C 16/448 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 21/658 (20130101)

Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for
H01L 31/028 (20130101)
H01L 31/0232 (20130101)
H01L 31/02161 (20130101)
H01L 31/02363 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324537 Li et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Materials Research (DMR)
APPLICANT(S) Wenzhi Li (Palmetto Bay, Florida);  Yuba Poudel (Miami, Florida)
ASSIGNEE(S) The Florida International University Board of Trustees (Miami, Florida)
INVENTOR(S) Wenzhi Li (Palmetto Bay, Florida);  Yuba Poudel (Miami, Florida)
ABSTRACT Filled carbon nanotubes (CNTs) and methods of synthesizing the same are provided. An in situ chemical vapor deposition technique can be used to synthesize CNTs filled with metal sulfide nanowires. The CNTs can be completely and continuously filled with the metal sulfide fillers up to several micrometers in length. The filled CNTs can be easily collected from the substrates used for synthesis using a simple ultrasonication method.
FILED Thursday, April 16, 2020
APPL NO 16/850687
CURRENT CPC
Non-metallic Elements; Compounds Thereof;
C01B 32/162 (20170801)
C01B 32/178 (20170801)
C01B 2202/06 (20130101)
C01B 2202/10 (20130101)

Indexing Scheme Relating to Structural and Physical Aspects of Solid Inorganic Compounds
C01P 2002/72 (20130101)
C01P 2002/82 (20130101)
C01P 2002/84 (20130101)
C01P 2004/03 (20130101)
C01P 2004/04 (20130101)

Coating Metallic Material; Coating Material With Metallic Material; Surface Treatment of Metallic Material by Diffusion into the Surface, by Chemical Conversion or Substitution; Coating by Vacuum Evaporation, by Sputtering, by Ion Implantation or by Chemical Vapour Deposition, in General
C23C 16/26 (20130101)

Single-crystal-growth; Unidirectional Solidification of Eutectic Material or Unidirectional Demixing of Eutectoid Material; Refining by Zone-melting of Material; Production of a Homogeneous Polycrystalline Material With Defined Structure; Single Crystals or Homogeneous Polycrystalline Material With Defined Structure; After-treatment of Single Crystals or a Homogeneous Polycrystalline Material With Defined Structure; Apparatus Therefor
C30B 25/186 (20130101)
C30B 29/46 (20130101)
C30B 29/66 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324539 Cera et al.
FUNDED BY
National Science Foundation (NSF)
APPLICANT(S) President and Fellows of Harvard College (Cambridge, Massachusetts)
ASSIGNEE(S)
INVENTOR(S) Luca Cera (Cambridge, Massachusetts);  Kevin Kit Parker (Cambridge, Massachusetts)
ABSTRACT The present invention provides methods for preparing an alpha-keratin solution comprising alpha-keratin protofibrils and intermediate filaments in liquid crystal phase and uses thereof for fabricating, e.g., shape-memory polymeric fibers, yarns, threads, fabrics, structures and objects.
FILED Friday, July 26, 2019
APPL NO 17/262318
CURRENT CPC
Additive Manufacturing, i.e Manufacturing of Three-dimensional [3-D] Objects by Additive Deposition, Additive Agglomeration or Additive Layering, e.g by 3-d Printing, Stereolithography or Selective Laser Sintering
B33Y 10/00 (20141201)
B33Y 70/00 (20141201)
B33Y 80/00 (20141201)

Mechanical Methods or Apparatus in the Manufacture of Artificial Filaments, Threads, Fibres, Bristles or Ribbons
D01D 1/02 (20130101) Original (OR) Class
D01D 5/06 (20130101)

Chemical Features in the Manufacture of Artificial Filaments, Threads, Fibres, Bristles or Ribbons; Apparatus Specially Adapted for the Manufacture of Carbon Filaments
D01F 4/00 (20130101)

Indexing Scheme Associated With Sublasses of Section D, Relating to Textiles
D10B 2211/02 (20130101)
D10B 2401/046 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210324550 Zhu et al.
FUNDED BY
National Science Foundation (NSF)
APPLICANT(S) North Carolina State University (Raleigh, North Carolina)
ASSIGNEE(S)
INVENTOR(S) Yong Zhu (Apex, North Carolina);  Shanshan Yao (Coram, New York)
ABSTRACT Multi-functional electronic textiles employing nanocomposite pattern elements and related methods are provided. An exemplary method for producing a textile product with an integrated electrical device includes applying conductive nanowires to a substrate to form a conductive nanowire network on the substrate and applying a thermoplastic elastomer to the nanowire network to form a nanocomposite layer on top of the substrate. The method also includes cutting the nanocomposite layer into a desired pattern to form an electrical device and transferring the electrical device from the substrate onto a textile fabric.
FILED Thursday, April 15, 2021
APPL NO 17/232095
CURRENT CPC
Outerwear; Protective Garments; Accessories
A41D 1/002 (20130101)

Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures
B82Y 30/00 (20130101)

Chemical Features in the Manufacture of Artificial Filaments, Threads, Fibres, Bristles or Ribbons; Apparatus Specially Adapted for the Manufacture of Carbon Filaments
D01F 8/04 (20130101)

Woven Fabrics; Methods of Weaving; Looms
D03D 1/0088 (20130101) Original (OR) Class

Treatment, Not Provided for Elsewhere in Class D06, of Fibres, Threads, Yarns, Fabrics, Feathers or Fibrous Goods Made From Such Materials
D06M 10/06 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325072 LIN et al.
FUNDED BY
Department of Energy (DOE)
Office of Energy Efficiency and Renewable Energy (EERE)
National Science Foundation (NSF)
Directorate for Computer and Information Science and Engineering (CISE)
Division of Computer and Network Systems (CNS)
APPLICANT(S) Robert Bosch GmbH (Stuttgart, Germany)
ASSIGNEE(S)
INVENTOR(S) Shan LIN (Jericho, New York);  Sirajum MUNIR (Pittsburgh, Pennsylvania)
ABSTRACT A thermal state of a plurality of zones of the building is updated according to a building thermal model and information received from temperature sensors of the building. Predicted occupant counts for an upcoming plurality of time slots for each of the plurality of zones are updated using actual occupancy counts for each of the plurality of zones. A misprediction type distribution for the upcoming plurality of time slots for each of the plurality of zones is updated, the misprediction type distribution indicating misprediction for true negatives, false positives, false negatives, and true positives. A total misprediction cost expectation is updated according to the predicted occupant counts and the misprediction type distribution. HVAC power for each of the plurality of zones is determined to optimize occupant thermal comfort weighted according to the predicted occupant counts while minimizing the total misprediction cost expectation. HVAC operation is controlled per the HVAC power.
FILED Thursday, April 16, 2020
APPL NO 16/850860
CURRENT CPC
Air-conditioning; Air-humidification; Ventilation; Use of Air Currents for Screening
F24F 11/47 (20180101)
F24F 11/48 (20180101)
F24F 11/65 (20180101) Original (OR) Class

Computer Systems Based on Specific Computational Models
G06N 3/08 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325185 Das
FUNDED BY
National Science Foundation (NSF)
APPLICANT(S) KUTZTOWN UNIVERSITY OF PENNSYLVANIA (Kutztown, Pennsylvania)
ASSIGNEE(S)
INVENTOR(S) Kunal Das (Reading, Pennsylvania)
ABSTRACT Embodiments relate to a sensor system configured to detect physical rotation, entire or relative, of one or more objects and/or their environment and/or proximity of a magnetic field, by measuring the degree of localization of a medium trapped in a ring-shaped artificial lattice. The lattice structure can be configured to comprise of lattice sites distributed with a lattice period around an azimuth of a closed ring. The site depths of the plurality of lattice sites can be configured to be modulated with a modulation period different from the lattice period to affect the onsite energies of each lattice site and the eigenstates of the system. Physical rotation of the sensor and/or the proximity of magnetic field will alter the localization properties so as to cause the degree of localization of the medium to change (e.g., the medium becomes more confined in space or more spread out in space).
FILED Tuesday, November 12, 2019
APPL NO 16/617894
CURRENT CPC
Measuring Distances, Levels or Bearings; Surveying; Navigation; Gyroscopic Instruments; Photogrammetry or Videogrammetry
G01C 19/58 (20130101) Original (OR) Class

Measuring Electric Variables; Measuring Magnetic Variables
G01R 33/032 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325282 DIMAURO
FUNDED BY
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Chemistry (CHE)
APPLICANT(S) Sunghee Lee DIMAURO (Stamford, Connecticut)
ASSIGNEE(S) Iona College (New Rochelle, New York)
INVENTOR(S) Sunghee Lee DIMAURO (Stamford, Connecticut)
ABSTRACT The present disclosure relates to compositions and methods for clearing biological materials. Specifically, the present disclosure relates to increasing the transparency of biological materials via contact with clearing composition comprising a solution of polyoxometallate salt.
FILED Sunday, June 27, 2021
APPL NO 17/359609
CURRENT CPC
Detergent Compositions; Use of Single Substances as Detergents; Soap or Soap-making; Resin Soaps; Recovery of Glycerol
C11D 3/168 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 1/34 (20130101) Original (OR) Class
G01N 21/41 (20130101)
G01N 33/4833 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325301 Porter et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Materials Research (DMR)
APPLICANT(S) The Regents of the University of Colorado, a body corporate (Denver, Colorado)
ASSIGNEE(S)
INVENTOR(S) Christina Porter (Superior, Colorado);  Daniel E. Adams (Thornton, Colorado);  Michael Tanksalvala (Longmont, Colorado);  Elisabeth Shanblatt (Boulder, Colorado);  Margaret M. Murnane (Boulder, Colorado);  Henry C. Kapteyn (Boulder, Colorado)
ABSTRACT Apparatus and methods for complex imaging reflectometry and refractometry using at least partially coherent light. Quantitative images yield spatially-dependent, local material information about a sample of interest. These images may provide material properties such as chemical composition, the thickness of chemical layers, dopant concentrations, mixing between layers of a sample, reactions at interfaces, etc. An incident beam of VUV wavelength or shorter is scattered off of a sample and imaged at various angles, wavelengths, and/or polarizations. The power of beam is also measured. This data is used to obtain images of a sample's absolute, spatially varying, complex reflectance or transmittance, which is then used to determine spatially-resolved, depth-dependent sample material properties.
FILED Monday, April 12, 2021
APPL NO 17/228178
CURRENT CPC
Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 21/33 (20130101)
G01N 21/45 (20130101)
G01N 21/956 (20130101)
G01N 21/4788 (20130101) Original (OR) Class
G01N 21/4795 (20130101)
G01N 2021/1782 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325329 Bandara et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Chemical, Bioengineering, Environmental and Transport Systems (CBET)
Division of Civil, Mechanical and Manufacturing Innovation (CMMI)
Directorate for Mathematical and Physical Sciences (MPS)
Division of Chemistry (CHE)
APPLICANT(S) Southern Methodist University (Dallas, Texas);  University of Rhode Island Board of Trustees (Kingston, Rhode Island)
ASSIGNEE(S)
INVENTOR(S) Y.M. Nuwan D.Y. Bandara (Canberra, Australia);  Buddini I. Karawdeniya (Canberra, Australia);  Jugal Saharia (Dallas, Texas);  Min Jun Kim (Plano, Texas);  Jason Rodger Dwyer (Providence, Rhode Island)
ABSTRACT The present invention includes one or more nanopores in a SixNy membrane comprising a monoprotic surface termination, methods of making, and methods of using the one or more nanopores, where the one or more nanopores are a chemically-tuned controlled dielectric breakdown (CT-CDB) nanopore membrane, wherein the CT-CDB allows for long-term stability of measurements in the presence of only electrolyte (open pore current stability) and ability to support many molecular detection events. In addition, the CT-CBD has pore that unclog spontaneously, in response to voltage cessation or application, or both.
FILED Friday, April 16, 2021
APPL NO 17/232624
CURRENT CPC
Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 27/127 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325386 McGrath
FUNDED BY
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Industrial Innovation and Partnerships (IIP)
APPLICANT(S) University of Rochester (Rochester, New York)
ASSIGNEE(S) University of Rochester (Rochester, New York)
INVENTOR(S) James L. McGrath (Fairport, New York)
ABSTRACT The invention provides devices and methods for detecting viruses, bacteria, and other analytes of interest in a fluid sample. The fluid sample flows through a first microfluidic channel to a nanoporous or microporous membrane on which are disposed ligands, such as antibodies, specific for the analyte. If the analyte of interest is captured by the ligand, it clogs the pores of the membrane, preventing the fluid sample from passing through the membrane and diverting the fluid into a second channel. Detecting movement of the fluid sample in the second channel signals the presence of the analyte in the fluid sample, while failure of the fluid sample to move in the second channel signals absence of the analyte in the fluid sample.
FILED Monday, February 15, 2021
APPL NO 17/176135
CURRENT CPC
Separation
B01D 39/2068 (20130101)

Chemical or Physical Laboratory Apparatus for General Use
B01L 3/502746 (20130101)

Specific Uses or Applications of Nanostructures; Measurement or Analysis of Nanostructures; Manufacture or Treatment of Nanostructures
B82Y 30/00 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/569 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325392 Buranda et al.
FUNDED BY
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of General Medical Sciences (NIGMS)
National Institute of Neurological Disorders and Stroke (NINDS)
National Science Foundation (NSF)
Directorate for Biological Sciences (BIO)
Division of Molecular and Cellular Biosciences (MCB)
APPLICANT(S) UNM RAINFOREST INNOVATIONS (Albuquerque, New Mexico)
ASSIGNEE(S)
INVENTOR(S) Tione Buranda (Albuquerque, New Mexico);  Jacob Ongudi Agola (Albuquerque, New Mexico);  Soumik BasuRay (Dallas, Texas);  Scarlett Swanson (Albuquerque, New Mexico);  Angela Wandinger-Ness (Albuquerque, New Mexico);  Peter C. Simons (Albuquerque, New Mexico);  Virginie Bondu (Albuquerque, New Mexico)
ABSTRACT In one embodiment, the invention provides a method of diagnosing sepsis or a virus-related infection (often a viral hemorrhagic fever infection) in a subject by detecting and measuring the level of a set of sepsis and virus infection-associated-GTPase biomarkers in a sample obtained from the subject using multiplexed flow cytometry. Related kits are also provided. In a preferred embodiment, the invention provides point of care diagnostic methods for determining an early stage sepsis or the severity of a virus infection, especially in a hospital or other setting.
FILED Tuesday, February 23, 2021
APPL NO 17/182859
CURRENT CPC
Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 33/86 (20130101)
G01N 33/573 (20130101) Original (OR) Class
G01N 2333/914 (20130101)
G01N 2800/26 (20130101)
G01N 2800/224 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325459 Hanna et al.
FUNDED BY
Department of Energy (DOE)
National Nuclear Security Administration (NNSA)
Kansas City National Security Campus (KCNSC)
Honeywell Federal Manufacturing and Technologies, LLC (FM&T)
National Science Foundation (NSF)
APPLICANT(S) Honeywell Federal Manufacturing and Technologies, LLC (KANSAS CITY, Missouri)
ASSIGNEE(S) Honeywell Federal Manufacturing and Technologies, LLC (KANSAS CITY, Missouri)
INVENTOR(S) Charles John Hanna (Gardner, Kansas);  Tuan N. Nguyen (Olathe, Kansas);  Will Schulte Plamann (Leawood, Kansas)
ABSTRACT A method of testing a PIN diode for a power limiter circuit comprises measuring a reverse bias current of the PIN diode; applying a reverse bias voltage to the PIN diode; increasing the reverse bias voltage until the reverse bias current of the PIN diode reaches a threshold current indicative of a reverse voltage breakdown; and determining whether the reverse bias breakdown voltage of the PIN diode is within an acceptable range of reverse bias breakdown voltages corresponding to a power range at which the power limiter circuit would enter power limiting mode with the PIN diode.
FILED Friday, April 17, 2020
APPL NO 16/851328
CURRENT CPC
Measuring Electric Variables; Measuring Magnetic Variables
G01R 31/31713 (20130101) Original (OR) Class

Control of Amplification
H03G 11/02 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325586 Van Dokkum et al.
FUNDED BY
National Science Foundation (NSF)
APPLICANT(S) Yale University (New Haven, Connecticut)
ASSIGNEE(S) Yale University (New Haven, Connecticut)
INVENTOR(S) Pieter Van Dokkum (New Haven, Connecticut);  Roberto Abraham (Oakville, Canada);  Deborah Lokhorst (Toronto, Canada)
ABSTRACT One aspect of the invention provides a telescope including: at least one lens or mirror arranged to receive collimated light defining an optical axis at a first end and form an image at a last end; and a narrowband interference filter positioned along the optical axis prior to the first end. The narrowband interference filter is tiltably mounted with respect to the optical axis. Another aspect of the invention provides an imager including: an optical collimator; a plurality of lenses or mirrors arranged relative to the optical collimator to receive collimated light from the optical collimator defining an optical axis at a first end and form an image at a second end; and a narrowband interference filter positioned along the optical axis between the optical collimator and the first end. The narrowband interference filter is tiltably mounted with respect to the optical axis.
FILED Thursday, April 15, 2021
APPL NO 17/231150
CURRENT CPC
Optical Elements, Systems, or Apparatus
G02B 5/28 (20130101) Original (OR) Class
G02B 23/00 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210325656 Liu et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
Congressionally Directed Medical Research Programs (CDMRP)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
National Science Foundation (NSF)
APPLICANT(S) University of Washington (Seattle, Washington)
ASSIGNEE(S) University of Washington (Seattle, Washington)
INVENTOR(S) Jonathan T.C. Liu (Seattle, Washington);  Lindsey A. Barner (Seattle, Washington);  Adam K. Glaser (Seattle, Washington)
ABSTRACT Apparatuses, systems, and methods for solid immersion meniscus lenses (SIMlenses). An optical system may include a sample holder with a first side which supports a sample, and a second side opposite the first side. The second side of the sample holder may be in contact with an immersion fluid. Light passing between the sample and an objective lens may pass through the sample holder, immersion fluid, and a SIMlens positioned between the immersion fluid and objective. The SIMlens may have a first curved surface and a second curved surface, each of which may be shaped to match a wavefront of the light as it passes through the SIMlens. The immersion fluid, SIMlens, and environment containing the objective may all have different refractive indices.
FILED Wednesday, June 23, 2021
APPL NO 17/356135
CURRENT CPC
Optical Elements, Systems, or Apparatus
G02B 21/26 (20130101)
G02B 21/0032 (20130101)
G02B 21/33 (20130101) Original (OR) Class
G02B 21/248 (20130101)
G02B 21/367 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210326163 Gopalan
FUNDED BY
National Science Foundation (NSF)
APPLICANT(S) The Research Foundation for The State University of New York (Binghamton, New York)
ASSIGNEE(S)
INVENTOR(S) Kartik Gopalan (Vestal, New York)
ABSTRACT A multi-hypervisor system, comprising: a plurality of hypervisors comprising a first hypervisor and a second hypervisor, at least one of the plurality of hypervisors being a transient hypervisor; and at least one Span VM, concurrently executing on each of the plurality of hypervisors, the at least one transient hypervisor being adapted to be dynamically at least one of injected and removed under the at least one Span VM concurrently with execution of the at least one Span VM on another hypervisor, wherein the at least one Span VM has a single and consistent at least one of memory space, virtual CPU state, and set of input/output resources, shared by the plurality of hypervisors.
FILED Monday, May 24, 2021
APPL NO 17/327828
CURRENT CPC
Electric Digital Data Processing
G06F 9/45558 (20130101) Original (OR) Class
G06F 2009/45562 (20130101)
G06F 2009/45566 (20130101)
G06F 2009/45579 (20130101)
G06F 2009/45583 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210326704 George
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
Department of the Navy (DON)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
NIH Office of the Director (NIHOD)
National Science Foundation (NSF)
APPLICANT(S) UNIVERISTY OF UTAH RESEARCH FOUNDATION (Salt Lake City, Utah)
ASSIGNEE(S)
INVENTOR(S) Jacob Anthony George (Salt Lake City, Utah)
ABSTRACT A method for training an artificial intelligence (AI) model for allowing a user to intuitively control an electronic device includes positioning a plurality of sensors at a plurality of particular positions on a human body for sensing electric signals. The method also includes recording a first set of electric signals from each of the plurality of sensors in a continuous manner. At the same time, a first set of motion intents associated with a first sequence of body movement is also recorded in a continuous manner. An AI regression model is trained using a neural network to map the first set of electric signals to the first set of motion intents. In response to receiving a second set of electric signals from the plurality of sensors in a continuous manner, the AI regression model predicts a motion intent, causing the electronic device to perform an action.
FILED Wednesday, April 14, 2021
APPL NO 17/230446
CURRENT CPC
Electric Digital Data Processing
G06F 3/014 (20130101)
G06F 3/015 (20130101)

Computer Systems Based on Specific Computational Models
G06N 3/04 (20130101)
G06N 3/08 (20130101) Original (OR) Class
G06N 3/063 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210327133 Redden et al.
FUNDED BY
National Science Foundation (NSF)
Small Business Administration (SBA)
Small Business Innovation Research (SBIR)
APPLICANT(S) Blue River Technology Inc. (Sunnyvale, California)
ASSIGNEE(S)
INVENTOR(S) Lee Kamp Redden (Palo Alto, California);  Nicholas Apostoloff (San Jose, California)
ABSTRACT A technique for generating virtual models of plants in a field is described. Generally, this includes recording images of plants in-situ; generating point clouds from the images; generating skeleton segments from the point cloud; classifying a subset of skeleton segments as unique plant features using the images; and growing plant skeletons from skeleton segments classified as unique plant feature. The technique may be used to generate a virtual model of a single, real plant, a portion of a real plant field, and/or the entirety of the real plant field. The virtual model can be analyzed to determine or estimate a variety of individual plant or plant population parameters, which in turn can be used to identify potential treatments or thinning practices, or predict future values for yield, plant uniformity, or any other parameter can be determined from the projected results based on the virtual model.
FILED Friday, May 21, 2021
APPL NO 17/327516
CURRENT CPC
Image Data Processing or Generation, in General
G06T 7/11 (20170101)
G06T 7/33 (20170101)
G06T 7/74 (20170101)
G06T 7/194 (20170101)
G06T 7/337 (20170101)
G06T 7/344 (20170101)
G06T 15/08 (20130101)
G06T 17/05 (20130101) Original (OR) Class
G06T 17/20 (20130101)
G06T 2210/56 (20130101)
G06T 2219/2008 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210327474 Seok et al.
FUNDED BY
National Science Foundation (NSF)
APPLICANT(S) The Trustees of Columbia University in the City of New York (New York, New York)
ASSIGNEE(S)
INVENTOR(S) Mingoo Seok (Tenafly, New Jersey);  Zhewei Jiang (Oakland Gardens, New York);  Jae-sun Seo (Tempe, Arizona);  Shihui Yin (Mesa, Arizona)
ABSTRACT In some embodiments, an in-memory-computing SRAM macro based on capacitive-coupling computing (C3) (which is referred to herein as “C3SRAM”) is provided. In some embodiments, a C3SRAM macro can support array-level fully parallel computation, multi-bit outputs, and configurable multi-bit inputs. The macro can include circuits embedded in bitcells and peripherals to perform hardware acceleration for neural networks with binarized weights and activations in some embodiments. In some embodiments, the macro utilizes analog-mixed-signal capacitive-coupling computing to evaluate the main computations of binary neural networks, binary-multiply-and-accumulate operations. Without needing to access the stored weights by individual row, the macro can assert all of its rows simultaneously and form an analog voltage at the read bitline node through capacitive voltage division, in some embodiments. With one analog-to-digital converter (ADC) per column, the macro cab realize fully parallel vector-matrix multiplication in a single cycle in accordance with some embodiments.
FILED Wednesday, June 23, 2021
APPL NO 17/356211
CURRENT CPC
Electric Digital Data Processing
G06F 7/501 (20130101)
G06F 7/5443 (20130101)

Static Stores
G11C 7/1036 (20130101) Original (OR) Class
G11C 7/1051 (20130101)
G11C 7/1078 (20130101)
G11C 16/3404 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210328021 Hone et al.
FUNDED BY
National Science Foundation (NSF)
APPLICANT(S) THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (New York, New York)
ASSIGNEE(S) THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (New York, New York)
INVENTOR(S) James Hone (New York, New York);  James T. Teherani (New York, New York);  Ankur Baburao Nipane (New York, New York);  Minsup Choi (New York, New York);  Younghun Jung (New York, New York);  Abhinandan Borah (New York, New York)
ABSTRACT Disclosed are compositions and methods of semiconductors including tungsten oxyselenide (TOS) as a p-type dopant. The TOS is formed by introducing a single layer of tungsten diselenide (WSe2) to a semiconductor and subject the tungsten diselenide to a room-temperature UV plus ozone process. This process forms a TOS monolayer, which can be used as a universal p-type dopant for a variety of different semiconductors. Suitable semiconductor materials include, for example, graphene, carbon nanotubes, tungsten diselenide, and dinaphthothienothiophene (DNTT).
FILED Wednesday, April 21, 2021
APPL NO 17/236404
CURRENT CPC
Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for
H01L 21/041 (20130101)
H01L 21/385 (20130101)
H01L 29/24 (20130101)
H01L 29/167 (20130101) Original (OR) Class
H01L 29/1606 (20130101)
H01L 51/002 (20130101)
H01L 51/0048 (20130101)
H01L 51/0074 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210328085 Bradley et al.
FUNDED BY
National Science Foundation (NSF)
APPLICANT(S) PixelEXX Systems, Inc. (Westmont, Illinois)
ASSIGNEE(S)
INVENTOR(S) Kenneth Forbes Bradley (Hinsdale, Illinois);  Marco Nardone (Bowling Green, Illinois);  Renee Kathryn Carder (Hinsdale, Illinois)
ABSTRACT A Mie photo sensor is described. A Mie photo sensor is configured to leverage Mie scattering to implement a photo sensor having a resonance. The resonance is based on various physical and material properties of the Mie photo sensor. In an example, a Mie photo sensor includes a layer of semiconductor material with one or more mesas. Each mesa of semiconductor material may include a scattering center. The scattering center is formed by the semiconductor material of the mesa being at least partially surround by a material with a different refractive index than the semiconductor material. The abutting refractive index materials create an interface that forms a scattering center and localizes the generation of free carriers during Mie resonance. One or more electrical contacts may be made to the mesa to measure the electrical properties of the mesa.
FILED Thursday, April 08, 2021
APPL NO 17/225994
CURRENT CPC
Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for
H01L 31/02327 (20130101)
H01L 31/035281 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210328087 BURGER et al.
FUNDED BY
Department of Defense (DOD)
Department of the Army (DOA)
U.S. Army
Army Research Office (ARO)
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Industrial Innovation and Partnerships (IIP)
APPLICANT(S) THE REGENTS OF THE UNIVERSITY OF MICHIGAN (Ann Arbor, Michigan)
ASSIGNEE(S) THE REGENTS OF THE UNIVERSITY OF MICHIGAN (Ann Arbor, Michigan)
INVENTOR(S) Tobias BURGER (Ann Arbor, Michigan);  Byungjun LEE (Ann Arbor, Michigan);  Dejiu FAN (Ann Arbor, Michigan);  Andrej LENERT (Ann Arbor, Michigan);  Stephen R. FORREST (Ann Arbor, Michigan)
ABSTRACT To reach high efficiencies, thermophotovoltaic cells must utilize the broad spectrum of a radiative thermal source. One promising approach to overcome this challenge is to have low-energy photons reflected and reabsorbed by the thermal emitter, where their energy can have another chance at contributing toward photogeneration in the cell. However, current methods for photon recuperation are limited by insufficient bandwidth or parasitic absorption, resulting in large efficiency losses relative to theoretical limits. This work demonstrates nearly perfect reflection of low-energy photons (˜99%) by embedding an air layer within the TPV cell. This result represents a four-fold reduction in parasitic absorption relative to existing TPV cells. As out-of-band reflectance approaches unity, TPV efficiency becomes nearly insensitive to cell bandgap and emitter temperature. Accessing this regime unlocks a range of possible materials and heat sources that were previously inaccessible to TPV energy conversion.
FILED Friday, April 16, 2021
APPL NO 17/232243
CURRENT CPC
Single-crystal-growth; Unidirectional Solidification of Eutectic Material or Unidirectional Demixing of Eutectoid Material; Refining by Zone-melting of Material; Production of a Homogeneous Polycrystalline Material With Defined Structure; Single Crystals or Homogeneous Polycrystalline Material With Defined Structure; After-treatment of Single Crystals or a Homogeneous Polycrystalline Material With Defined Structure; Apparatus Therefor
C30B 25/04 (20130101)
C30B 25/22 (20130101)

Photomechanical Production of Textured or Patterned Surfaces, e.g for Printing, for Processing of Semiconductor Devices; Materials Therefor; Originals Therefor; Apparatus Specially Adapted Therefor;
G03F 7/0005 (20130101)

Semiconductor Devices; Electric Solid State Devices Not Otherwise Provided for
H01L 31/043 (20141201)
H01L 31/0264 (20130101)
H01L 31/0687 (20130101) Original (OR) Class
H01L 31/0735 (20130101)
H01L 31/1852 (20130101)
H01L 31/1896 (20130101)
H01L 31/02327 (20130101)
H01L 33/0093 (20200501)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210328252 Yang et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Civil, Mechanical and Manufacturing Innovation (CMMI)
APPLICANT(S) The Texas A and M University System (College Station, Texas)
ASSIGNEE(S)
INVENTOR(S) Gang Yang (College Station, Texas);  Choongho Yu (College Station, Texas)
ABSTRACT Embodiments of the claimed invention are directed to a device, comprising: an anode that includes a lithiated silicon-based or lithiated carbon-based material or pure lithium metal or metal oxides and a sandwich-type sulfur-based cathode, wherein the anode and the cathode are designed to have porous structures. An additional embodiment of the invention is directed to a scalable method of manufacturing sandwich-type Li—S batteries at a significantly reduced cost compared to traditional methods. An additional embodiment is directed to the use of exfoliated CNT sponges for enlarging the percentage of sulfur in the cathode to have large energy density.
FILED Tuesday, February 09, 2021
APPL NO 17/171828
CURRENT CPC
Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy
H01M 4/38 (20130101)
H01M 4/80 (20130101)
H01M 4/663 (20130101)
H01M 10/052 (20130101) Original (OR) Class
H01M 10/0585 (20130101)
H01M 2004/021 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210328319 Krueger
FUNDED BY
Department of Energy (DOE)
National Nuclear Security Administration (NNSA)
Kansas City National Security Campus (KCNSC)
Honeywell Federal Manufacturing and Technologies, LLC (FM&T)
National Science Foundation (NSF)
APPLICANT(S) HONEYWELL FEDERAL MANUFACTURING and TECHNOLOGIES, LLC (KANSAS CITY, Missouri)
ASSIGNEE(S) HONEYWELL FEDERAL MANUFACTURING and TECHNOLOGIES, LLC (KANSAS CITY, Missouri)
INVENTOR(S) Daniel Scott Krueger (Liberty, Missouri)
ABSTRACT Waveguides and methods for manufacturing a waveguide that include forming a first channel in a first layer of dielectric material, the first channel comprising one or more walls; forming a second channel in a second layer of dielectric material, the second channel comprising one or more walls; depositing electrically conductive material on the one or more walls of the first channel; depositing electrically conductive material on the one or more walls of the second channel; arranging the first layer adjacent to the second layer to form a stack with the first channel axially aligned with and facing the second channel; and heating the stack so that the conductive material on the one or more walls of the first channel and the conductive material on the one or more walls of the second channel connect to form the waveguide.
FILED Friday, April 17, 2020
APPL NO 16/851486
CURRENT CPC
Waveguides; Resonators, Lines, or Other Devices of the Waveguide Type
H01P 3/16 (20130101)
H01P 3/121 (20130101) Original (OR) Class
H01P 11/006 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210328360 Yoon et al.
FUNDED BY
National Science Foundation (NSF)
APPLICANT(S) University of Florida Research Foundation, Inc. (Gainesville, Florida)
ASSIGNEE(S)
INVENTOR(S) Yong Kyu Yoon (Gainesville, Florida);  Renuka Bowrothu (Gainesville, Florida);  Haein Kim (Gainesville, Florida);  Seahee Hwangbo (Beaverton, Oregon)
ABSTRACT The present disclosure describes various embodiments of systems, apparatuses, and methods for implementing an array antenna having a combination of ferromagnetic and nonferromagnetic conductors in alternating multilayers. One such antenna device comprises an array of patch antennas on a substrate, wherein the patch antennas are formed of a combination of ferromagnetic and nonferromagnetic conductors in alternating multilayers; and a microstrip feeding line coupled to the array of patch antennas. Other systems, apparatuses, and methods are also presented.
FILED Wednesday, April 14, 2021
APPL NO 17/230347
CURRENT CPC
Antennas, i.e Radio Aerials
H01Q 1/422 (20130101)
H01Q 9/0414 (20130101)
H01Q 21/065 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210328777 BROOKS et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Computer and Information Science and Engineering (CISE)
Office of Advanced Cyberinfrastructure (OAC)
APPLICANT(S) Clemson University (Clemson, South Carolina)
ASSIGNEE(S) Clemson University (Clemson, South Carolina);  University of Tennessee Research Foundation (Knoxville, Tennessee)
INVENTOR(S) RICHARD R. BROOKS (Clemson, South Carolina);  LU YU (Clemson, South Carolina);  ANTHONY SKJELLUM (Knoxville, Tennessee)
ABSTRACT The system can be for the management of access authorization using an immutable ledger comprising and can include a server having a computer readable medium in communications with an immutable ledger. A set of computer readable instructions can be included in the server and can be configured for: receiving a set of data, encrypting the set of data with a data-encryption-key and storing the encrypted data on the immutable ledger, creating a key tree having a node associated with a user, creating a key-encryption-key associated with the node and the user, and, distributing the key-encryption-key to the user wherein the key-encryption-key is configured to decrypt the data-encryption-key thereby providing access to the data for the user.
FILED Tuesday, April 20, 2021
APPL NO 17/235279
CURRENT CPC
Transmission of Digital Information, e.g Telegraphic Communication
H04L 9/0822 (20130101) Original (OR) Class
H04L 9/0836 (20130101)
H04L 9/0894 (20130101)
H04L 9/3297 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210328841 Wu et al.
FUNDED BY
National Science Foundation (NSF)
Directorate for Engineering (ENG)
Division of Industrial Innovation and Partnerships (IIP)
APPLICANT(S) RENSSELAER POLYTECHNIC INSTITUTE (Troy, New York)
ASSIGNEE(S) RENSSELAER POLYTECHNIC INSTITUTE (Troy, New York)
INVENTOR(S) Kefei Wu (Portland, Oregon);  Mona Mostafa Hella (Watervliet, New York)
ABSTRACT A millimeter wave (MMW) circuitry includes a phase modulation circuitry, a plurality of amplifier multiplier chain circuitries and a power combiner circuitry. The phase modulation circuitry is configured to receive input data and a plurality of divided input signals and to provide as output a plurality of phase modulation circuitry output signals. Each phase modulation circuitry output signal corresponds to a respective divided input signal. At least one phase modulation circuitry output signal has a nonzero phase relative to the divided input signals that is related to the input data. Each amplifier multiplier chain circuitry is configured to amplify and frequency multiply and phase multiply the respective phase modulation circuitry output signal to yield a respective power combiner input signal. The power combiner circuitry is configured to sum a plurality of power combiner input signals to yield an output signal. A modulation of the output signal is related to the input data.
FILED Thursday, July 11, 2019
APPL NO 17/259585
CURRENT CPC
Amplifiers
H03F 3/245 (20130101)
H03F 2200/451 (20130101)

Pulse Technique
H03K 5/00006 (20130101)
H03K 2005/00286 (20130101)

Transmission
H04B 1/04 (20130101)
H04B 2001/0408 (20130101)

Transmission of Digital Information, e.g Telegraphic Communication
H04L 27/20 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210329026 Bogdan et al.
FUNDED BY
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
Department of the Navy (DON)
National Science Foundation (NSF)
APPLICANT(S) UNIVERSITY OF SOUTHERN CALIFORNIA (Los Angeles, California)
ASSIGNEE(S)
INVENTOR(S) Paul Bogdan (Los Angeles, California);  Yuankun Xue (Los Angeles, California)
ABSTRACT Methods, systems, devices and apparatuses for reconstructing a network. The network reconstruction system includes a processor. The processor is configured to determine an unknown sub-network of a network. The unknown sub-network includes multiple unknown nodes and multiple unknown links. The processor is configured to determine the unknown sub-network based on a known sub-network that has multiple known nodes and multiple known links, a network model and an attacker's statistical behavior to reconstruct the network. The processor is configured to determine one or more network parameters of the network. The network processor is configured to provide a probability of an outcome of an input or observation into the network or into a second network that has the one or more network parameters of the network.
FILED Monday, April 12, 2021
APPL NO 17/227966
CURRENT CPC
Computer Systems Based on Specific Computational Models
G06N 7/005 (20130101)

Transmission of Digital Information, e.g Telegraphic Communication
H04L 41/145 (20130101)
H04L 41/147 (20130101)
H04L 41/0866 (20130101)
H04L 63/1425 (20130101)
H04L 63/1441 (20130101) Original (OR) Class
VIEW PATENT @ USPTO:  Full Text   PDF 

Department of Energy (DOE) 

US 20210321934 Arnold et al.
FUNDED BY
Department of Energy (DOE)
National Nuclear Security Administration (NNSA)
National Technology and Engineering Solutions of Sandia, LLC (NTESS)
Sandia National Laboratories (SNL)
APPLICANT(S) KNOW BIOLOGICAL, INC. (Milton, Georgia);  National Technology and Engineering Solutions of Sandia, LLC (Albuquerque, New Mexico)
ASSIGNEE(S)
INVENTOR(S) Gary Stephen Arnold (Cumming, Georgia);  Matthew Wallace Moorman (Albuquerque, New Mexico);  Joshua Jonathan Whiting (Albuquerque, New Mexico)
ABSTRACT A volatile organic compound collector can include a collector material configured to collect volatile organic compounds given off from a patient's skin; a wrapping configured to isolate the collector material from an external environment; a heater comprising a heating element, the heating element configured to emit a thermal pulse to desorb the volatile organic compounds from the collector material; and a mesh layer configured to prevent the collector material from contacting the patient's skin, wherein the collector material is received between the wrapping and the mesh layer.
FILED Wednesday, April 28, 2021
APPL NO 17/242441
CURRENT CPC
Diagnosis; Surgery; Identification
A61B 5/443 (20130101)
A61B 5/4094 (20130101) Original (OR) Class
A61B 5/6831 (20130101)
A61B 5/6833 (20130101)
A61B 10/00 (20130101)
A61B 2010/0083 (20130101)

Investigating or Analysing Materials by Determining Their Chemical or Physical Properties
G01N 30/00 (20130101)
G01N 30/20 (20130101)
G01N 30/64 (20130101)
G01N 30/80 (20130101)
G01N 2030/025 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322405 Ding et al.
FUNDED BY
Department of Energy (DOE)
Battelle Memorial Institute (BATTELLE)
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
APPLICANT(S) Washington University (St. Louis, Missouri);  The General Hospital Corporation d/b/a Massachusetts General Hospital (Boston, Massachusetts);  The Broad Institute, Inc. (Cambridge, Massachusetts);  Battelle Memorial Institute (Richland, Washington)
ASSIGNEE(S)
INVENTOR(S) Li Ding (St. Louis, Missouri);  Song Cao (St. Louis, Missouri);  Yige Wu (St. Louis, Missouri);  Alla Karpova (St. Louis, Missouri);  Liang-Bo Wang (St. Louis, Missouri);  Milan Chheda (St. Louis, Missouri);  Feng Chen (St. Louis, Missouri);  Ramaswamy Govindan (St. Louis, Missouri);  Albert Kim (St. Louis, Missouri);  Michael Gillette (Boston, Massachusetts);  Steven Carr (02142, Massachusetts);  Shankha Satpathy (Cambridge, Massachusetts);  Tao Liu (Richland, Washington);  Karin D. Rodland (Richland, Washington);  Richard D. Smith (Richland, Washington)
ABSTRACT The present disclosure provides for compositions and methods of treating cancer. In some embodiments, PTPN11 is targeted with and anti-PTPN11 drug, such as a Shp2 inhibitor (e.g., SHP099). In some embodiments, other upregulated, hyperphosphorylated, or hyperacetylated target proteins are inhibited or targeted.
FILED Thursday, April 15, 2021
APPL NO 17/231273
CURRENT CPC
Preparations for Medical, Dental, or Toilet Purposes
A61K 31/497 (20130101) Original (OR) Class
A61K 31/685 (20130101)
A61K 31/702 (20130101)
A61K 31/4985 (20130101)
A61K 45/06 (20130101)

Specific Therapeutic Activity of Chemical Compounds or Medicinal Preparations
A61P 35/00 (20180101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322609 Bohnert et al.
FUNDED BY
Department of Energy (DOE)
National Nuclear Security Administration (NNSA)
Kansas City National Security Campus (KCNSC)
Honeywell Federal Manufacturing and Technologies, LLC (FM&T)
APPLICANT(S) Honeywell Federal Manufacturing and Technologies, LLC (Kansas City, Missouri)
ASSIGNEE(S) Honeywell Federal Manufacturing and Technologies, LLC (Kansas City, Missouri)
INVENTOR(S) George William Bohnert (Harrisonville, Missouri);  Darren Radke (Overland Park, Kansas);  Domenick Leto (Overland Park, Kansas)
ABSTRACT A hydrogen peroxide sterilization device for sterilizing a medical device, the hydrogen peroxide sterilization device including a hermetic outer container, a hydrogen peroxide pouch, and a hydrogen peroxide solution in the solution chamber. The hermetic outer container includes a sterilization enclosure configured to receive the medical device. The hydrogen peroxide pouch includes a permeable membrane enclosing a solution chamber and is configured to be positioned in the sterilization enclosure of the outer container. The permeable membrane is configured to allow hydrogen peroxide vapor to diffuse from the solution chamber through the permeable membrane into the sterilization enclosure.
FILED Thursday, September 03, 2020
APPL NO 17/011601
CURRENT CPC
Methods or Apparatus for Sterilising Materials or Objects in General; Disinfection, Sterilisation, or Deodorisation of Air; Chemical Aspects of Bandages, Dressings, Absorbent Pads, or Surgical Articles; Materials for Bandages, Dressings, Absorbent Pads, or Surgical Articles
A61L 2/208 (20130101) Original (OR) Class
A61L 2202/24 (20130101)
A61L 2202/122 (20130101)
A61L 2202/181 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322909 Liu et al.
FUNDED BY
Department of Energy (DOE)
Lawrence Livermore National Laboratory (LLNL)
APPLICANT(S) The Regents of the University of California (Oakland, California)
ASSIGNEE(S) The Regents of the University of California (Oakland, California)
INVENTOR(S) Kai Liu (Falls Church, Virginia);  James D. Malloy (Arlington, Virginia)
ABSTRACT A metal foam-based filtration system and method for removing sub-micron particles and contaminants from a gas or fluid flow with the use of ultralow density metal nanowire meshes that have nanometer to micron scale pores for trapping air/fluid-borne particulates. Filters can use metal foams and coated metal foams alone or in tandem. The size and density of pores in the foam can be adjusted with synthesis conditions. Foams with pore size gradients promote the trapping of different sized particulates at different regions of a foam. Multiple rounds of electrodeposition may be applied to increase the surface area and curvature of a nanowire mesh and strengthen the mesh to make it self-supporting, free-standing and capable of supporting a much heavier mass without collapse. A metal and/or a coated metal foam can act as a catalyst or substrate for absorption or adsorption to capture target particles and/or contaminants.
FILED Thursday, April 29, 2021
APPL NO 17/244796
CURRENT CPC
Separation
B01D 39/10 (20130101)
B01D 39/2051 (20130101) Original (OR) Class
B01D 46/0001 (20130101)
B01D 46/0026 (20130101)
B01D 46/0032 (20130101)
B01D 2239/10 (20130101)
B01D 2239/0478 (20130101)
B01D 2239/1216 (20130101)

Processes for the Electrolytic or Electrophoretic Production of Coatings; Electroforming; Apparatus Therefor
C25D 1/04 (20130101)
C25D 1/006 (20130101)
C25D 1/08 (20130101)
C25D 7/0607 (20130101)
VIEW PATENT @ USPTO:  Full Text   PDF 
US 20210322946 Wegeng et al.
FUNDED BY
Department of Energy (DOE)
Battelle Memorial Institute (BATTELLE)
Pacific Northwest National Laboratory (PNNL)
APPLICANT(S) Battelle Memorial Institute (Richland, Washington)
ASSIGNEE(S)
INVENTOR(S) Robert S. Wegeng (Richland, Washington);  Paul H. Humble (Kennewick, Washington);  Shankar Krishnan (Wilsonville, Oregon);  Steven D. Leith (Albany, Oregon);  Daniel R. Palo (Chisholm, Minnesota);  Robert A. Dagle (Richland, Washington)
ABSTRACT A solar thermochemical processing system is disclosed. The system includes a first unit operation for receiving concentrated solar energy. Heat from the solar energy is used to drive the first unit operation. The first unit operation also receives a first set of reactants and produces a first set of products. A second unit operation receives the first set of products from the first unit operation and produces a second set of products. A third unit operation receives heat from the second unit operation to produce a portion of the first set of reactants.
FILED Monday, June 28, 2021
APPL NO 17/361213
CURRENT CPC
Chemical or Physical Processes, e.g Catalysis or Colloid Chemistry; Their Relevant Apparatus
B01J 19/127 (20130101) Original (OR) Class
B01J 2219/00006 (20130101)
B01J 2219/089 (20130101)
B01J 2219/00159 (20130101)
B01J 2219/0883 (20130101)

Non-metallic Elements; Compounds Thereof;
C01B 3/48 (20130101)
C01B 3/384 (20130101)
C01B 2203/061 (20130101)
C01B 2203/0233 (20130101)
C01B 2203/0283 (20130101)
C01B 2203/0445 (20130101)
C01B 2203/0855 (20130101)
C01B 2203/1288 (20130101)

Cracking Hydrocarbon Oils; Production of Liquid Hydrocarbon Mixtures, e.g by Destructive Hydrogenation, Oligomerisation, Polymerisation; Recovery of Hydrocarbon Oils From Oil-shale, Oil-sand, or Gases; Refining Mixtures Mainly Consisting of Hydrocarbons; Reforming of Naphtha; Mineral Waxes
C10G 2/30 (20130101)

Purifying or Modifying the Chemical Composition of Combustible Gases Containing Carbon Monoxide
C10K 3/04 (20130101)

Steam Engine Plants; Steam Accumulators; Engine Plants Not Otherwise Provided For; Engines Using Special Working Fluids or Cycles
F01K 3/188 (20130101)

Methods of Steam Generation; Steam Boilers
F22B 1/006 (20130101)

Solar Heat Collectors; Solar Heat Systems
F24S 20/20 (20180501)

Processes or Means, e.g Batteries, for the Direct Conversion of Chemical Energy into Electrical Energy
H01M 8/0612 (20130101)

Reduction of Greenhouse Gas [GHG] Emissions, Related to Energy Generation, Transmission or Distribution